Staging of alzheimer's disease-related neurofibrillary ch

Neurobiology of Aging 16, 271-278 DOI: 10.1016/0197-4580(95)00021-6

Citation Report

#	Article	IF	CITATIONS
1	Alzheimer's disease—new approaches to old problems. International Review of Psychiatry, 1995, 7, 419-435.	1.4	1
2	Interleukin-6-associated inflammatory processes in Alzheimer's disease: New therapeutic options. Neurobiology of Aging, 1996, 17, 795-800.	1.5	87
3	Conventional MRI volumetric measures of parietal and insular cortex in Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1996, 20, 1131-1144.	2.5	13
4	Evolution of the neuropathology of Alzheimer's disease. Acta Neurologica Scandinavica, 1996, 94, 3-12.	1.0	573
5	Topical Review: Functional Anatomy of Human Hippocampal Formation and Related Structures. Journal of Child Neurology, 1996, 11, 265-275.	0.7	100
6	Pattern of brain destruction in Parkinson's and Alzheimer's diseases. Journal of Neural Transmission, 1996, 103, 455-490.	1.4	309
7	Cognitive predictors of incident Alzheimer's disease: A prospective longitudinal study Neuropsychology, 1997, 11, 413-420.	1.0	149
8	Comparison of temporal order memory in early and middle stage Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 1997, 19, 83-100.	0.8	15
9	Alzheimer's disease, Lewy body disease and aging: a comparative study of the perforant pathway. Journal of the Neurological Sciences, 1997, 147, 161-166.	0.3	32
10	Normal and Pathological Tau Proteins as Factors for Microtubule Assembly. International Review of Cytology, 1997, 171, 167-224.	6.2	112
11	Transneuronal Degeneration in the Spread of Alzheimer's Disease Pathology: Immunohistochemical Evidence for the Transmission of Tau Hyperphosphorylation. Neurobiology of Disease, 1997, 4, 365-375.	2.1	91
12	Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Research Reviews, 1997, 23, 134-143.	9.1	257
13	Association of cholinesterases with amyloid in extracellular neurofibrillary tangles. Brain Research, 1997, 769, 173-177.	1.1	4
14	Lesioning of the inferior olive using a ventral surgical approach. Molecular and Chemical Neuropathology, 1997, 31, 245-264.	1.0	9
15	Early diagnosis of alzheimer's disease. New Directions for Mental Health Services, 1997, 24, 39-51.	0.4	3
16	Isolation of single immunohistochemically identified whole neuronal cell bodies from post-mortem human brain for simultaneous analysis of multiple gene expression. Journal of Neuroscience Methods, 1997, 77, 43-48.	1.3	16
17	The link between knowledge and remembering in Alzheimer's disease. Scandinavian Journal of Psychology, 1998, 39, 131-139.	0.8	17
18	Vulnerable neuronal subsets in Alzheimer's and Pick's disease are distinguished by their ? isoform distribution and phosphorylation. Annals of Neurology, 1998, 43, 193-204.	2.8	227

#	Article	IF	CITATIONS
19	Amyloid plaques in Guam amyotrophic lateral sclerosis/ parkinsonism-dementia complex contain species of Al² similar to those found in the amyloid plaques of Alzheimer's disease and pathological aging. Acta Neuropathologica, 1998, 95, 117-122.	3.9	39
20	Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. Journal of Neural Transmission, 1998, 105, 439.	1.4	256
21	Evolution in the Conceptualization of Dementia and Alzheimer's Disease: Greco-Roman Period to the 1960s. Neurobiology of Aging, 1998, 19, 173-189.	1.5	311
22	Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiology of Aging, 1998, 19, 287-296.	1.5	182
23	Visual-discrimination learning ability and β-amyloid accumulation in the dog. Neurobiology of Aging, 1998, 19, 415-425.	1.5	160
24	Reduced O-glycosylated clathrin assembly protein AP180: implication for synaptic vesicle recycling dysfunction in Alzheimer's disease. Neuroscience Letters, 1998, 252, 33-36.	1.0	60
25	Lewy Bodies Contain Altered α-Synuclein in Brains of Many Familial Alzheimer's Disease Patients with Mutations in Presenilin and Amyloid Precursor Protein Genes. American Journal of Pathology, 1998, 153, 1365-1370.	1.9	484
26	Chapter 28 The glutamate synapse in neuropsychiatric disorders: Focus on schizophrenia and Alzheimer's disease. Progress in Brain Research, 1998, 116, 421-437.	0.9	134
27	Chapter 24 Neurodegenerative Alzheimer-like pathology in PDAPP 717V→F transgenic mice. Progress in Brain Research, 1998, 117, 327-334.	0.9	33
28	Chapter 26 Reduced neuronal activity and reactivation in Alzheimer's disease. Progress in Brain Research, 1998, 117, 343-377.	0.9	59
29	Chapter 20 Neuropathological hallmarks of Alzheimer's and Parkinson's diseases. Progress in Brain Research, 1998, 117, 267-285.	0.9	119
30	Influences of cognitive support on episodic remembering: Tracing the process of loss from normal aging to Alzheimer's disease Psychology and Aging, 1998, 13, 267-276.	1.4	65
31	Gamma Oscillations in the Entorhinal Cortex of the Freely Behaving Rat. Journal of Neuroscience, 1998, 18, 388-398.	1.7	795
32	Reduction of O-Linked <i>N</i> -Acetylglucosamine-Modified Assembly Protein-3 in Alzheimer's Disease. Journal of Neuroscience, 1998, 18, 2399-2411.	1.7	90
33	Ectopic Cell Cycle Proteins Predict the Sites of Neuronal Cell Death in Alzheimer's Disease Brain. Journal of Neuroscience, 1998, 18, 2801-2807.	1.7	512
34	Neurofibrillary Tangles in Nondemented Elderly Subjects and Mild Alzheimer Disease. Archives of Neurology, 1999, 56, 713.	4.9	194
35	Cognitive Support at Episodic Encoding and Retrieval: Similar Patterns of Utilization in Community-Based Samples of Alzheimer's Disease and Vascular Dementia Patients. Journal of Clinical and Experimental Neuropsychology, 1999, 21, 816-830.	0.8	41
36	Clinical and Pathological Evidence for a Frontal Variant of Alzheimer Disease. Archives of Neurology, 1999, 56, 1233.	4.9	375

#	Article	IF	CITATIONS
37	Brain regions associated with episodic retrieval in normal aging and Alzheimer's disease. Neurology, 1999, 52, 1861-1861.	1.5	204
38	A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology, 1999, 52, 1146-1146.	1.5	70
39	Scale of attentional focus in visual search. Perception & Psychophysics, 1999, 61, 837-859.	2.3	96
40	Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology. Journal of Neural Transmission, 1999, 106, 525-535.	1.4	113
41	Neuropathological changes in the nucleus basalis correlate with clinical measures of dementia. Acta Neuropathologica, 1999, 98, 186-196.	3.9	61
42	Antibodies to ?-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease. Annals of Neurology, 1999, 45, 353-357.	2.8	289
43	The external globus pallidus in patients with Parkinson's disease and progressive supranuclear palsy. Movement Disorders, 1999, 14, 626-633.	2.2	35
44	Ca2+ and Mg2+ selectively induce aggregates of PHF-tau but not normal human tau. Journal of Neuroscience Research, 1999, 55, 36-43.	1.3	28
45	A unifying hypothesis of Alzheimer's disease. II. Pathophysiological processes. Human Psychopharmacology, 1999, 14, 525-581.	0.7	27
46	Attention and executive deficits in Alzheimer's disease: A critical review. Brain, 1999, 122, 383-404.	3.7	899
47	The Internal Globus Pallidus Is Affected in Progressive Supranuclear Palsy and Parkinson's Disease. Experimental Neurology, 1999, 158, 135-142.	2.0	38
48	Deposition of β-Amyloid Subtypes 40 and 42 Differentiates Dementia With Lewy Bodies From Alzheimer Disease. Archives of Neurology, 1999, 56, 1111.	4.9	45
49	Differential decline in word generation from phonemic and semantic categories during the course of Alzheimer's disease: Implications for the integrity of semantic memory. Journal of the International Neuropsychological Society, 1999, 5, 692-703.	1.2	98
50	Neural expression profile of α-synuclein in developing human cortex. NeuroReport, 1999, 10, 2799-2803.	0.6	60
51	The Course of Cognitive Impairment in Preclinical Alzheimer Disease. Archives of Neurology, 2000, 57, 839.	4.9	312
52	Fate of Patients with Questionable (Very Mild) Alzheimer's Disease: Longitudinal Profiles of Individual Subjects' Decline. Dementia and Geriatric Cognitive Disorders, 2000, 11, 342-349.	0.7	54
53	Comparison of the serial position effect in very mild Alzheimer's disease, mild Alzheimer's disease, and amnesia associated with electroconvulsive therapy. Journal of the International Neuropsychological Society, 2000, 6, 290-298.	1.2	67
54	The frontal aging hypothesis evaluated. Journal of the International Neuropsychological Society, 2000, 6, 705-726.	1.2	252

#	Article	IF	CITATIONS
55	The evolution of Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathology and Applied Neurobiology, 2000, 26, 553-567.	1.8	108
56	The nature and staging of attention dysfunction in early (minimal and mild) Alzheimer's disease: relationship to episodic and semantic memory impairment. Neuropsychologia, 2000, 38, 252-271.	0.7	410
57	Functional brain imaging as a looking-glass into the degraded brain: reviewing evidence from Alzheimer disease in relation to normal aging. Acta Psychologica, 2000, 105, 255-277.	0.7	16
58	Practical measures to simplify the Braak tangle staging method for routine pathological screening. Acta Neuropathologica, 2000, 99, 199-208.	3.9	42
59	The neuroprotectant properties of glutamate antagonists and antiglutamatergic drugs. Neurotoxicity Research, 2000, 2, 179-203.	1.3	11
61	Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene. Brain, 2000, 123, 880-893.	3.7	277
62	AMY plaques in familial AD. Neurology, 2000, 54, 100-100.	1.5	13
63	Alzheimer-Related Ï"-Pathology in the Perforant Path Target Zone and in the Hippocampal Stratum Oriens and Radiatum Correlates with Onset and Degree of Dementia. Experimental Neurology, 2000, 163, 98-110.	2.0	148
64	nNOS Expression in Reactive Astrocytes Correlates with Increased Cell Death Related DNA Damage in the Hippocampus and Entorhinal Cortex in Alzheimer's Disease. Experimental Neurology, 2000, 165, 12-26.	2.0	102
65	Expression of Human Apolipoprotein E4 in Neurons Causes Hyperphosphorylation of Protein Tau in the Brains of Transgenic Mice. American Journal of Pathology, 2000, 156, 951-964.	1.9	222
66	Morphology of spiny neurons in the human entorhinal cortex: intracellular filling with Lucifer Yellow. Neuroscience, 2000, 96, 515-522.	1.1	10
67	Wnt signaling function in Alzheimer's disease. Brain Research Reviews, 2000, 33, 1-12.	9.1	275
68	Clathrin assembly protein AP-2 is detected in both neurons and glia, and its reduction is prominent in layer II of frontal cortex in Alzheimer's disease. Neurobiology of Aging, 2000, 21, 921-929.	1.5	12
70	Complement Association with Neurons and β-Amyloid Deposition in the Brains of Aged Individuals with Down Syndrome. Neurobiology of Disease, 2001, 8, 252-265.	2.1	89
71	Neuronal subpopulations and genetic background in tauopathies: a catch 22 story?. Neurobiology of Aging, 2001, 22, 115-118.	1.5	9
72	Cdc2 phosphorylation of nucleolin demarcates mitotic stages and Alzheimer's disease pathology. Neurobiology of Aging, 2001, 22, 517-528.	1.5	84
73	MRI of human entorhinal cortex: a reliable protocol for volumetric measurement. Neurobiology of Aging, 2001, 22, 737-745.	1.5	74
74	MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease â~† â~†This research was supported by grants P01 AC09466 and P30 AC10161 from the National Institute on Aging, National Institutes of Health Neurobiology of Aging, 2001, 22, 747-754.	1.5	447

#	Article	IF	CITATIONS
75	Tau and transgenic animal models. Brain Research Reviews, 2001, 35, 266-286.	9.1	142
76	Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2001, 70, 157-164.	0.9	270
77	Dementias. , 2001, , 667-670.		1
78	Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochemical Journal, 2001, 357, 759.	1.7	78
79	Phosphorylation-mimicking glutamate clusters in the proline-rich region are sufficient to simulate the functional deficiencies of hyperphosphorylated tau protein. Biochemical Journal, 2001, 357, 759-767.	1.7	99
80	Canaries in a Coal Mine. Archives of General Psychiatry, 2001, 58, 859.	13.8	26
81	Amyloid, PHF-tau, Ubiquitin and Synaptic Markers in the Progression of Alzheimer's Disease: Immunochemical Analyses of Frontal Cortex from Prospectively Studied Elderly Humans. , 0, , 165-180.		5
82	Clinical Validity of Aß-Protein Deposition Staging in Brain Aging and Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2001, 60, 946-952.	0.9	56
83	MRI of Entorhinal Cortex and Hippocampus in Alzheimer's Disease, Subcortical Ischemic Vascular Dementia and Mixed Dementia. , 0, , 229-236.		2
84	Modeling the time-course of Alzheimer dementia. Current Psychiatry Reports, 2001, 3, 20-28.	2.1	69
85	Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathologica, 2001, 101, 2-8.	3.9	229
86	The autonomic higher order processing nuclei of the lower brain stem are among the early targets of the Alzheimer's disease-related cytoskeletal pathology. Acta Neuropathologica, 2001, 101, 555-564.	3.9	89
87	Cerebral blood flow and metabolic abnormalities in Alzheimer's disease. Annals of Nuclear Medicine, 2001, 15, 85-92.	1.2	195
88	A novel fluorescent method for direct visualization of neurofibrillary pathology in Alzheimer's disease. Journal of Neuroscience Methods, 2001, 111, 17-27.	1.3	7
89	Altered apolipoprotein D expression in the brain of patients with Alzheimer disease. Journal of Neuroscience Research, 2001, 64, 61-69.	1.3	61
90	Apolipoprotein E immunoreactivity in neurons and neurofibrillary degeneration of aged non-demented and alzheimer's disease patients. Microscopy Research and Technique, 2001, 55, 48-58.	1.2	5
91	Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Annals of Neurology, 2001, 49, 355-361.	2.8	256
92	Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Abeta 42 Fibrils. Science, 2001, 293, 1491-1495.	6.0	1,410

#	ARTICLE	IF	CITATIONS
93	Alterations of Striatal Dopamine Receptor Binding in Alzheimer Disease Are Associated With Lewy Body Pathology and Antemortem Psychosis. Archives of Neurology, 2001, 58, 466-72.	4.9	72
94	Hippocampal Plasticity in Alzheimer's Disease. Reviews in the Neurosciences, 2001, 12, 311-25.	1.4	17
95	A double dissociation between accuracy and time of execution on attentional tasks in Alzheimer's disease and multi-infarct dementia. Brain, 2001, 124, 731-738.	3.7	77
96	Frontal MRI Findings Associated with Impairment on the Executive Interview (EXIT25). Experimental Aging Research, 2001, 27, 293-308.	0.6	38
97	Rating of Different Olfactory Judgements in Alzheimer's Disease. Chemical Senses, 2001, 26, 409-417.	1.1	47
98	Early Detection and Differential Diagnosis of Alzheimer's Disease and Depression with Neuropsychological Tasks. Dementia and Geriatric Cognitive Disorders, 2001, 12, 265-280.	0.7	328
99	Stability of the preclinical episodic memory deficit in Alzheimer's disease. Brain, 2001, 124, 96-102.	3.7	362
100	Severe Dysosmia Is Specifically Associated with Alzheimer-Like Memory Deficits in Nondemented Elderly Retirees. Neuroepidemiology, 2002, 21, 68-73.	1.1	71
101	Protein aggregates and dementia: is there a common toxicity?. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 152-161.	0.9	59
102	Cyclin D1 and Cyclin E Are Co-Localized with Cyclo-Oxygenase 2 (COX-2) in Pyramidal Neurons in Alzheimer Disease Temporal Cortex. Journal of Neuropathology and Experimental Neurology, 2002, 61, 678-688.	0.9	102
103	C-Reactive Protein in Ischemic Stroke. Stroke, 2002, 33, 2146-2147.	1.0	8
104	Re: Clinical and Imaging Findings in Cryptogenic Stroke Patients With and Without Patent Foramen Ovale. Stroke, 2002, 33, 2149-2150.	1.0	16
105	Decrements in Nuclear Glucocorticoid Receptor (GR) Protein Levels and DNA Binding in Aged Rat Hippocampus. Endocrinology, 2002, 143, 1362-1370.	1.4	79
106	Selective reduction of <i>N</i> -acetylaspartate in medial temporal and parietal lobes in AD. Neurology, 2002, 58, 928-935.	1.5	132
107	Effects of subcortical ischemic vascular dementia and AD on entorhinal cortex and hippocampus. Neurology, 2002, 58, 1635-1641.	1.5	122
108	Presenile dementia syndromes: an update on taxonomy and diagnosis. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, 691-700.	0.9	75
109	Global Cerebral Edema After Subarachnoid Hemorrhage. Stroke, 2002, 33, 2153-2154.	1.0	9
110	Correlation of Regional Proton Magnetic Resonance Spectroscopic Metabolic Changes With Cognitive Deficits in Mild Alzheimer Disease. Archives of Neurology, 2002, 59, 955.	4.9	84

		CITATION R	EPORT	
#	Article		IF	Citations
111	Alzheimer Disease as a Vascular Disorder: Nosological Evidence. Stroke, 2002, 33, 2147	2148.	1.0	14
112	Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Der Hippocampal Sclerosis in the State of Florida Brain Bank. Alzheimer Disease and Associa 2002, 16, 203-212.	nentia, and ted Disorders,	0.6	568
113	Body Temperature in Acute Stroke. Stroke, 2002, 33, 2154-2155.		1.0	24
114	Pathological Determinants of the Transition to Clinical Dementia in Alzheimer's Disease. Aging Research, 2002, 28, 143-162.	Experimental	0.6	93
115	Niemann-Pick Disease Type C Yields Possible Clue for Why Cerebellar Neurons Do Not Fo Neurofibrillary Tangles. Neurobiology of Disease, 2002, 11, 285-297.	orm	2.1	58
116	Functional neuroimaging in Alzheimer's type dementia. Journal of the Neurological Scier 203-204, 247-251.	ces, 2002,	0.3	24
117	Brain aging and Alzheimer's disease; use it or lose it. Progress in Brain Research, 2002, 1	38, 343-373.	0.9	89
118	The Neural Basis for Categorization in Semantic Memory. NeuroImage, 2002, 17, 1549-2	.561.	2.1	143
119	Olfactory impairment increases as a function of age in persons with Down syndrome. No of Aging, 2002, 23, 65-73.	urobiology	1.5	41
120	Risk Factors for Aneurysmal Subarachnoid Hemorrhage. Stroke, 2002, 33, 2152-2153.		1.0	10
121	Evaluation of Risk Factors for Stroke/Embolism and of Complications Due to Anticoagula Atrial Fibrillation. Stroke, 2002, 33, 2150-2152.	ant Therapy in	1.0	1
122	Recurrent Cerebral Venous Thrombosis in a 24-Year-Old Puerperal Woman. Stroke, 2002	2, 33, 2148-2149.	1.0	4
123	Relationship between attentional performance and corpus callosum morphometry in par Alzheimer's disease. Neuropsychologia, 2002, 40, 946-956.	ients with	0.7	22
124	Corticostriatal circuitry mediates fast-track visual categorization. Cognitive Brain Resear 53-59.	ch, 2002, 13,	3.3	17
125	Comparison of automated and manual MRI volumetry of hippocampus in normal aging a Journal of Magnetic Resonance Imaging, 2002, 16, 305-310.	ınd dementia.	1.9	198
126	Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: N neuronal number for the output, internal relay, and striatal modulating nuclei. Journal of Comparative Neurology, 2002, 445, 238-255.		0.9	223
127	Biological markers of Alzheimer's disease. Drug Development Research, 2002, 56, 74-84		1.4	14
129	Memory functions and rCBF 99mTc-HMPAO SPET: developing diagnostics in Alzheimer's European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 1140-1148.	disease.	3.3	34

#	Article	IF	CITATIONS
130	Disentangling the pathology of schizophrenia and paraphrenia. Acta Neuropathologica, 2002, 103, 313-320.	3.9	39
131	Altered glycosylation of acetylcholinesterase in APP (SW) Tg2576 transgenic mice occurs prior to amyloid plaque deposition. Journal of Neurochemistry, 2002, 81, 441-448.	2.1	41
132	Neuropathological diagnosis of Alzheimer's disease in forensic autopsy of elderly persons with fatal accident. Legal Medicine, 2002, 4, 223-231.	0.6	7
133	Memory deficits in Alzheimer's disease: The encoding hypothesis and cholinergic function. Psychonomic Bulletin and Review, 2002, 9, 426-437.	1.4	54
134	Tau and Axonopathy in Neurodegenerative Disorders. NeuroMolecular Medicine, 2002, 2, 131-150.	1.8	120
135	C-terminal fragments of amyloid-beta peptide cause cholinergic axonal degeneration by a toxic effect rather than by physical injury in the nondemented human brain. Neurochemical Research, 2003, 28, 493-498.	1.6	3
136	Amyloid β plaque-associated proteins C1q and SAP enhance the Aβ1–42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathologica, 2003, 105, 135-144.	3.9	129
137	In vitro metabolism of dehydroepiandrosterone (DHEA) to 7α-hydroxy-DHEA and Δ5-androstene-3β,17β-diol in specific regions of the aging brain from Alzheimer's and non-demented patients. Brain Research, 2003, 969, 117-125.	1.1	89
138	Differences in regional and subcellular localization of Gq/11 and RGS4 protein levels in Alzheimer's disease: Correlation with muscarinic M1 receptor binding parameters. Synapse, 2003, 47, 58-65.	0.6	39
139	Improvement in learning associated with increase in hippocampal formation volume. Biological Psychiatry, 2003, 53, 233-238.	0.7	140
140	Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease. Biological Psychiatry, 2003, 54, 136-141.	0.7	51
141	Preservation of hippocampal pyramidal cells in paraphrenia. Schizophrenia Research, 2003, 62, 141-146.	1.1	7
142	Subicular Dendritic Arborization in Alzheimer's Disease Correlates with Neurofibrillary Tangle Density. American Journal of Pathology, 2003, 163, 1615-1621.	1.9	76
143	A reliable MR measurement of medial temporal lobe width from the Sunnybrook Dementia Study. Neurobiology of Aging, 2003, 24, 49-56.	1.5	30
144	Comparison of methods for measuring longitudinal brain change in cognitive impairment and dementia. Neurobiology of Aging, 2003, 24, 537-544.	1.5	87
145	MR spectroscopy in Alzheimer's disease: gender differences in probabilistic learning capacity. Neurobiology of Aging, 2003, 24, 545-552.	1.5	31
146	Ultrastructural and behavioural changes precede amyloid deposition in a transgenic model of Alzheimer's disease. Neuroscience, 2003, 122, 213-228.	1.1	80
147	Hyperphosphorylated tau and paired helical filament-like structures in the brains of mice carrying mutant amyloid precursor protein and mutant presenilin-1 transgenes. Neurobiology of Disease, 2003, 14, 89-97.	2.1	94

#	Article	IF	CITATIONS
148	The Diagnosis of Alzheimer Disease Before It Is Alzheimer Dementia. Archives of Neurology, 2003, 60, 1023.	4.9	8
149	Decline in Learning Ability Best Predicts Future Dementia Type: The Freedom House Study. Experimental Aging Research, 2003, 29, 385-406.	0.6	19
150	Atrophy rates of entorhinal cortex in AD and normal aging. Neurology, 2003, 60, 481-486.	1.5	165
151	Homogeneity and heterogeneity in mild cognitive impairment and Alzheimer's disease: a crossâ€sectional and longitudinal study of 55 cases. Brain, 2003, 126, 2350-2362.	3.7	197
152	Role of cdk5 in the Pathogenesis of Alzheimer's Disease. NeuroSignals, 2003, 12, 209-214.	0.5	54
153	The Amyloid Hypothesis and the clearance and degradation of Alzheimer's β-peptide. Journal of Alzheimer's Disease, 2004, 6, 303-314.	1.2	22
154	Neuropathologic Correlates of Late-Onset Major Depression. Neuropsychopharmacology, 2004, 29, 2242-2250.	2.8	96
155	Early N-Terminal Changes and Caspase-6 Cleavage of Tau in Alzheimer's Disease. Journal of Neuroscience, 2004, 24, 7895-7902.	1.7	199
156	The Parahippocampal Gyrus in the Baboon: Anatomical, Cytoarchitectonic and Magnetic Resonance Imaging (MRI) Studies. Cerebral Cortex, 2004, 14, 231-246.	1.6	22
157	Animal models of tau phosphorylation and tauopathy – what have they taught us?. Advances in Cell Aging and Gerontology, 2004, 16, 153-175.	0.1	0
158	Post mortem sampling of the brain and other tissues in neurodegenerative disease. Histopathology, 2004, 44, 309-317.	1.6	28
159	Multiple cognitive deficits during the transition to Alzheimer's disease. Journal of Internal Medicine, 2004, 256, 195-204.	2.7	241
160	Abnormal fronto-parietal coupling of brain rhythms in mild Alzheimer's disease: a multicentric EEG study. European Journal of Neuroscience, 2004, 19, 2583-2590.	1.2	137
161	Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy. Molecular Psychiatry, 2004, 9, 664-683.	4.1	248
162	Age and ApoE genotype interaction in Alzheimer's disease: an FDG-PET study. Psychiatry Research - Neuroimaging, 2004, 130, 141-151.	0.9	39
163	Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Research, 2004, 1003, 26-35.	1.1	92
164	Delayed recall, hippocampal volume and Alzheimer neuropathology. Neurology, 2004, 62, 428-432.	1.5	82
165	Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology, 2004, 63, 1168-1174.	1.5	554

#	Article	IF	CITATIONS
166	Induction of Dickkopf-1, a Negative Modulator of the Wnt Pathway, Is Associated with Neuronal Degeneration in Alzheimer's Brain. Journal of Neuroscience, 2004, 24, 6021-6027.	1.7	337
167	Cognitive Functioning in Aging and Dementia: The Kungsholmen Project. Aging, Neuropsychology, and Cognition, 2004, 11, 212-244.	0.7	44
169	Quantitative EEG and perfusional single photon emission computed tomography correlation during long-term donepezil therapy in Alzheimer's disease. Clinical Neurophysiology, 2004, 115, 39-49.	0.7	47
170	Towards defining the neuropathological substrates of vascular dementia. Journal of the Neurological Sciences, 2004, 226, 75-80.	0.3	252
171	Signal transduction during amyloid-β-peptide neurotoxicity: role in Alzheimer disease. Brain Research Reviews, 2004, 47, 275-289.	9.1	121
172	MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiology of Aging, 2004, 25, 1197-1203.	1.5	303
173	Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. Neurobiology of Aging, 2004, 25, 685-691.	1.5	75
174	Expression of the Small Heat-Shock Protein αB-Crystallin in Tauopathies with Glial Pathology. American Journal of Pathology, 2004, 164, 155-166.	1.9	112
175	Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. Neurobiology of Disease, 2004, 15, 492-499.	2.1	57
176	Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer?s disease. Neurochemistry International, 2004, 45, 583-595.	1.9	782
177	Dementia severity and Lewy bodies affect circadian rhythms in Alzheimer disease. Neurobiology of Aging, 2004, 25, 771-781.	1.5	105
178	Amyloidâ€induced neurofibrillary tangle formation in Alzheimer's disease: insight from transgenic mouse and tissueâ€culture models. International Journal of Developmental Neuroscience, 2004, 22, 453-465.	0.7	122
179	The role of GSK-3beta in the formation of neurofibrillary tangles. Psychogeriatrics, 2004, 4, S51-S56.	0.6	1
180	Activation in the premotor cortex during mental calculation in patients with Alzheimer's disease: relevance of reduction in posterior cingulate metabolism. NeuroImage, 2004, 22, 155-163.	2.1	16
181	Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease. Neurobiology of Aging, 2004, 25, 63-69.	1.5	108
182	Linear width of the medial temporal lobe can discriminate Alzheimer's disease from normal aging: the Sunnybrook Dementia Study. Neurobiology of Aging, 2004, 25, 441-448.	1.5	17
183	Pathological Aging of the Brain. Topics in Magnetic Resonance Imaging, 2004, 15, 369-389.	0.7	60
184	MR diffusion tensor imaging (DTI) and neuropsychological testing for neuronal connectivity in Alzheimer's disease (AD) patients. , 2004, 5369, 238.		3

#	Article	IF	CITATIONS
185	Hippocampal volume and retention in Alzheimer's disease. Journal of the International Neuropsychological Society, 2004, 10, 639-643.	1.2	72
186	Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology, 2004, 62, 422-427.	1.5	182
187	Pathology of the Insular Cortex in Alzheimer Disease Depends on Cortical Architecture. Journal of Neuropathology and Experimental Neurology, 2005, 64, 910-922.	0.9	87
188	Effects of Apolipoprotein E Genotype on Spatial Attention, Working Memory, and Their Interaction in Healthy, Middle-Aged Adults: Results From the National Institute of Mental Health's BIOCARD Study Neuropsychology, 2005, 19, 199-211.	1.0	153
189	Prostaglandin H2-derived adducts of proteins correlate with Alzheimer's disease severity. Journal of Neurochemistry, 2005, 94, 1140-1145.	2.1	60
190	Effects of Aβ1â~'42 fibrils and of the tetrapeptide Pr-IIGL on the phosphorylation state of the Ï"-protein and on the α7 nicotinic acetylcholine receptor in vitro. European Journal of Neuroscience, 2005, 21, 879-888.	1.2	9
191	The novel cytosolic RING finger protein dactylidin is up-regulated in brains of patients with Alzheimer's disease. European Journal of Neuroscience, 2005, 21, 1289-1298.	1.2	19
192	Novel 'inflammatory plaque' pathology in presenilin-1 Alzheimer's disease. Neuropathology and Applied Neurobiology, 2005, 31, 503-511.	1.8	19
193	Creutzfeldt-Jakob disease in a patient with an R208H mutation of the prion protein gene (PRNP) and a 17-kDa prion protein fragment. Acta Neuropathologica, 2005, 109, 443-448.	3.9	29
194	Stereological studies of capillary length density in the frontal cortex of schizophrenics. Acta Neuropathologica, 2005, 109, 510-518.	3.9	66
195	Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and α-synuclein pathology. Acta Neuropathologica, 2005, 110, 135-144.	3.9	57
196	The unfolded protein response is activated in Alzheimer's disease. Acta Neuropathologica, 2005, 110, 165-172.	3.9	488
197	Depth of word processing in Alzheimer patients and normal controls: a magnetoencephalographic (MEG) study. Journal of Neural Transmission, 2005, 112, 713-730.	1.4	26
198	MRI predictors of risk of incident Alzheimer disease: A longitudinal study. Neurology, 2005, 64, 1520-1524.	1.5	185
199	Borna Disease Virus Replication in Organotypic Hippocampal Slice Cultures from Rats Results in Selective Damage of Dentate Granule Cells. Journal of Virology, 2005, 79, 11716-11723.	1.5	30
200	Truncation and Activation of Calcineurin A by Calpain I in Alzheimer Disease Brain. Journal of Biological Chemistry, 2005, 280, 37755-37762.	1.6	150
201	Effects of AÂ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology, 2005, 64, 1563-1572.	1.5	527
202	Cognitive impairment in preclinical Alzheimer's disease: A meta-analysis Neuropsychology, 2005, 19, 520-531.	1.0	592

#	Article	IF	CITATIONS
203	Conceptualizing communication enhancement in dementia for family caregivers using the WHO- <i>ICF</i> framework. International Journal of Speech-Language Pathology, 2005, 7, 187-202.	0.5	33
204	Advanced Glycation End Products Enhance Expression of Pro-apoptotic Genes and Stimulate Fibroblast Apoptosis through Cytoplasmic and Mitochondrial Pathways. Journal of Biological Chemistry, 2005, 280, 12087-12095.	1.6	175
205	Neuropathological investigation of dementia: a guide for neurologists. Journal of Neurology, Neurosurgery and Psychiatry, 2005, 76, v8-v14.	0.9	53
206	Referential Communication in Alzheimer's Type Dementia. Cortex, 2005, 41, 520-534.	1.1	74
207	Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease. Clinical Neurophysiology, 2005, 116, 364-375.	0.7	51
208	Verbal episodic memory impairment in Alzheimer's disease: a combined structural and functional MRI study. NeuroImage, 2005, 25, 253-266.	2.1	177
209	A Clinical Perspective of Mild Cognitive Impairment: What Radiologists Should Know. Neuroimaging Clinics of North America, 2005, 15, 779-788.	0.5	3
210	Pseudo-phosphorylation of tau at Ser202 and Thr205 affects tau filament formation. Molecular Brain Research, 2005, 138, 84-93.	2.5	75
211	Can a herpes simplex virus type 1 neuroinvasive score be correlated to other risk factors in Alzheimer's disease?. Medical Hypotheses, 2005, 64, 320-327.	0.8	14
212	Tau protein as a differential biomarker of tauopathies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1739, 179-197.	1.8	262
213	Mean cell spacing abnormalities in the neocortex of patients with schizophrenia. Psychiatry Research, 2005, 133, 1-12.	1.7	28
214	Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. Journal of Neuroinflammation, 2005, 2, 23.	3.1	213
215	Phenomenological Model of Diffuse Global and Regional Atrophy Using Finite-Element Methods. IEEE Transactions on Medical Imaging, 2006, 25, 1417-1430.	5.4	32
217	Validation Study of the Three-Objects-Three-Places Test: A Screening Test for Alzheimer's Disease. Experimental Aging Research, 2006, 32, 395-410.	0.6	14
218	Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Brain, 2006, 130, 1159-1166.	3.7	391
219	Declarative memory impairments in Alzheimer's disease and semantic dementia. NeuroImage, 2006, 30, 1010-1020.	2.1	343
220	N-Terminal Fragments of Tau Inhibit Full-Length Tau Polymerization in Vitroâ€. Biochemistry, 2006, 45, 12859-12866.	1.2	68
221	Measures of cognitive and emotional changes in multiple sclerosis and underlying models of brain dysfunction. Journal of the Neurological Sciences, 2006, 245, 15-20.	0.3	11

#	Article	IF	CITATIONS
222	Reduced hippocampal volume in non-demented carriers of the apolipoprotein E ɛ4: Relation to chronological age and recognition memory. Neuroscience Letters, 2006, 396, 23-27.	1.0	112
223	Lower levels of cerebrospinal fluid amyloid ß (Aß) in non-demented Indian controls. Neuroscience Letters, 2006, 407, 121-123.	1.0	6
224	Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. International Journal of Developmental Neuroscience, 2006, 24, 157-165.	0.7	142
225	A comparison of immunohistochemical and silver staining methods for the detection of diffuse plaques in the aged canine brain. Neurobiology of Aging, 2006, 27, 293-305.	1.5	51
226	Similarities between CSF–brain extracellular transfer and neurofibrillary tangle invasion in Alzheimer's disease. Neurobiology of Aging, 2006, 27, 402-412.	1.5	2
227	White matter changes in mild cognitive impairment and AD: A diffusion tensor imaging study. Neurobiology of Aging, 2006, 27, 663-672.	1.5	423
228	In vivo MRI and histological evaluation of brain atrophy in APP/PS1 transgenic mice. Neurobiology of Aging, 2006, 27, 835-847.	1.5	91
229	Associative and motor learning in 12-month-old transgenic APP+PS1 mice. Neurobiology of Aging, 2006, 27, 1118-1128.	1.5	47
230	Regionally specific atrophy of the corpus callosum in AD, MCI and cognitive complaints. Neurobiology of Aging, 2006, 27, 1613-1617.	1.5	99
231	Vascular determinants of cholinergic deficits in Alzheimer disease and vascular dementia. Neurobiology of Aging, 2006, 27, 1769-1785.	1.5	181
232	Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behavioural Pharmacology, 2006, 17, 411-424.	0.8	118
233	Formation of Phospho-SAPK/JNK Granules in the Hippocampus Is an Early Event in Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2006, 65, 455-464.	0.9	59
234	Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease. Journal of the International Neuropsychological Society, 2006, 12, 707-735.	1.2	210
235	Posterior Cingulate Neurometabolite Profiles and Clinical Phenotype in Frontotemporal Dementia. Cognitive and Behavioral Neurology, 2006, 19, 185-189.	0.5	12
236	Cytoskeletal Transport in the Aging Brain: Focus on the Cholinergic System. Reviews in the Neurosciences, 2006, 17, 581-618.	1.4	19
237	Reduction of Neuronal Intranuclear Rodlets Immunoreactive for Tubulin and Glucocorticoid Receptor in Alzheimer's Disease. Brain Pathology, 2002, 12, 300-307.	2.1	26
238	The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. Journal of Neurochemistry, 2006, 96, 635-644.	2.1	123
239	Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. Journal of Neurochemistry, 2006, 97, 1005-1014.	2.1	143

#	Article	IF	CITATIONS
240	From Healthy Aging to Early Alzheimer's Disease: <i>In Vivo</i> Detection of Entorhinal Cortex Atrophy. Annals of the New York Academy of Sciences, 2000, 911, 240-253.	1.8	188
241	<i>In Vivo</i> Analysis of Wildâ€ŧype and FTDPâ€┨7 Tau Transgenic Mice. Annals of the New York Academy of Sciences, 2000, 920, 126-133.	1.8	23
242	Quantification of Alzheimer pathology in ageing and dementia: age-related accumulation of amyloid-beta(42) peptide in vascular dementia. Neuropathology and Applied Neurobiology, 2006, 32, 103-118.	1.8	131
243	Auditory event-related potentials in subcortical vascular cognitive impairment and in Alzheimer's disease. Journal of Neural Transmission, 2006, 113, 1779-1786.	1.4	31
244	The significance of neuroinflammation in understanding Alzheimer's disease. Journal of Neural Transmission, 2006, 113, 1685-1695.	1.4	243
245	Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathologica, 2006, 112, 389-404.	3.9	2,318
246	Relation of hippocampal phospho-SAPK/JNK granules in Alzheimer's disease and tauopathies to granulovacuolar degeneration bodies. Acta Neuropathologica, 2006, 113, 63-73.	3.9	38
247	Imaging Alzheimer's disease pathology: one target, many ligands. Drug Discovery Today, 2006, 11, 1093-1099.	3.2	57
248	Diagnosing prodromal Alzheimer's disease: Role of CSF biochemical markers. Mechanisms of Ageing and Development, 2006, 127, 129-132.	2.2	93
249	Population-based neuropathological studies of dementia: design, methods and areas of investigation – a systematic review. BMC Neurology, 2006, 6, 2.	0.8	97
250	Anterior-medial thalamic lesions in dementia: frequent, and volume dependently associated with sudden cognitive decline. Journal of Neurology, Neurosurgery and Psychiatry, 2006, 77, 1307-1312.	0.9	37
251	Genetically Modified Mice Models for Alzheimers Disease. Current Topics in Medicinal Chemistry, 2006, 6, 609-627.	1.0	14
252	Reduction of Aβ Levels in the Sprague Dawley Rat After Oral Administration of the Functional g-Secretase Inhibitor, DAPT: A Novel Non- Transgenic Model for Aβ Production Inhibitors. Current Pharmaceutical Design, 2006, 12, 671-676.	0.9	39
253	Neuroprotective Therapies for Alzheimers Disease. Current Pharmaceutical Design, 2006, 12, 705-717.	0.9	38
254	Heterogeneity in Executive Impairment in Patients with Very Mild Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2006, 22, 54-59.	0.7	48
255	Alzheimer's centennial legacy: origins, landmarks and the current status of knowledge concerning cognitive aspects. Brain, 2006, 129, 2811-2822.	3.7	175
256	Therapeutic approaches to Alzheimer's disease. Brain, 2006, 129, 2840-2855.	3.7	310
257	DNA Polymerase-beta Is Expressed Early in Neurons of Alzheimer's Disease Brain and Is Loaded into DNA Replication Forks in Neurons Challenged with beta-Amyloid. Journal of Neuroscience, 2006, 26, 10949-10957	1.7	76

#	Article	IF	CITATIONS
258	An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 9673-9678.	3.3	206
259	Hippocampal disconnection contributes to memory dysfunction in individuals at risk for Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10041-10045.	3.3	167
260	Properties of glutamate receptors of Alzheimer's disease brain transplanted to frog oocytes. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 2956-2960.	3.3	27
261	Neuropathology and treatment of Alzheimer disease: did we lose the forest for the trees?. Expert Review of Neurotherapeutics, 2007, 7, 473-485.	1.4	41
262	Neurophysiologic analyses of low- and high-level visual processing in Alzheimer disease. Neurology, 2007, 68, 2066-2076.	1.5	46
263	Volume, neuron density and total neuron number in five subcortical regions in schizophrenia. Brain, 2007, 130, 678-692.	3.7	167
264	Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology, 2007, 69, 2205-2212.	1.5	133
265	Sp3 and Sp4 Transcription Factor Levels Are Increased in Brains of Patients with Alzheimer's Disease. Neurodegenerative Diseases, 2007, 4, 413-423.	0.8	33
266	Advanced glycation end products induce apoptosis in fibroblasts through activation of ROS, MAP kinases, and the FOXO1 transcription factor. American Journal of Physiology - Cell Physiology, 2007, 292, C850-C856.	2.1	141
267	Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort. Journal of Neuropathology and Experimental Neurology, 2007, 66, 1136-1146.	0.9	258
268	Preserved Implicit Memory in Dementia: A Potential Model for Care. American Journal of Alzheimer's Disease and Other Dementias, 2007, 22, 286-293.	0.9	69
269	Subcortical Hyperintensities in Alzheimer's Disease: No Clear Relationship with Executive Function and Frontal Perfusion on SPECT. Dementia and Geriatric Cognitive Disorders, 2007, 24, 380-388.	0.7	7
270	Functional plasticity in cognitive aging: Review and hypothesis Neuropsychology, 2007, 21, 657-673.	1.0	276
271	Tau protein abnormalities associated with the progression of alzheimer disease type dementia. Neurobiology of Aging, 2007, 28, 1-7.	1.5	77
272	Alzheimer' s disease, oxidative stress and gammahydroxybutyrate. Neurobiology of Aging, 2007, 28, 1340-1360.	1.5	103
273	Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?. Neurobiology of Aging, 2007, 28, 1465-1480.	1.5	124
274	Distinct Memory Profiles in Alzheimer's Disease. Cortex, 2007, 43, 846-857.	1.1	48
275	Deterioration of Visual-Perceptual Organization Ability in Alzheimer's Disease. Cortex, 2007, 43, 967-975.	1.1	41

#	Article	IF	CITATIONS
277	Polyfluorinated Bis-styrylbenzene β-Amyloid Plaque Binding Ligands. Journal of Medicinal Chemistry, 2007, 50, 4986-4992.	2.9	63
278	Small molecule inhibitors of A beta assembly. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2007, 14, 185-197.	1.4	59
280	A Functional Magnetic Resonance Imaging Study of Amygdala Responses to Human Faces in Aging and Mild Alzheimer's Disease. Biological Psychiatry, 2007, 62, 1388-1395.	0.7	82
281	Hippocampal atrophy and disconnection in incipient and mild Alzheimer's disease. Progress in Brain Research, 2007, 163, 741-823.	0.9	64
282	Morphology and ontogeny of rat perirhinal cortical neurons. Journal of Comparative Neurology, 2007, 505, 493-510.	0.9	31
283	Sequential expression of cell-cycle regulators and Alzheimer's disease–related proteins in entorhinal cortex after hippocampal excitotoxic damage. Journal of Neuroscience Research, 2007, 85, 1744-1751.	1.3	32
284	Relationship between neuronal loss and ?inflammatory plaques? in early onset Alzheimer's disease. Neuropathology and Applied Neurobiology, 2007, 33, 328-333.	1.8	11
285	Rab6 is increased in Alzheimer's disease brain and correlates with endoplasmic reticulum stress. Neuropathology and Applied Neurobiology, 2007, 33, 070615152525001-???.	1.8	60
286	Modulation of hippocampal calcium signalling and plasticity by serine/threonine protein phosphatases. Journal of Neurochemistry, 2007, 102, 1009-1023.	2.1	28
287	Downâ€regulation of cAMPâ€dependent protein kinase by overâ€activated calpain in Alzheimer disease brain. Journal of Neurochemistry, 2007, 103, 2462-2470.	2.1	123
288	Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. Journal of Pineal Research, 2007, 43, 404-409.	3.4	135
289	Abnormal processing of tau in the brain of aged TgCRND8 mice. Neurobiology of Disease, 2007, 27, 328-338.	2.1	61
290	Neuroprotective Mechanisms: Oxidative Stress as a Target for Neuroprotective Therapies in Alzheimer's and Parkinson's Disease. , 2007, , 77-102.		2
291	Magnetic resonance imaging of Alzheimer's disease. European Radiology, 2007, 17, 347-362.	2.3	61
292	Gene Expression Alterations in the Sphingolipid Metabolism Pathways during Progression of Dementia and Alzheimer's Disease: A Shift Toward Ceramide Accumulation at the Earliest Recognizable Stages of Alzheimer's Disease?. Neurochemical Research, 2007, 32, 845-856.	1.6	213
293	In Vitro Imaging Techniques in Neurodegenerative Diseases. Molecular Imaging and Biology, 2007, 9, 161-175.	1.3	28
294	Assessing the cognitive impact of Alzheimer disease pathology and vascular burden in the aging brain: the Geneva experience. Acta Neuropathologica, 2007, 113, 1-12.	3.9	94
295	Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathologica, 2007, 113, 389-402.	3.9	76

		CITATION REPORT		
#	Article		IF	CITATIONS
296	Phosphorylation and cleavage of tau in non-AD tauopathies. Acta Neuropathologica, 20	07, 113, 513-520.	3.9	60
297	Metabolic correlates of executive dysfunction. Journal of Neurology, 2007, 254, 1052-1	065.	1.8	29
298	Immunoreactivities and Levels of Mineralocorticoid and Glucocorticoid Receptors in the CA1 Region and Dentate Gyrus of Adult and Aged Dogs. Neurochemical Research, 2008	Hippocampal 3, 33, 562-568.	1.6	9
299	Neuropsychological Contributions to the Early Identification of Alzheimer's Disease Neuropsychology Review, 2008, 18, 73-90.		2.5	166
300	Individual cerebral metabolic deficits in Alzheimer's disease and amnestic mild cogn an FDG PET study. European Journal of Nuclear Medicine and Molecular Imaging, 2008,	itive impairment: 35, 1357-1366.	3.3	97
301	Oligomeric and fibrillar species of β-amyloid (Aβ42) both impair mitochondrial functior transgenic mice. Journal of Molecular Medicine, 2008, 86, 1255-1267.	in P301L tau	1.7	123
303	Increased EEG gamma band activity in Alzheimer's disease and mild cognitive impai Neural Transmission, 2008, 115, 1301-1311.	rment. Journal of	1.4	133
304	Phosphorylated tau in neuritic plaques of APPsw/Tauvlw transgenic mice and Alzheimer Neuropathologica, 2008, 116, 409-418.	disease. Acta	3.9	20
305	Differential MRI patterns of brain atrophy in double or single transgenic mice for APP ar Journal of Neuroscience Research, 2008, 86, 3275-3284.	ıd/or SOD.	1.3	37
306	Motion tracking of the outer tips of microtubules. Medical Image Analysis, 2008, 12, 68	9-702.	7.0	22
307	Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transge Brain Research, 2008, 1216, 92-103.	nic model.	1.1	239
308	Fatty acids, lipid metabolism and Alzheimer pathology. European Journal of Pharmacolo 176-196.	gy, 2008, 585,	1.7	94
309	Accumulation of nuclear DNA damage or neuron loss: Molecular basis for a new approa understanding selective neuronal vulnerability in neurodegenerative diseases. DNA Rep 1087-1097.		1.3	65
310	C4b-binding protein in Alzheimer's disease: Binding to Aβ1–42 and to dead cells. Mo 2008, 45, 3649-3660.	lecular Immunology,	1.0	46
311	Network dysfunction in Alzheimer's disease: does synaptic scaling drive disease progres in Molecular Medicine, 2008, 14, 103-108.	sion?. Trends	3.5	78
312	Quantitative EEG in early Alzheimer's disease patients — Power spectrum and comple International Journal of Psychophysiology, 2008, 68, 75-80.	xity features.	0.5	128
313	Decreased amplitude of auditory event-related delta responses in Alzheimer's disease. In Journal of Psychophysiology, 2008, 70, 23-32.	nternational	0.5	61
314	Automated cortical thickness measurements from MRI can accurately separate Alzheim from normal elderly controls. Neurobiology of Aging, 2008, 29, 23-30.	er's patients	1.5	242

#	Article	IF	CITATIONS
315	No disease in the brain of a 115-year-old woman. Neurobiology of Aging, 2008, 29, 1127-1132.	1.5	69
316	Neurofibrillary changes of the Alzheimer type in very elderly individuals: Neither inevitable nor benign. Neurobiology of Aging, 2008, 29, 1133-1136.	1.5	24
317	Neuronal distribution in the neocortex of schizophrenic patients. Psychiatry Research, 2008, 158, 267-277.	1.7	33
318	Tau kinase inhibitors protect hippocampal synapses despite of insoluble tau accumulation. Molecular and Cellular Neurosciences, 2008, 37, 559-567.	1.0	14
319	Variability in cognitive presentation of Alzheimer's disease. Cortex, 2008, 44, 185-195.	1.1	108
320	Retinal tau pathology in human glaucomas. Canadian Journal of Ophthalmology, 2008, 43, 53-60.	0.4	106
321	THE COMBINATION OF SILVER TECHNIQUES FOR STUDYING THE PATHOLOGY OF ALZHEIMER'S DISEASE. International Journal of Neuroscience, 2008, 118, 257-266.	0.8	7
322	Fully automatic hippocampus segmentation discriminates between early Alzheimer's disease and normal aging. , 2008, , .		11
323	Executive Dysfunction and Neuropsychological Testing. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 35-52.	1.0	9
324	Patterns and stages of α-synucleinopathy. Neurology, 2008, 70, 1042-1048.	1.5	226
325	A Neuronal Microtubule-Interacting Agent, NAPVSIPQ, Reduces Tau Pathology and Enhances Cognitive Function in a Mouse Model of Alzheimer's Disease. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 146-153.	1.3	214
326	Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview. , 2007, , 1-24.		5
327	Discrimination between Alzheimer Disease, Mild Cognitive Impairment, and Normal Aging by Using Automated Segmentation of the Hippocampus. Radiology, 2008, 248, 194-201.	3.6	233
328	Nature or nurture. Neurology, 2008, 70, 1725-1727.	1.5	4
329	Inflammatory Mediators in the Frontal Lobe of Patients with Mixed and Vascular Dementia. Dementia and Geriatric Cognitive Disorders, 2008, 25, 278-286.	0.7	30
330	Reaction Times and Performance Variability in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology, 2008, 21, 204-218.	1.2	112
331	Education, cognitive function, and severity of neuropathology in Alzheimer disease. Neurology, 2008, 70, 1732-1739.	1.5	91
332	Memory profiling with paired associate learning in Alzheimer's disease, mild cognitive impairment, and healthy aging Neuropsychology, 2008, 22, 718-728.	1.0	18

ARTICLE IF CITATIONS Chapter 5.4 Memory and cognitive performance in preclinical Alzheimer's disease and preclinical 333 0.7 1 vascular disease. Handbook of Behavioral Neuroscience, 2008, 18, 537-551. Cyclooxygenase-1 and -2 in the Different Stages of Alzheimers Disease Pathology. Current 334 128 Pharmaceutical Design, 2008, 14, 1419-1427. Interaction of Neuritic Plaques and Education Predicts Dementia. Alzheimer Disease and Associated 335 0.6 28 Disorders, 2008, 22, 188-193. Alzheimer disease neuropathology:understanding autonomic dysfunction. Dementia E Neuropsychologia, 2008, 2, 183-191. 336 0.3 Diffusion tensor imaging investigations in Alzheimer's disease: the resurgence of white 337 matter compromise in the cortical dysfunction of the aging brain. Neuropsychiatric Disease 1.0 47 and Treatment, 2008, 4, 737. An update on the toxicity of Aβ in Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2008, 4, 1033. 1.0 Memory and Cognition in Preclinical Dementia: What We Know and What We Do Not Know. Canadian 339 0.9 39 Journal of Psychiatry, 2008, 53, 354-360. Melatonin, aging, and Alzheimer's disease., 0, , 97-106. 340 In Vitro Evidence for Competitive TSPO Binding of the Imaging Biomarker Candidates Vinpocetine and 341 Two lodinated DAA1106 Analogues in Post Mortem Autoradiography Experiments on Whole Hemisphere 0.3 4 Human Brain Slices. Current Radiopharmaceuticals, 2009, 2, 42-48. Diffusion Tensor Imaging in Alzheimer's Disease and Mild Cognitive Impairment. Behavioural 342 1.1 192 Neurology, 2009, 21, 39-49. Neuropathology of dementia., 0,, 142-160. 343 2 Familial FTDP-17 Missense Mutations Inhibit Microtubule Assembly-promoting Activity of Tau by Increasing Phosphorylation at Ser202 in Vitro. Journal of Biological Chemistry, 2009, 284, 13422-13433. 344 1.6 38 Alzheimer Abnormalities of the Amygdala With Klüver-Bucy Syndrome Symptoms. Archives of 345 4.9 28 Neurology, 2009, 66, 125-9. Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's 346 3.7 disease. Brain, 2009, 132, 1820-1832. Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding 347 0.2 80 to microtubules. FASEB Journal, 2009, 23, 1146-1152. Single- and Multiple-Domain Amnestic Mild Cognitive Impairment: Two Sides of the Same Coin. Dementia 348 and Geriatric Cognitive Disorders, 2009, 28, 541-549. Large Vessel Cerebral Atherosclerosis Is Not in Direct Association with Neuropathological Lesions of 349 0.6 34 Alzheimer's Disease. European Neurology, 2009, 62, 93-98. Patterns of Cortical Thickness according to APOE Genotype in Alzheimer's Disease. Dementia and 38 Geriatric Cognitive Disorders, 2009, 28, 461-470.

#	Article	IF	CITATIONS
351	Brains With Medial Temporal Lobe Neurofibrillary Tangles But No Neuritic Amyloid Plaques Are a Diagnostic Dilemma But May Have Pathogenetic Aspects Distinct From Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2009, 68, 774-784.	0.9	92
352	Increased binding to 5-HT1A and 5-HT2A receptors is associated with large vessel infarction and relative preservation of cognition. Brain, 2009, 132, 1858-1865.	3.7	32
353	Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8332-8337.	3.3	113
354	Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neurology, 2009, 72, 354-360.	1.5	136
355	Measurement of ERK 1/2 in CSF from Patients with Neuropsychiatric Disorders and Evidence for the Presence of the Activated Form. Journal of Alzheimer's Disease, 2009, 18, 613-622.	1.2	18
356	Memory performance is related to amyloid and tau pathology in the hippocampus. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 715-721.	0.9	30
357	Discrete dynamic Bayesian network analysis of fMRI data. Human Brain Mapping, 2009, 30, 122-137.	1.9	51
358	Entorhinal cortex structure and functional MRI response during an associative verbal memory task. Human Brain Mapping, 2009, 30, 3981-3992.	1.9	37
359	Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI. Hippocampus, 2009, 19, 579-587.	0.9	283
360	Cytomorphologic manifestations of Alzheimer's disease using brain squash smears: An autopsy study with histology–cytology correlation. Diagnostic Cytopathology, 2009, 37, 654-660.	0.5	2
361	Boom in the development of nonâ€peptidic βâ€secretase (BACE1) inhibitors for the treatment of Alzheimer's disease. Medicinal Research Reviews, 2009, 29, 295-338.	5.0	120
362	Evidence of angiogenic vessels in Alzheimer's disease. Journal of Neural Transmission, 2009, 116, 587-597.	1.4	126
363	Co-localization of hyperphosphorylated tau and caspases in the brainstem of Alzheimer's disease patients. Biogerontology, 2009, 10, 457-469.	2.0	34
364	A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathologica, 2009, 118, 505-517.	3.9	41
365	Dysregulation of Calcium Homeostasis in Alzheimer's Disease. Neurochemical Research, 2009, 34, 1824-1829.	1.6	94
366	Memory for Music in Alzheimer's Disease: Unforgettable?. Neuropsychology Review, 2009, 19, 85-101.	2.5	142
367	Small-Molecule Mediated Neuroprotection in an In Situ Model of Tauopathy. Neurotoxicity Research, 2009, 15, 274-283.	1.3	20
368	Support vector machine-based classification of Alzheimer's disease from whole-brain anatomical MRI. Neuroradiology, 2009, 51, 73-83.	1.1	409

		CITATION RE	PORT	
#	Article		IF	CITATIONS
369	The role of tau in neurodegeneration. Molecular Neurodegeneration, 2009, 4, 13.		4.4	353
370	An unusual cause of dysphagia and dysarthria. Neuropathology and Applied Neurobiolog 218-221.	y, 2009, 35,	1.8	1
371	Brain glucose transporters, <i>O</i> â€GlcNAcylation and phosphorylation of tau in diabe Alzheimer's disease. Journal of Neurochemistry, 2009, 111, 242-249.	etes and	2.1	167
372	Computational selection of inhibitors of $A^{\hat{l}2}$ aggregation and neuronal toxicity. Bioorgani Medicinal Chemistry, 2009, 17, 5189-5197.	c and	1.4	36
373	Genetic Control of Human Brain Transcript Expression in Alzheimer Disease. American Jou Human Genetics, 2009, 84, 445-458.	ırnal of	2.6	290
374	The Hygiene Hypothesis and Darwinian Medicine. , 2009, , .			23
375	Ubiquitination and cysteine nitrosylation during aging and Alzheimer's disease. Brain Res Bulletin, 2009, 80, 233-241.	earch	1.4	59
376	An MRI-based method for measuring volume, thickness and surface area of entorhinal, pe posterior parahippocampal cortex. Neurobiology of Aging, 2009, 30, 420-431.	rirhinal, and	1.5	56
377	Neural correlates of incidental memory in mild cognitive impairment: An fMRI study. Neu Aging, 2009, 30, 717-730.	obiology of	1.5	57
378	Progressive impairment in olfactory working memory in a mouse model of Mild Cognitive Neurobiology of Aging, 2009, 30, 1430-1443.	Impairment.	1.5	55
379	Rck/p54 interacts with APP mRNA as part of a multi-protein complex and enhances APP n protein expression in neuronal cell lines. Neurobiology of Aging, 2009, 30, 1962-1974.	וRNA and	1.5	12
380	Assessing neuronal networks: Understanding Alzheimer's disease. Progress in Neurobiolo 125-133.	gy, 2009, 89,	2.8	109
381	Cognitive archaeology: Uses, methods, and results. Journal of Neurolinguistics, 2009, 22,	250-265.	0.5	19
382	A comparative autoradiography study in post mortem whole hemisphere human brain sliv Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogue affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochemistry Internat 54, 28-36.	es with high	1.9	66
383	Levels of soluble and insoluble tau reflect overall status of tau phosphorylation in vivo. Neuroscience Letters, 2009, 450, 51-55.		1.0	12
384	Absent gender differences of hippocampal atrophy in amnestic type mild cognitive impai Neuroscience Letters, 2009, 450, 85-89.	rment.	1.0	25
385	Abnormal white matter independent of hippocampal atrophy in amnestic type mild cogn impairment. Neuroscience Letters, 2009, 462, 147-151.	tive	1.0	16
386	Abnormal Functional Connectivity of Hippocampus During Episodic Memory Retrieval Pro Network in Amnestic Mild Cognitive Impairment. Biological Psychiatry, 2009, 65, 951-95	ocessing 8.	0.7	175

#	Article	IF	CITATIONS
387	Hippocampal dysfunction in amnestic-type mild cognitive impairment: implications for predicting Alzheimer's risk. Future Neurology, 2009, 4, 649-662.	0.9	5
388	Neurobiological Significance of Automatic Segmentation: Application to the Early Diagnosis of Alzheimer's Disease. Lecture Notes in Computer Science, 2009, , 134-141.	1.0	1
389	Activated astrocytes: a therapeutic target in Alzheimer's disease?. Expert Review of Neurotherapeutics, 2009, 9, 1585-1594.	1.4	73
390	Common Pathological Processes and Transcriptional Pathways in Alzheimer's Disease and Type 2 Diabetes. Journal of Alzheimer's Disease, 2009, 16, 787-808.	1.2	49
391	Animal Models of Human Cognitive Aging. , 2009, , .		8
392	Multidimensional classification of hippocampal shape features discriminates Alzheimer's disease and mild cognitive impairment from normal aging. NeuroImage, 2009, 47, 1476-1486.	2.1	354
393	Neural correlates of Alzheimer's disease and mild cognitive impairment: A systematic and quantitative meta-analysis involving 1351 patients. NeuroImage, 2009, 47, 1196-1206.	2.1	288
394	Comparison of phantom and registration scaling corrections using the ADNI cohort. NeuroImage, 2009, 47, 1506-1513.	2.1	54
395	The Complexity of Activities of Daily Living and Their Relationship to Attention in Alzheimer Disease. Topics in Geriatric Rehabilitation, 2009, 25, 365-374.	0.2	0
396	Neuropathological Correlates of Dementia in Over-80-Year-Old Brain Donors from the Population-Based Cambridge City over-75s Cohort (CC75C) Study. Journal of Alzheimer's Disease, 2009, 18, 645-658.	1.2	157
397	Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship. Journal of Neuropathology and Experimental Neurology, 2009, 68, 1-14.	0.9	492
398	Alzheimer's Disease Selective Vulnerability and Modeling in Transgenic Mice. Journal of Alzheimer's Disease, 2009, 18, 243-251.	1.2	29
399	Structural and Functional Patterns in Healthy Aging, Mild Cognitive Impairment, and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2010, 24, 1-10.	0.6	26
400	Thinking Outside the Box: Alzheimer-Type Neuropathology That Does Not Map Directly Onto Current Consensus Recommendations. Journal of Neuropathology and Experimental Neurology, 2010, 69, 449-454.	0.9	33
401	Combined Volumetry and DTI in Subcortical Structures of Mild Cognitive Impairment and Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2010, 19, 1273-1282.	1.2	107
402	Grey and White Matter Changes at Different Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 147-159.	1.2	135
403	The efficacy of a voxel-based morphometry on the analysis of imaging in schizophrenia, temporal lobe epilepsy, and Alzheimer's disease/mild cognitive impairment: a review. Neuroradiology, 2010, 52, 711-721.	1.1	61
404	Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Aβ42 immunisation in Alzheimer's disease. Acta Neuropathologica, 2010, 120, 13-20.	3.9	80

#	Article	IF	CITATIONS
405	Variably protease-sensitive prionopathy in a PRNP codon 129 heterozygous UK patient with co-existing tau, α synuclein and Aβ pathology. Acta Neuropathologica, 2010, 120, 821-823.	3.9	30
406	Theta power responses in mild Alzheimer's disease during an auditory oddball paradigm: lack of theta enhancement during stimulus processing. Journal of Neural Transmission, 2010, 117, 1195-1208.	1.4	40
407	Magnetic resonance imaging of Alzheimer's disease: from diagnosis to therapeutic evaluation. Chinese Journal of Integrative Medicine, 2010, 16, 276-282.	0.7	4
408	ABC efflux transporters in brain vasculature of Alzheimer's subjects. Brain Research, 2010, 1358, 228-238.	1.1	112
409	Assessment of white matter tract damage in mild cognitive impairment and Alzheimer's disease. Human Brain Mapping, 2010, 31, 1862-1875.	1.9	119
411	Hippocampal hyperactivation in presymptomatic familial Alzheimer's disease. Annals of Neurology, 2010, 68, 865-875.	2.8	195
412	REGIONAL BRAIN CORTICAL THINNING AND SYSTEMIC INFLAMMATION IN OLDER PERSONS WITHOUT DEMENTIA. Journal of the American Geriatrics Society, 2010, 58, 1823-1825.	1.3	24
413	ATYPICAL CASE OF ALZHEIMER'S DISEASE MIMICKING CREUTZFELDTâ€JAKOB DISEASE: INTEREST OF CEREBROSPINAL FLUID BIOMARKERS IN THE DIFFERENTIAL DIAGNOSIS. Journal of the American Geriatrics Society, 2010, 58, 1821-1823.	1.3	9
414	Pharmacology of epigenetics in brain disorders. British Journal of Pharmacology, 2010, 159, 285-303.	2.7	55
415	Modeling the Association between 43 Different Clinical and Pathological Variables and the Severity of Cognitive Impairment in a Large Autopsy Cohort of Elderly Persons. Brain Pathology, 2010, 20, 66-79.	2.1	204
416	Neurosteroid Biosynthetic Pathway Changes in Substantia Nigra and Caudate Nucleus in Parkinson's Disease. Brain Pathology, 2010, 20, 945-951.	2.1	60
417	Low HDL cholesterol is associated with lower gray matter volume in cognitively healthy adults. Frontiers in Aging Neuroscience, 2010, 2, .	1.7	47
418	Neurogenetic effects on cognition in aging brains: a window of opportunity for intervention?. Frontiers in Aging Neuroscience, 2010, 2, 143.	1.7	10
419	Pericellular innervation of neurons expressing abnormally hyperphosphorylated tau in the hippocampal formation of Alzheimer's disease patients. Frontiers in Neuroanatomy, 2010, 4, 20.	0.9	23
420	New Developments in the Diagnosis of Dementia. Deutsches Ärzteblatt International, 2010, 107, 677-83.	0.6	36
421	Uncovering Molecular Biomarkers That Correlate Cognitive Decline with the Changes of Hippocampus' Gene Expression Profiles in Alzheimer's Disease. PLoS ONE, 2010, 5, e10153.	1.1	121
422	Are Guidelines Needed for the Diagnosis and Management of Incipient Alzheimer's Disease and Mild Cognitive Impairment?. International Journal of Alzheimer's Disease, 2010, 2010, 1-7.	1.1	5
423	Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Human Molecular Genetics, 2010, 19, 3295-3301.	1.4	223

#	Article	IF	CITATIONS
424	Functional Alterations in Brain Activation and Deactivation in Mild Cognitive Impairment in Response to a Graded Working Memory Challenge. Dementia and Geriatric Cognitive Disorders, 2010, 30, 553-568.	0.7	46
425	Galantamine for Alzheimer's disease. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 345-354.	1.5	69
426	Selective Vulnerability of Neurons in Layer II of the Entorhinal Cortex during Aging and Alzheimer's Disease. Neural Plasticity, 2010, 2010, 1-8.	1.0	143
427	Phosphodiesterase Inhibition to Target the Synaptic Dysfunction in Alzheimer's Disease. Topics in Medicinal Chemistry, 2010, , 57-90.	0.4	11
428	Astrocytes in Alzheimer's Disease: Emerging Roles in Calcium Dysregulation and Synaptic Plasticity. Journal of Alzheimer's Disease, 2010, 22, 699-714.	1.2	78
429	Cerebral Microbleeds in the Elderly. Stroke, 2010, 41, 2782-2785.	1.0	153
430	Recollection and familiarity in amnesic mild cognitive impairment Neuropsychology, 2010, 24, 316-326.	1.0	60
431	Tauâ€tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDPâ€17 tauâ€mutant mice. FASEB Journal, 2010, 24, 2904-2915.	0.2	32
432	Olfactory Performance in AD, aMCI, and Healthy Ageing: A Unirhinal Approach. Chemical Senses, 2010, 35, 855-862.	1.1	32
433	Advanced Glycation Endproducts and Rat Dental Implant Osseointegration. Journal of Oral Implantology, 2010, 36, 97-103.	0.4	22
434	Tensor-based morphometry with stationary velocity field diffeomorphic registration: Application to ADNI. NeuroImage, 2010, 51, 956-969.	2.1	23
435	A multimodal MRI investigation of the subventricular zone in mild cognitive impairment and Alzheimer's disease patients. Neuroscience Letters, 2010, 469, 214-218.	1.0	36
436	Amyloid load in nondemented brains correlates with APOE e4. Neuroscience Letters, 2010, 473, 168-171.	1.0	76
437	Rate of entorhinal and hippocampal atrophy in incipient and mild AD: Relation to memory function. Neurobiology of Aging, 2010, 31, 1089-1098.	1.5	93
438	Evidence that volume of anterior medial temporal lobe is reduced in seniors destined for mild cognitive impairment. Neurobiology of Aging, 2010, 31, 1099-1106.	1.5	73
439	Stroke risk modifies regional white matter differences in mild cognitive impairment. Neurobiology of Aging, 2010, 31, 1721-1731.	1.5	24
440	Dysregulated microRNAs in neurodegenerative disorders. Seminars in Cell and Developmental Biology, 2010, 21, 768-773.	2.3	91
441	Daytime sleepiness is associated with dementia and cognitive decline in older Italian adults: A population-based study. Sleep Medicine, 2010, 11, 372-377.	0.8	155

#	Article	IF	CITATIONS
442	Aβ Accelerates the Spatiotemporal Progression of Tau Pathology and Augments Tau Amyloidosis in an Alzheimer Mouse Model. American Journal of Pathology, 2010, 177, 1977-1988.	1.9	179
443	Screening and Case-Finding Tools for the Detection of Dementia. Part II: Evidence-Based Meta-Analysis of Single-Domain Tests. American Journal of Geriatric Psychiatry, 2010, 18, 783-800.	0.6	38
444	A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 798-805.	0.9	84
445	Neuroanatomical Correlates of Cognitive Reserve in Alzheimer Disease. Rejuvenation Research, 2011, 14, 143-151.	0.9	62
446	APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease. NeuroImage, 2011, 55, 909-919.	2.1	116
447	PMD2 A META-ANALYSIS OF BIOMARKERS AND DIAGNOSTIC IMAGING IN ALZHEIMER'S DISEASE. Value in Health, 2011, 14, A79.	0.1	0
448	Brain aging, Alzheimer's disease, and mitochondria. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1630-1639.	1.8	251
449	Detection of age-dependent working memory deterioration in APP751SL mice. Behavioural Brain Research, 2011, 218, 129-137.	1.2	7
450	Post-translational modifications of tau protein: Implications for Alzheimer's disease. Neurochemistry International, 2011, 58, 458-471.	1.9	517
451	Discrimination of AD and normal subjects from MRI: Anatomical versus statistical regions. Neuroscience Letters, 2011, 487, 113-117.	1.0	12
452	Testosterone levels and cognition in elderly men: A review. Maturitas, 2011, 69, 322-337.	1.0	164
453	Biomarkers for Alzheimer's disease therapeutic trials. Progress in Neurobiology, 2011, 95, 579-593.	2.8	119
454	Staging Alzheimer's disease progression with multimodality neuroimaging. Progress in Neurobiology, 2011, 95, 535-546.	2.8	68
455	40-Hz steady state response in Alzheimer's disease and mild cognitive impairment. Neurobiology of Aging, 2011, 32, 24-30.	1.5	67
456	Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer's disease. Neurobiology of Aging, 2011, 32, 1466-1476.	1.5	172
457	Aging-related changes in calcium-binding proteins in rat perirhinal cortex. Neurobiology of Aging, 2011, 32, 1693-1706.	1.5	36
458	Interference with reelin signaling in the lateral entorhinal cortex impairs spatial memory. Neurobiology of Learning and Memory, 2011, 96, 150-155.	1.0	31
460	SVM-based diagnosis of the Alzheimer's disease using 18F-FDG PET with Fisher discriminant rate. , 2011, ,		1

	Сітатіо	n Report	
#	ARTICLE	IF	CITATIONS
461	Mathematical Modelling and Feature Extraction for Probing Crucial Changes Associated with Alzheimers Disease. Current Medical Imaging, 2011, 7, 43-50.	0.4	1
462	Evidence for Elevated Cerebrospinal Fluid ERK1/2 Levels in Alzheimer Dementia. International Journal of Alzheimer's Disease, 2011, 2011, 1-9.	1.1	12
463	Neuroevolution and neurodegeneration: two sides of the same coin?. , 0, , 133-149.		0
464	Structural and Toxic Properties of Protein Aggregates: Towards a Molecular Understanding of Alzheimer's Disease. , 0, , .		0
465	Alzheimer's Diseases: Towards Biomarkers for an Early Diagnosis. , 2011, , .		0
466	Joint Assessment of Structural, Perfusion, and Diffusion MRI in Alzheimer's Disease and Frontotemporal Dementia. International Journal of Alzheimer's Disease, 2011, 2011, 1-11.	1.1	58
467	Profiles of Alzheimer's Disease-Related Pathology in an Aging Urban Population Sample in India. Journal of Alzheimer's Disease, 2011, 24, 187-196.	1.2	15
468	Interaction between -Synuclein and Other Proteins in Neurodegenerative Disorders. Scientific World Journal, The, 2011, 11, 1893-1907.	0.8	57
469	Homeostatic Disinhibition in the Aging Brain and Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 15-24.	1.2	49
470	"End-Stage―Neurofibrillary Tangle Pathology in Preclinical Alzheimer's Disease: Fact or Fiction?. Journal of Alzheimer's Disease, 2011, 25, 445-453.	1.2	42
471	Multiple Indices of Diffusion Identifies White Matter Damage in Mild Cognitive Impairment and Alzheimer's Disease. PLoS ONE, 2011, 6, e21745.	1.1	108
472	Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice. PLoS ONE, 2011, 6, e26860.	1.1	142
473	Mass and relative elution time profiling: two-dimensional analysis of sphingolipids in Alzheimer's disease brains. Biochemical Journal, 2011, 438, 165-175.	1.7	45
474	Removing Protein Aggregates: The Role of Proteolysis in Neurodegeneration. Current Medicinal Chemistry, 2011, 18, 2459-2476.	1.2	80
475	Cognition and Neuropathology in Aging: Multidimensional Perspectives from the Rush Religious Orders Study and Rush Memory and Aging Project. Current Alzheimer Research, 2011, 8, 336-340.	0.7	75
476	Genetic Polymorphisms in Sigma-1 Receptor and Apolipoprotein E Interact to Influence the Severity of Alzheimers Disease. Current Alzheimer Research, 2011, 8, 765-770.	0.7	48
477	Rescuing neurons in prion disease. Biochemical Journal, 2011, 433, 19-29.	1.7	21
478	THE QUEST FOR BIOMARKERS OF ALZHEIMER'S DISEASE. Journal of the American Geriatrics Society, 2011, 59, 377-378.	1.3	0

CITATION REPORT	~		<u> </u>	
	ITA'	τιον	KED	ORT

#	Article	IF	CITATIONS
479	FUNCTIONAL ABNORMALITIES AND CEREBRAL ATROPHY IN POSTTRAUMATIC STRESS DISORDER AND DEMENTIA: IS THERE A CAUSAL LINK BETWEEN THE TWO DISEASES?. Journal of the American Geriatrics Society, 2011, 59, 378-379.	1.3	0
480	Physical exercise alleviates debilities of normal aging and Alzheimer's disease. Acta Neurologica Scandinavica, 2011, 123, 221-238.	1.0	82
481	Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease. Nature Reviews Neuroscience, 2011, 12, 67-72.	4.9	1,147
482	Endoplasmic reticulum stress activates autophagy but not the proteasome in neuronal cells: implications for Alzheimer's disease. Cell Death and Differentiation, 2011, 18, 1071-1081.	5.0	113
483	Novel screening cascade identifies MKK4 as key kinase regulating Tau phosphorylation at Ser422. Molecular and Cellular Biochemistry, 2011, 357, 199-207.	1.4	8
484	Category Cued Recall Following Controlled Encoding as a Neuropsychological Tool in the Diagnosis of Alzheimer's Disease: A Review of the Evidence. Neuropsychology Review, 2011, 21, 54-65.	2.5	51
485	Tau, prions and $A\hat{l}^2$: the triad of neurodegeneration. Acta Neuropathologica, 2011, 121, 5-20.	3.9	84
486	Risk genotypes at TMEM106B are associated with cognitive impairment in amyotrophic lateral sclerosis. Acta Neuropathologica, 2011, 121, 373-380.	3.9	102
487	The importance of appropriate partial volume correction for PET quantification in Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1104-1119.	3.3	262
488	Modes of Aβ toxicity in Alzheimer's disease. Cellular and Molecular Life Sciences, 2011, 68, 3359-3375.	2.4	78
489	Matrix-assisted laser desorption ionization imaging mass spectrometry in lipidomics. Analytical and Bioanalytical Chemistry, 2011, 401, 29-51.	1.9	80
490	Segmentation ciblée d'images IRM et maladie d'Alzheimer. Irbm, 2011, 32, 19-26.	3.7	3
491	Staging Neurodegenerative Disorders: Structural, Regional, Biomarker, and Functional Progressions. Neurotoxicity Research, 2011, 19, 211-234.	1.3	25
492	Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. Journal of Pathology, 2011, 225, 54-62.	2.1	401
493	Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex. Journal of Neuroscience Research, 2011, 89, 822-832.	1.3	26
494	Interplay between glycogen synthase kinaseâ€3β and tau in the cerebellum of Hsp27 transgenic mouse. Journal of Neuroscience Research, 2011, 89, 1267-1275.	1.3	10
495	The new indirubin derivative inhibitors of glycogen synthase kinaseâ€3, 6â€BIDECO and 6â€BIMYEO, prevent tau phosphorylation and apoptosis induced by the inhibition of protein phosphataseâ€2A by okadaic acid in cultured neurons. Journal of Neuroscience Research, 2011, 89, 1802-1811.	1.3	31
496	Advanced glycation end products downregulate glucokinase in mice. Diabetes/Metabolism Research and Reviews, 2011, 27, 557-563.	1.7	10

		CITATION RE	PORT	
#	Article		IF	Citations
497	Brief update on different roles of tau in neurodegeneration. IUBMB Life, 2011, 63, 495	-502.	1.5	42
498	Quantization and analysis of hippocampal morphometric changes due to dementia of using metric distances based on large deformation diffeomorphic metric mapping. Con Medical Imaging and Graphics, 2011, 35, 275-293.	Alzheimer type nputerized	3.5	10
499	Application of machine learning methods to describe the effects of conjugated equine therapy on region-specific brain volumes. Magnetic Resonance Imaging, 2011, 29, 546		1.0	20
500	Immunohistochemistry utilization in autopsy pathology: A Canadian experience. Patho and Practice, 2011, 207, 241-246.	logy Research	1.0	4
501	Review and Meta-Analysis of Biomarkers and Diagnostic Imaging in Alzheimer's Diseas Alzheimer's Disease, 2011, 26, 627-645.	e. Journal of	1.2	228
502	Mutual gaze in Alzheimer's disease, frontotemporal and semantic dementia couples. S and Affective Neuroscience, 2011, 6, 359-367.	ocial Cognitive	1.5	52
503	β-Amyloid Peptide Variants in Brains and Cerebrospinal Fluid from Amyloid Precursor F Transgenic Mice. Journal of Biological Chemistry, 2011, 286, 33747-33758.	rotein (APP)	1.6	53
504	Cyclic AMP-dependent Protein Kinase Regulates the Alternative Splicing of Tau Exon 10 Biological Chemistry, 2011, 286, 14639-14648.	D. Journal of	1.6	76
505	Left Anterior Temporal Lobe Sustains Naming in Alzheimers Dementia and Mild Cognit Current Alzheimer Research, 2011, 8, 893-901.	ive Impairment.	0.7	27
506	Targeting Post-translational Modifications on Tau as a Therapeutic Strategy for Alzheir Journal of Neurogenetics, 2011, 25, 127-133.	ner's Disease.	0.6	36
507	Cognitive Decline Is Associated with Reduced Reelin Expression in the Entorhinal Corte Cerebral Cortex, 2011, 21, 392-400.	ex of Aged Rats.	1.6	85
508	Cerebral Metabolism, Cognition, and Functional Abilities in Alzheimer Disease. Journal Psychiatry and Neurology, 2011, 24, 127-134.	of Geriatric	1.2	40
509	Oxidative Stress Mediated-Alterations of the MicroRNA Expression Profile in Mouse Hip Neurons. International Journal of Molecular Sciences, 2012, 13, 16945-16960.	pocampal	1.8	67
510	Bezafibrate administration improves behavioral deficits and tau pathology in P301S m Molecular Genetics, 2012, 21, 5091-5105.	ice. Human	1.4	77
511	Gender-Dependent Levels of Hyaluronic Acid in Cerebrospinal Fluid of Patients with Neurodegenerative Dementia. Current Alzheimer Research, 2012, 9, 257-266.		0.7	17
512	Potential neuroprotective strategies against tauopathy. Biochemical Society Transaction 656-660.	ons, 2012, 40,	1.6	4
514	Cellular mechanisms of protein aggregate propagation. Current Opinion in Neurology, 721-726.	2012, 25,	1.8	66
515	Atypical Motor and Behavioral Presentations of Alzheimer Disease. Neurologist, 2012,	18, 266-272.	0.4	37

#	Article	IF	CITATIONS
516	The Role of Methylglyoxal-Modified Proteins in Gastric Ulcer Healing. Current Medicinal Chemistry, 2012, 19, 137-144.	1.2	5
517	Hippocampal BDNF Expression in a Tau Transgenic Mouse Model. Current Alzheimer Research, 2012, 9, 406-410.	0.7	12
519	Goodpasture Antigen-binding Protein/Ceramide Transporter Binds to Human Serum Amyloid P-Component and Is Present in Brain Amyloid Plaques. Journal of Biological Chemistry, 2012, 287, 14897-14911.	1.6	31
520	Perceived Eye Region and the Processing of Fearful Expressions in Mild Cognitive Impairment Patients. Dementia and Geriatric Cognitive Disorders, 2012, 33, 43-49.	0.7	11
521	Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease. Neurology, 2012, 78, 379-386.	1.5	141
522	Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain, 2012, 135, 3005-3014.	3.7	222
523	Tau Phosphorylation and Sevoflurane Anesthesia. Anesthesiology, 2012, 116, 779-787.	1.3	195
524	Recent Advances in Imaging Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 33, S313-S327.	1.2	21
525	Digital Pathology and Image Analysis for Robust High-Throughput Quantitative Assessment of Alzheimer Disease Neuropathologic Changes. Journal of Neuropathology and Experimental Neurology, 2012, 71, 1075-1085.	0.9	57
526	Metric Distances between Hippocampal Shapes Indicate Different Rates of Change over Time in Nondemented and Demented Subjects. Current Alzheimer Research, 2012, 9, 972-981.	0.7	3
527	Cholesterol Increases Ventricular Volume in a Rabbit Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 29, 283-292.	1.2	18
528	Strategies, Development, and Pitfalls of Therapeutic Options for Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 241-281.	1.2	51
529	Alzheimer's Disease: A Clinical Practice-Oriented Review. Frontiers in Neurology, 2012, 3, 63.	1.1	53
530	Altered Parietal-Motor Connections in Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2012, 33, 525-533.	1.2	27
531	Why have we Failed to Cure Alzheimer's Disease?. Journal of Alzheimer's Disease, 2012, 29, 275-282.	1.2	38
532	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	0.9	1,599
533	Classification of Alzheimer's disease patients with hippocampal shape, wrapper based feature selection and support vector machine. Proceedings of SPIE, 2012, , .	0.8	2
534	The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. CNS Spectrums, 2012, 17, 176-206.	0.7	28

#	Article	IF	CITATIONS
535	Spreading of Neurodegenerative Pathology via Neuron-to-Neuron Transmission of Â-Amyloid. Journal of Neuroscience, 2012, 32, 8767-8777.	1.7	219
536	NUB1 modulation of GSK3Î ² reduces tau aggregation. Human Molecular Genetics, 2012, 21, 5254-5267.	1.4	29
537	Amyotrophic lateral sclerosis and organ donation: Is there risk of disease transmission?. Annals of Neurology, 2012, 72, 832-836.	2.8	15
538	Intraneuronal βâ€amyloid and its interactions with proteins and subcellular organelles. Electrophoresis, 2012, 33, 3608-3616.	1.3	23
539	Initial Mini-Mental State and Cerebral Perfusion in Alzheimer's Disease. Clinical Neuroradiology, 2012, 22, 219-226.	1.0	5
540	Limited cleavage of tau with matrix-metalloproteinase MMP-9, but not MMP-3, enhances tau oligomer formation. Experimental Neurology, 2012, 237, 470-476.	2.0	41
541	Clobal gray matter changes in posterior cortical atrophy: A serial imaging study. Alzheimer's and Dementia, 2012, 8, 502-512.	0.4	45
543	Characterizing the Preclinical Stages of Alzheimer's Disease and the Prospect of Presymptomatic Intervention. Journal of Alzheimer's Disease, 2012, 33, S405-S416.	1.2	73
544	Atrophy and dysfunction of parahippocampal white matter in mild Alzheimer's disease. Neurobiology of Aging, 2012, 33, 43-52.	1.5	28
545	Cognition, glucose metabolism and amyloid burden in Alzheimer's disease. Neurobiology of Aging, 2012, 33, 215-225.	1.5	122
546	Increased fMRI signal with age in familial Alzheimer's disease mutation carriers. Neurobiology of Aging, 2012, 33, 424.e11-424.e21.	1.5	17
547	Age-related changes in the mesial temporal lobe: the parahippocampal white matter region. Neurobiology of Aging, 2012, 33, 1168-1176.	1.5	21
548	Parasympathetic autonomic dysfunction is common in mild cognitive impairment. Neurobiology of Aging, 2012, 33, 2324-2333.	1.5	86
549	New visual rating system for medial temporal lobe atrophy: a simple diagnostic tool for routine examinations. Psychogeriatrics, 2012, 12, 88-92.	0.6	6
550	The challenges of tau imaging. Future Neurology, 2012, 7, 409-421.	0.9	82
551	Trans-cellular Propagation of Tau Aggregation by Fibrillar Species. Journal of Biological Chemistry, 2012, 287, 19440-19451.	1.6	483
552	Should Alzheimer's disease be equated with human brain ageing?: A maladaptive interaction between brain evolution and senescence. Ageing Research Reviews, 2012, 11, 104-122.	5.0	18
553	Semantic knowledge of newly coined words in mild cognitive impairment and Alzheimer's disease. Journal of Neurolinguistics, 2012, 25, 263-275.	0.5	4

#	Article	IF	CITATIONS
554	Insights into spared memory capacity in amnestic MCI and Alzheimer's Disease via minimal interference. Brain and Cognition, 2012, 78, 189-199.	0.8	45
555	Smallâ€vessel disease in patients with Parkinson's disease: A clinicopathological study. Movement Disorders, 2012, 27, 1506-1512.	2.2	49
556	Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals. BMC Medicine, 2012, 10, 127.	2.3	46
557	The use of errorless learning strategies for patients with Alzheimer's disease. International Journal of Rehabilitation Research, 2012, 35, 292-298.	0.7	10
558	Soluble forms of tau are toxic in Alzheimer's disease. Translational Neuroscience, 2012, 3, 223-233.	0.7	185
559	Memantine combined with environmental enrichment improves spatial memory and alleviates Alzheimer's disease-like pathology in senescence-accelerated prone-8 (SAMP8) mice. Journal of Biomedical Research, 2012, 26, 439.	0.7	16
561	Roles of Glycogen Synthase Kinase-3 in Alzheimer's Disease: From Pathology toÂTreatment Target. Journal of Experimental and Clinical Medicine, 2012, 4, 135-139.	0.2	7
562	Quantitative magnetization transfer provides information complementary to grey matter atrophy in Alzheimer's disease brains. NeuroImage, 2012, 59, 1114-1122.	2.1	58
563	Sphingolipids: Critical players in Alzheimer's disease. Progress in Lipid Research, 2012, 51, 378-393.	5.3	143
564	Neurodegeneration as an RNA disorder. Progress in Neurobiology, 2012, 99, 293-315.	2.8	52
565	Voxelwise meta-analysis of gray matter anomalies in Alzheimer's disease and mild cognitive impairment using anatomic likelihood estimation. Journal of the Neurological Sciences, 2012, 316, 21-29.	0.3	129
566	Hippocampal atrophy in Alzheimer's disease. Neurodegenerative Disease Management, 2012, 2, 197-209.	1.2	2
567	Alzheimer's Disease Pathologic Cascades: Who Comes First, What Drives What. Neurotoxicity Research, 2012, 22, 182-194.	1.3	59
568	Ligand electronic properties modulate tau filament binding site density. Biophysical Chemistry, 2012, 170, 25-33.	1.5	9
569	Effects of Environmental Enrichment Exposure on Synaptic Transmission and Plasticity in the Hippocampus. Current Topics in Behavioral Neurosciences, 2012, 15, 165-187.	0.8	59
570	Frontotemporal Dementia. Neuroscientist, 2012, 18, 373-385.	2.6	113
571	Phytochemicals, Signal Transduction, and Neurological Disorders. , 2012, , .		33
572	Rates of Decline in Alzheimer Disease Decrease with Age. PLoS ONE, 2012, 7, e42325.	1.1	89

#	Article	IF	CITATIONS
573	Posterior Cingulum White Matter Disruption and Its Associations with Verbal Memory and Stroke Risk in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2012, 29, 589-603.	1.2	74
574	Unpicking the Semantic Impairment in Alzheimer's Disease: Qualitative Changes with Disease Severity. Behavioural Neurology, 2012, 25, 23-34.	1.1	20
575	A Clinical Approach to Early-Onset Inheritable Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2012, 27, 154-161.	0.9	16
576	ERK activation and expression of neuronal cell cycle markers in the hippocampus after entorhinal cortex lesion. Journal of Neuroscience Research, 2012, 90, 2116-2126.	1.3	9
577	Damage to the cingulum contributes to alzheimer's disease pathophysiology by deafferentation mechanism. Human Brain Mapping, 2012, 33, 1295-1308.	1.9	91
578	Interaction between pathogenic proteins in neurodegenerative disorders. Journal of Cellular and Molecular Medicine, 2012, 16, 1166-1183.	1.6	104
579	Tauâ€ŧargeted treatment strategies in Alzheimer's disease. British Journal of Pharmacology, 2012, 165, 1246-1259.	2.7	114
580	The HSPB8â€BAG3 chaperone complex is upregulated in astrocytes in the human brain affected by protein aggregation diseases. Neuropathology and Applied Neurobiology, 2012, 38, 39-53.	1.8	76
581	MicroRNA networks surrounding APP and amyloid-β metabolism — Implications for Alzheimer's disease. Experimental Neurology, 2012, 235, 447-454.	2.0	90
582	Topography of cortical thinning areas associated with hippocampal atrophy (HA) in patients with Alzheimer's disease (AD). Archives of Gerontology and Geriatrics, 2012, 54, e122-e129.	1.4	10
583	Olfactory ERPs in an odor/visual congruency task differentiate ApoE ε4 carriers from non-carriers. Brain Research, 2012, 1442, 55-65.	1.1	28
584	Insulin signaling, glucose metabolism and mitochondria: Major players in Alzheimer's disease and diabetes interrelation. Brain Research, 2012, 1441, 64-78.	1.1	164
585	Dysfunction of TGF-β1 signaling in Alzheimer's disease: perspectives for neuroprotection. Cell and Tissue Research, 2012, 347, 291-301.	1.5	96
586	Prion-Like Propagation of Protein Aggregation and Related Therapeutic Strategies. Neurotherapeutics, 2013, 10, 371-382.	2.1	33
587	Glia Maturation Factor Expression in Entorhinal Cortex of Alzheimer's Disease Brain. Neurochemical Research, 2013, 38, 1777-1784.	1.6	27
588	Neurogenesis and Neural Plasticity. Current Topics in Behavioral Neurosciences, 2013, , .	0.8	7
589	Distinct cognitive phenotypes in Alzheimer's disease in older people. International Psychogeriatrics, 2013, 25, 1659-1666.	0.6	8
590	Dysfunction of the mTOR pathway is a risk factor for Alzheimer's disease. Acta Neuropathologica Communications, 2013, 1, 3.	2.4	55

#	Article	IF	CITATIONS
591	Word List and Story Recall Elicit Different Patterns of Memory Deficit in Patients with Alzheimer's Disease, Frontotemporal Dementia, Subcortical Ischemic Vascular Disease, and Lewy Body Dementia. Journal of Alzheimer's Disease, 2013, 37, 99-107.	1.2	36
592	Accurate multimodal probabilistic prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment. NeuroImage: Clinical, 2013, 2, 735-745.	1.4	209
593	Non-cognitive symptoms and related conditions in the Alzheimer's disease: a literature review. Neurological Sciences, 2013, 34, 1275-1282.	0.9	34
594	Longitudinal white matter changes in Alzheimer's disease: A tractography-based analysis study. Brain Research, 2013, 1515, 12-18.	1.1	43
595	The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in the Pathophysiology of Neurodegeneration: A Literature Study. Journal of Alzheimer's Disease, 2013, 37, 273-283.	1.2	49
596	Youthful Memory Capacity in Old Brains: Anatomic and Genetic Clues from the Northwestern SuperAging Project. Journal of Cognitive Neuroscience, 2013, 25, 29-36.	1.1	126
597	Biology and Genetics of Prions Causing Neurodegeneration. Annual Review of Genetics, 2013, 47, 601-623.	3.2	384
598	Does variation in neurodegenerative disease susceptibility and phenotype reflect cerebral differences at the network level?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 487-493.	1.1	22
599	Proteopathic Seeds and Neurodegenerative Diseases. Research and Perspectives in Alzheimer's Disease, 2013, , .	0.1	4
600	Episodic-like memory is sensitive to both Alzheimer's-like pathological accumulation and normal ageing processes in mice. Behavioural Brain Research, 2013, 254, 73-82.	1.2	56
601	Foreign language training as cognitive therapy for age-related cognitive decline: A hypothesis for future research. Neuroscience and Biobehavioral Reviews, 2013, 37, 2689-2698.	2.9	144
602	Heightened emotional contagion in mild cognitive impairment and Alzheimer's disease is associated with temporal lobe degeneration. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 9944-9949.	3.3	133
603	Reelin immunoreactivity in neuritic varicosities in the human hippocampal formation of non-demented subjects and Alzheimer's disease patients. Acta Neuropathologica Communications, 2013, 1, 27.	2.4	20
604	Memory consolidation — Mechanisms and opportunities for enhancement. Translational Neuroscience, 2013, 4, 448-457.	0.7	2
605	Understanding cognitive deficits in Alzheimer's disease based on neuroimaging findings. Trends in Cognitive Sciences, 2013, 17, 510-516.	4.0	32
606	A brief olfactory test for Alzheimer's disease. Journal of the Neurological Sciences, 2013, 333, 19-24.	0.3	73
607	Cellular, synaptic, and biochemical features of resilient cognition in Alzheimer's disease. Neurobiology of Aging, 2013, 34, 157-168.	1.5	94
608	A touch screen-automated cognitive test battery reveals impaired attention, memory abnormalities, and increased response inhibition in the TgCRND8 mouse model of Alzheimer's disease. Neurobiology of Aging, 2013, 34, 731-744.	1.5	93

		EPORT	
#	Article	IF	CITATIONS
609	Nucleotide excision repair in chronic neurodegenerative diseases. DNA Repair, 2013, 12, 568-577.	1.3	25
610	Effectiveness of regional DTI measures in distinguishing Alzheimer's disease, MCI, and normal aging. NeuroImage: Clinical, 2013, 3, 180-195.	1.4	277
611	Fortress Brain. Medical Hypotheses, 2013, 80, 118-121.	0.8	1
612	Identification of promethazine as an amyloid-binding molecule using a fluorescence high-throughput assay and MALDI imaging mass spectrometry. NeuroImage: Clinical, 2013, 2, 620-629.	1.4	20
613	Distinct neuroanatomical bases of episodic and semantic memory performance in Alzheimer's disease. Neuropsychologia, 2013, 51, 930-937.	0.7	72
614	Functional plasticity in Alzheimer's disease: Effect of cognitive training on language-related ERP components. Neuropsychologia, 2013, 51, 1638-1648.	0.7	25
615	APOE associated hemispheric asymmetry of entorhinal cortical thickness in aging and Alzheimer's disease. Psychiatry Research - Neuroimaging, 2013, 214, 212-220.	0.9	64
616	Longitudinal, regionâ€specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer's disease. Alzheimer's and Dementia, 2013, 9, 519-528.	0.4	91
617	Caspase-6 activity predicts lower episodic memory ability in aged individuals. Neurobiology of Aging, 2013, 34, 1815-1824.	1.5	35
618	Neuropathologic Basis of Age-Associated Brain Atrophy. JAMA Neurology, 2013, 70, 616.	4.5	90
619	βâ€ a myloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Movement Disorders, 2013, 28, 296-301.	2.2	77
620	α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?. Acta Neuropathologica, 2013, 125, 753-769.	3.9	369
621	Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2077.e11-2077.e18.	1.5	124
622	Widening Spectrum of Prions Causing Neurodegenerative Diseases. Research and Perspectives in Alzheimer's Disease, 2013, , 1-17.	0.1	1
623	Preclinical sporadic Alzheimer's disease: target for personalized diagnosis and preventive intervention. Metabolism: Clinical and Experimental, 2013, 62, S30-S33.	1.5	38
624	Relevance of Magnetic Resonance Imaging for Early Detection and Diagnosis of Alzheimer Disease. Medical Clinics of North America, 2013, 97, 399-424.	1.1	151
625	Gray and white matter degeneration revealed by diffusion in an Alzheimer mouse model. Neurobiology of Aging, 2013, 34, 1440-1450.	1.5	61
626	Neuropathologic basis of white matter hyperintensity accumulation with advanced age. Neurology, 2013, 81, 977-983.	1.5	179

#	Article	IF	CITATIONS
627	Beneficial Effects of Curcumin on Neurological Disorders. , 2013, , 151-197.		2
628	CREB regulates the expression of neuronal glucose transporter 3: a possible mechanism related to impaired brain glucose uptake in Alzheimer's disease. Nucleic Acids Research, 2013, 41, 3240-3256.	6.5	55
629	Amyloid imaging in dementia. Reviews in Clinical Gerontology, 2013, 23, 43-60.	0.5	0
630	Changes in Brain Function Occur Years before the Onset of Cognitive Impairment. Journal of Neuroscience, 2013, 33, 18008-18014.	1.7	179
631	Young APOE4 targeted replacement mice exhibit poor spatial learning and memory, with reduced dendritic spine density in the medial entorhinal cortex. Learning and Memory, 2013, 20, 256-266.	0.5	107
632	Verbal and Visuospatial Span in Logopenic Progressive Aphasia and Alzheimer's Disease. Journal of the International Neuropsychological Society, 2013, 19, 247-253.	1.2	47
633	Amyloid-Î ² Load Predicts Medial Temporal Lobe Dysfunction in Alzheimer Dementia. Journal of Nuclear Medicine, 2013, 54, 1909-1914.	2.8	21
634	Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology. Journal of Biological Chemistry, 2013, 288, 33081-33095.	1.6	141
635	Learning in Alzheimer's disease is facilitated by social interaction. Journal of Comparative Neurology, 2013, 521, 4356-4369.	0.9	26
636	Stereological assessment of the dorsal anterior cingulate cortex in schizophrenia: absence of changes in neuronal and glial densities. Neuropathology and Applied Neurobiology, 2013, 39, 348-361.	1.8	24
637	Polymorphism â^'116 <scp>C</scp> / <scp>G</scp> of Human <scp>X</scp> â€boxâ€Binding Protein 1 Promoter is Associated with Risk of <scp>A</scp> lzheimer's Disease. CNS Neuroscience and Therapeutics, 2013, 19, 229-234.	1.9	48
638	Improved Spatial Learning Strategy and Memory in Aged Alzheimer AβPPswe/PS1dE9 Mice on a Multi-Nutrient Diet. Journal of Alzheimer's Disease, 2013, 37, 233-245.	1.2	31
639	Mild Cognitive Impairment: Same Identity for Different Entities. Journal of Alzheimer's Disease, 2013, 33, 1157-1165.	1.2	39
640	Entorhinal Cortex Thickness Predicts Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 755-766.	1.2	105
641	Diffusion Tensor Magnetic Resonance Imaging of the Brain in APP Transgenic Mice: A Cohort Study. PLoS ONE, 2013, 8, e67630.	1.1	19
642	Evaluating Alzheimer's Disease Progression Using Rate of Regional Hippocampal Atrophy. PLoS ONE, 2013, 8, e71354.	1.1	80
643	Alzheimer's Disease Susceptibility Genes APOE and TOMM40, and Hippocampal Volumes in the Lothian Birth Cohort 1936. PLoS ONE, 2013, 8, e80513.	1.1	29
644	Structural Characterization by NMR of a Double Phosphorylated Chimeric Peptide Vaccine for Treatment of Alzheimer's Disease. Molecules, 2013, 18, 4929-4941.	1.7	Ο

#	Article	IF	CITATIONS
645	Constructional Apraxia as a Distinctive Cognitive and Structural Brain Feature of Pre-Senile Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 38, 391-402.	1.2	36
646	Cholesterol and Copper Affect Learning and Memory in the Rabbit. International Journal of Alzheimer's Disease, 2013, 2013, 1-12.	1.1	12
647	Increased Hippocampal Excitability in the 3xTgAD Mouse Model for Alzheimer's Disease In Vivo. PLoS ONE, 2014, 9, e91203.	1.1	58
648	Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine. BioMed Research International, 2014, 2014, 1-13.	0.9	11
649	Alzheimerââ,¬â"¢s disease and the fornix. Frontiers in Aging Neuroscience, 2014, 6, 241.	1.7	58
650	Neural Correlates of Spatial Navigation Changes in Mild Cognitive Impairment and Alzheimerââ,¬â,,¢s Disease. Frontiers in Behavioral Neuroscience, 2014, 8, 89.	1.0	84
651	10-Minute Delayed Recall from the Modified Mini-Mental State Test Predicts Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2014, 39, 575-582.	1.2	14
652	Acupuncture Stimulation of Taichong (Liv3) and Hegu (Ll4) Modulates the Default Mode Network Activity in Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 739-748.	0.9	67
653	Extracellular Monomeric Tau Protein Is Sufficient to Initiate the Spread of Tau Protein Pathology. Journal of Biological Chemistry, 2014, 289, 956-967.	1.6	153
654	The unfolded protein response mediates reversible tau phosphorylation induced by metabolic stress. Cell Death and Disease, 2014, 5, e1393-e1393.	2.7	78
655	Greater medial temporal hypometabolism and lower cortical amyloid burden in ApoE4-positive AD patients. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 266-273.	0.9	47
656	Dual-retrieval models and neurocognitive impairment Journal of Experimental Psychology: Learning Memory and Cognition, 2014, 40, 41-65.	0.7	17
657	Correlated Inflammatory Responses and Neurodegeneration in Peptide-Injected Animal Models of Alzheimer's Disease. BioMed Research International, 2014, 2014, 1-9.	0.9	24
658	Acupuncture Modulates Resting State Hippocampal Functional Connectivity in Alzheimer Disease. PLoS ONE, 2014, 9, e91160.	1.1	64
659	Axonal tract tracing for delineating interacting brain regions: implications for Alzheimer's disease-associated memory. Future Neurology, 2014, 9, 89-98.	0.9	3
660	Amyloid deposition is decreasing in aging brains. Neurology, 2014, 82, 326-331.	1.5	38
661	Micro <scp>RNA</scp> â€125b induces tau hyperphosphorylation and cognitive deficits in Alzheimer's disease. EMBO Journal, 2014, 33, 1667-1680.	3.5	257
662	Spatial discrimination deficits as a function of mnemonic interference in aged adults with and without memory impairment. Hippocampus, 2014, 24, 303-314.	0.9	65

# 663	ARTICLE Active Invasion of Porphyromonas gingivalis and Infection-Induced Complement Activation in ApoE-/- Mice Brains. Journal of Alzheimer's Disease, 2014, 43, 67-80.	lF 1.2	Citations
664	Transition from an M1 to a mixed neuroinflammatory phenotype increases amyloid deposition in APP/PS1 transgenic mice. Journal of Neuroinflammation, 2014, 11, 127.	3.1	40
665	Memory difficulties are not always a sign of incipient dementia: a review of the possible causes of loss of memory efficiency. British Medical Bulletin, 2014, 112, 71-81.	2.7	54
666	Biomarkers for Alzheimer's Disease and Frontotemporal Lobar Degeneration: Imaging. , 2014, , 159-178.		0
667	Time course of brain volume changes in the preclinical phase of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 143.	0.4	52
668	Dynamin protein in stroke and vascular dementia. Neuroscience Letters, 2014, 563, 118-122.	1.0	3
669	Variance in the identification of microRNAs deregulated in Alzheimer's disease and possible role of lincRNAs in the pathology: The need of larger datasets. Ageing Research Reviews, 2014, 17, 43-53.	5.0	55
670	Dysregulation of leptin signaling in Alzheimer disease: evidence for neuronal leptin resistance. Journal of Neurochemistry, 2014, 128, 162-172.	2.1	110
671	Hippocampus-specific deficiency in RNA editing of GluA2 in Alzheimer's disease. Neurobiology of Aging, 2014, 35, 1785-1791.	1.5	94
672	Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. Acta Neuropathologica Communications, 2014, 2, 9.	2.4	138
673	Neuroimaging and genetic risk for Alzheimer's disease and addiction-related degenerative brain disorders. Brain Imaging and Behavior, 2014, 8, 217-233.	1.1	14
674	Caspase-6 activity in the CA1 region of the hippocampus induces age-dependent memory impairment. Cell Death and Differentiation, 2014, 21, 696-706.	5.0	45
675	Neurodegenerative Diseases. , 2014, , .		3
676	Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1039-1050.	1.5	33
677	The Ubiquitin-Proteasome System in Neurodegeneration. Antioxidants and Redox Signaling, 2014, 21, 2302-2321.	2.5	116
678	Integrating the molecular and the population approaches to dementia research to help guide the future development of appropriate therapeutics. Biochemical Pharmacology, 2014, 88, 652-660.	2.0	6
679	Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer's disease. Nature Medicine, 2014, 20, 1254-1262.	15.2	367
680	Aging in the Canine and Feline Brain. Veterinary Clinics of North America - Small Animal Practice, 2014, 44, 1113-1129.	0.5	50

#	Article	IF	Citations
681	Nuclear Medicine Imaging and Therapy: Gender Biases in Disease. Seminars in Nuclear Medicine, 2014, 44, 413-422.	2.5	2
682	Neural correlates of spelling difficulties in Alzheimer's disease. Neuropsychologia, 2014, 65, 12-17.	0.7	10
683	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	3.9	1,060
684	Oral Inflammation, Tooth Loss, Risk Factors, and Association with Progression of Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 723-737.	1.2	76
685	Functional and Structural MRI in Alzheimer's Disease: A Multimodal Approach. , 2014, , 371-422.		0
686	Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain, 2014, 137, 2493-2508.	3.7	232
687	Emotional and Behavioral Symptoms in Neurodegenerative Disease: A Model for Studying the Neural Bases of Psychopathology. Annual Review of Clinical Psychology, 2014, 10, 581-606.	6.3	139
688	Variation in the oxytocin receptor gene is associated with increased risk for anxiety, stress and depression in individuals with a history of exposure to early life stress. Journal of Psychiatric Research, 2014, 59, 93-100.	1.5	78
689	Imaging prodromal Parkinson disease. Neurology, 2014, 83, 1739-1746.	1.5	138
690	Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition. Journal of Neuroinflammation, 2014, 11, 111.	3.1	144
691	Heat shock proteins in neurodegenerative disorders and aging. Journal of Cell Communication and Signaling, 2014, 8, 293-310.	1.8	145
692	In vivo evaluation of a novel tau imaging tracer for Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 816-826.	3.3	156
693	Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings. Acta Neuropathologica, 2014, 128, 81-98.	3.9	37
694	Impact of aging on heat shock protein expression in the substantia nigra and striatum of the female rat. Cell and Tissue Research, 2014, 357, 43-54.	1.5	25
695	MRI parcellation of ex vivo medial temporal lobe. NeuroImage, 2014, 93, 252-259.	2.1	37
696	Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. Neurobiology of Aging, 2014, 35, 819-826.	1.5	67
697	Grey-matter volume as a potential feature for the classification of Alzheimer's disease and mild cognitive impairment: an exploratory study. Neuroscience Bulletin, 2014, 30, 477-489.	1.5	45
698	Brain stem hemorrhage due to cerebral amyloid angiopathy: The autopsy of a patient with Alzheimer's disease at a young age. Legal Medicine, 2014, 16, 98-101.	0.6	3

#	Article	IF	CITATIONS
699	MRI in Psychiatry. , 2014, , .		3
700	Physicochemical Properties of Cells and Their Effects on Intrinsically Disordered Proteins (IDPs). Chemical Reviews, 2014, 114, 6661-6714.	23.0	391
701	Proteopathic tau seeding predicts tauopathy in vivo. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4376-85.	3.3	474
702	Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease. Neurobiology of Aging, 2014, 35, 600-613.	1.5	55
703	Multi-resolutional shape features via non-Euclidean wavelets: Applications to statistical analysis of cortical thickness. Neurolmage, 2014, 93, 107-123.	2.1	25
704	Hippocampal sclerosis dementia with the C9ORF72 hexanucleotide repeat expansion. Neurobiology of Aging, 2014, 35, 2419.e17-2419.e21.	1.5	21
705	The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals. Neurobiology of Aging, 2014, 35, 1318-1324.	1.5	109
706	Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities. Neurobiology of Aging, 2014, 35, 2021-2028.	1.5	40
707	Insulin growth factor binding protein 7 is a novel target to treat dementia. Neurobiology of Disease, 2014, 62, 135-143.	2.1	40
708	Neuronal activity regulates extracellular tau in vivo. Journal of Experimental Medicine, 2014, 211, 387-393.	4.2	429
709	Autonomic Dysfunction in Alzheimer's Disease: Tools for Assessment and Review of the Literature. Journal of Alzheimer's Disease, 2014, 42, 369-377.	1.2	94
710	InÂvivo tau imaging: Obstacles and progress. , 2014, 10, S254-S264.		84
711	Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies. Neuron, 2014, 82, 1271-1288.	3.8	822
712	Motor features in posterior cortical atrophy and their imaging correlates. Neurobiology of Aging, 2014, 35, 2845-2857.	1.5	29
713	Single nucleotide polymorphism rs7294919 on chromosome 12q24.22 is associated with late-onset Alzheimer's disease in Han Chinese. Neuroscience Letters, 2014, 560, 67-70.	1.0	3
714	Inclusion of an Informant Yields Strong Associations between Cognitive Complaint and Longitudinal Cognitive Outcomes in Non-Demented Elders. Journal of Alzheimer's Disease, 2014, 43, 121-132.	1.2	33
715	Melatonin Therapy in Patients with Alzheimer's Disease. Antioxidants, 2014, 3, 245-277.	2.2	59
716	Fingolimod for the treatment of neurological diseasesââ,¬â€state of play and future perspectives. Frontiers in Cellular Neuroscience, 2014, 8, 283.	1.8	113

#	Article	IF	CITATIONS
717	Alzheimer's disease: is a vaccine possible?. Brazilian Journal of Medical and Biological Research, 2014, 47, 438-444.	0.7	11
718	Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex – evidence from two transgenic mouse models. Alzheimer's Research and Therapy, 2014, 6, 2.	3.0	118
719	Imaging and Cerebrospinal Fluid Biomarkers in the Search for Alzheimer's Disease Mechanisms. Neurodegenerative Diseases, 2014, 13, 163-165.	0.8	13
720	Kynurenic Acid Levels in Cerebrospinal Fluid from Patients with Alzheimer's Disease or Dementia with Lewy Bodies. International Journal of Tryptophan Research, 2014, 7, IJTR.S13958.	1.0	36
721	O1-12-02: AMYLOID BURDEN, CORTICAL THICKNESS, AND COGNITIVE FUNCTION IN THE WISCONSIN REGISTRY FOR ALZHEIMER'S PREVENTION. , 2014, 10, P153-P153.		1
722	Effect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (Review). Molecular Medicine Reports, 2015, 12, 3-12.	1.1	77
723	Poorly controlled cholesterol is associated with cognitive impairment in T2DM: a resting-state fMRI study. Lipids in Health and Disease, 2015, 14, 47.	1.2	30
725	Multimodal Voxel-Based Meta-Analysis of White Matter Abnormalities in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 495-507.	1.2	31
726	APOE Affects the Volume and Shape of the Amygdala and the Hippocampus in Mild Cognitive Impairment and Alzheimer's Disease: Age Matters. Journal of Alzheimer's Disease, 2015, 47, 645-660.	1.2	35
727	Sensitive Detection of Proteopathic Seeding Activity with FRET Flow Cytometry. Journal of Visualized Experiments, 2015, , e53205.	0.2	60
728	Subjective Memory Complaint Only Relates to Verbal Episodic Memory Performance in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 44, 309-318.	1.2	25
729	Re-examining tau-immunoreactive pathology in the population: granulovacuolar degeneration and neurofibrillary tangles. Alzheimer's Research and Therapy, 2015, 7, 57.	3.0	10
730	In-vivo brain neuroimaging provides a gateway for integrating biological and clinical biomarkers of Alzheimer's disease. Current Opinion in Neurology, 2015, 28, 351-357.	1.8	14
731	The Fornix in Mild Cognitive Impairment and Alzheimerââ,¬â"¢s Disease. Frontiers in Aging Neuroscience, 2015, 7, 1.	1.7	194
732	Misframed ubiquitin and impaired protein quality control: an early event in Alzheimer's disease. Frontiers in Molecular Neuroscience, 2015, 8, 47.	1.4	34
733	Blood Pressure and Heart Rate Variability in Alzheimer's Disease. Dementia and Neurocognitive Disorders, 2015, 14, 128.	0.4	4
734	Pathology in Captive Wild Felids at German Zoological Gardens. PLoS ONE, 2015, 10, e0130573.	1.1	58
735	Neuroimaging Analysis of the Dopamine Basis for Apathetic Behaviors in an MPTP-Lesioned Primate Model. PLoS ONE, 2015, 10, e0132064.	1.1	21

#	Article	IF	Citations
736	Alzheimer's Disease-Related Protein Expression in the Retina of Octodon degus. PLoS ONE, 2015, 10, e0135499.	1.1	45
737	Lower Urinary Tract Symptoms Are Associated with Increased Risk of Dementia among the Elderly: A Nationwide Study. BioMed Research International, 2015, 2015, 1-7.	0.9	25
738	Altered Neurotransmission Prior to Cognitive Decline in AβPP/PS1 Mice, a Model of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 771-776.	1.2	40
739	A Voxel-Based Morphometry Study in AlzheimerÃ,'s Disease and Mild Cognitive Impairment. African Journal of Psychiatry, 2015, 18, .	0.1	0
740	Reassessment of Risk Genotypes (<i>GRN</i> , <i>TMEM106B</i> , and <i>ABCC9</i> Variants) Associated With Hippocampal Sclerosis of Aging Pathology. Journal of Neuropathology and Experimental Neurology, 2015, 74, 75-84.	0.9	50
741	Role of Adult Hippocampal Neurogenesis in Cognition in Physiology and Disease: Pharmacological Targets and Biomarkers. Handbook of Experimental Pharmacology, 2015, 228, 99-155.	0.9	41
742	Aneuploidy in Lewy body diseases. Neurobiology of Aging, 2015, 36, 1253-1260.	1.5	23
743	The effects of white matter hyperintensities and amyloid deposition on Alzheimer dementia. NeuroImage: Clinical, 2015, 8, 246-252.	1.4	43
744	Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study. Neurology, 2015, 84, 2292-2292.	1.5	3
745	Microglial K ⁺ channel expression in young adult and aged mice. Glia, 2015, 63, 664-672.	2.5	57
746	Autonomic, Behavioral, and Subjective Pain Responses in Alzheimer's Disease. Pain Medicine, 2015, 16, 1930-1942.	0.9	31
747	The Emerging Role of MitomiRs in the Pathophysiology of Human Disease. Advances in Experimental Medicine and Biology, 2015, 888, 123-154.	0.8	65
748	Advanced classification of Alzheimer's disease and healthy subjects based on EEG markers. , 2015, , .		10
750	Automated volumetry and regional thickness analysis of hippocampal subfields and medial temporal cortical structures in mild cognitive impairment. Human Brain Mapping, 2015, 36, 258-287.	1.9	454
751	Improving MRI Brain Image Classification with Anatomical Regional Kernels. Lecture Notes in Computer Science, 2015, , 45-53.	1.0	1
752	The backup is active in Alzheimer's disease: A hypothesis from problem theory. Medical Hypotheses, 2015, 84, 241-248.	0.8	0
753	Olfactory identification in amnestic and non-amnestic mild cognitive impairment and its neuropsychological correlates. Journal of the Neurological Sciences, 2015, 349, 179-184.	0.3	34
754	Amyloid and tau pathology of familial Alzheimer's disease APP/PS1 mouse model in a senescence phenotype background (SAMP8). Age, 2015, 37, 9747.	3.0	36

#	Article	IF	CITATIONS
755	Progression of Seedâ€Induced <scp>A</scp> β Deposition within the Limbic Connectome. Brain Pathology, 2015, 25, 743-752.	2.1	45
756	Astrocytic adenosine receptor A2A and Gs-coupled signaling regulate memory. Nature Neuroscience, 2015, 18, 423-434.	7.1	221
757	Tauâ€ŧargeting passive immunization modulates aspects of pathology in tau transgenic mice. Journal of Neurochemistry, 2015, 132, 135-145.	2.1	70
758	Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: Towards a harmonized segmentation protocol. NeuroImage, 2015, 111, 526-541.	2.1	284
759	Prostate stem cell antigen interacts with nicotinic acetylcholine receptors and is affected in Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1629-1638.	1.5	28
760	Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study. Journal of the Neurological Sciences, 2015, 355, 174-179.	0.3	62
761	Behavioral and neural correlates of visual emotion discrimination and empathy in mild cognitive impairment. Behavioural Brain Research, 2015, 294, 111-122.	1.2	9
762	The hippocampus in aging and disease: From plasticity to vulnerability. Neuroscience, 2015, 309, 1-16.	1.1	306
763	Vitamin D deficiency and Alzheimer disease: Common links. Neurobiology of Disease, 2015, 84, 84-98.	2.1	48
764	Brain collection, standardized neuropathologic assessment, and comorbidity in Alzheimer's Disease Neuroimaging Initiative 2 participants. Alzheimer's and Dementia, 2015, 11, 815-822.	0.4	46
765	Alzheimerâ $€$ ™s Disease and the Search for Environmental Risk Factors. , 2015, , 315-327.		0
766	Genome instability biomarkers and blood micronutrient risk profiles associated with mild cognitive impairment and Alzheimer's disease. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2015, 776, 54-83.	0.4	14
767	Heat shock protein defenses in the neocortex and allocortex of the telencephalon. Neurobiology of Aging, 2015, 36, 1924-1937.	1.5	15
768	Gaussian process classification of Alzheimer's disease and mild cognitive impairment from resting-state fMRI. Neurolmage, 2015, 112, 232-243.	2.1	152
769	Alpha-synucleinopathy and neuropsychological symptoms in a population-based cohort of the elderly. Alzheimer's Research and Therapy, 2015, 7, 19.	3.0	11
770	Olfactory Dysfunction in ApoE ɛ4/4 Homozygotes with Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 791-803.	1.2	21
771	Therapeutical Implications of Melatonin in Alzheimer's and Parkinson's Diseases. Molecular and Integrative Toxicology, 2015, , 197-238.	0.5	0
773	Optical coherence tomography visualizes neurons in human entorhinal cortex. Neurophotonics, 2015, 2, 015004.	1.7	52

#	Article	IF	CITATIONS
775	Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I. Journal of Biological Chemistry, 2015, 290, 15219-15237.	1.6	51
776	Neurodegenerative Diseases: Expanding the Prion Concept. Annual Review of Neuroscience, 2015, 38, 87-103.	5.0	278
777	Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer's disease. Journal of Neural Transmission, 2015, 122, 577-592.	1.4	101
778	Mapping the Progression of Atrophy in Early- and Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 46, 351-364.	1.2	71
779	Microglial Malfunction: The Third Rail in the Development of Alzheimer's Disease. Trends in Neurosciences, 2015, 38, 621-636.	4.2	134
780	Phonological short-term memory in logopenic variant primary progressive aphasia and mild Alzheimer's disease. Cortex, 2015, 71, 183-189.	1.1	32
781	Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. Journal of Neuroscience, 2015, 35, 14234-14250.	1.7	186
782	Predicting the conversion of mild cognitive impairment to Alzheimer's disease based on the volumetric measurements of the selected brain structures in magnetic resonance imaging. Neurologia I Neurochirurgia Polska, 2015, 49, 349-353.	0.6	14
783	Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 160-169.	1.2	34
784	A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example. BBA Clinical, 2015, 4, 1-6.	4.1	2
785	Distinct Therapeutic Mechanisms of Tau Antibodies. Journal of Biological Chemistry, 2015, 290, 21652-21662.	1.6	100
786	Autophagy in Alzheimer's disease: A Cleaning Service Out-of-order?. Current Topics in Neurotoxicity, 2015, , 123-142.	0.4	0
787	Associations of brain lesions at autopsy with polysomnography features before death. Neurology, 2015, 84, 296-303.	1.5	50
788	Increased acetyl and total histone levels in post-mortem Alzheimer's disease brain. Neurobiology of Disease, 2015, 74, 281-294.	2.1	112
789	Neuroanatomy and Pathology of Sporadic Alzheimer's Disease. Advances in Anatomy, Embryology and Cell Biology, 2015, , .	1.0	81
790	Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits. Neurobiology of Aging, 2015, 36, 265-272.	1.5	86
791	Tau aggregation and its interplay with amyloid- \hat{l}^2 . Acta Neuropathologica, 2015, 129, 207-220.	3.9	283
793	Mismatch negativity indexes illness-specific impairments of cortical plasticity in schizophrenia: A comparison with bipolar disorder and Alzheimer's disease. International Journal of Psychophysiology, 2015, 95, 145-155.	0.5	89

ARTICLE IF CITATIONS Synaptic Plasticity and Memory. Neuroscientist, 2015, 21, 490-502. 794 2.6 49 Cross talk between PI3K-AKT-CSK-3Î² and PP2A pathways determines tau hyperphosphorylation. 795 1.5 99 Neurobiology of Aging, 2015, 36, 188-200. Neuropathology of Depression in Alzheimer's Disease: Current Knowledge and the Potential for New 796 1.2 47 Treatments. Journal of Alzheimer's Disease, 2015, 44, 27-41. Eph receptors: New players in Alzheimer's disease pathogenesis. Neurobiology of Disease, 2015, 73, 797 34 137-149. At the interface of sensory and motor dysfunctions and Alzheimer's disease. Alzheimer's and 798 0.4 420 Dementia, 2015, 11, 70-98. Temperature controlled ionic liquid-based dispersive micro-extraction using two ligands, for determination of aluminium in scalp hair samples of Alzheimer's patients: A multivariate study. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2015, 137, 877-885. 799 800 Human secreted tau increases amyloid-beta production. Neurobiology of Aging, 2015, 36, 693-709. 1.5 200 Alterations in Olfaction during Alzheimer Disease, Parkinson Disease and Lewy Body Disease., 2016, 6, . 802 Overview of Alzheimer's disease., 2016, , . 0 Voxel-based morphometry: current perspectives. Neuroscience and Neuroeconomics, 0, Volume 5, 19-35. Expression of Alzheimer-Type Neurofibrillary Epitopes in Primary Rat Cortical Neurons Following 804 9 1.7 Infection with Enterococcus faecalis. Frontiers in Aging Neuroscience, 2015, 7, 259. Identify the Atrophy of Alzheimer's Disease, Mild Cognitive Impairment and Normal Aging Using 26 Morphometric MRI Analysis. Frontiers in Aging Neuroscience, 2016, 08, 243. Structural and Functional MRI Differences in Master Sommeliers: A Pilot Study on Expertise in the 806 1.0 22 Brain. Frontiers in Human Neuroscience, 2016, 10, 414. Turning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in 1.4 122 Alzheimer's and Parkinson's Disease. Frontiers in Neuroscience, 2015, 9, 500. Classification of Single Normal and Alzheimer's Disease Individuals from Cortical Sources of Resting 808 73 1.4 State EEG Rhythms. Frontiers in Neuroscience, 2016, 10, 47. Exploring Patterns of Alteration in Alzheimer's Disease Brain Networks: A Combined Structural and 809 1.4 38 Functional Connectomics Analysis. Frontiers in Neuroscience, 2016, 10, 380. 810 Characteristics of Tau and Its Ligands in PET Imaging. Biomolecules, 2016, 6, 7. 1.8 86 Tau PET Imaging for Dementia in Clinical Practice. Radioisotopes, 2016, 65, 517-522. 0.1

#	Article	IF	CITATIONS
812	Greater loss of object than spatial mnemonic discrimination in aged adults. Hippocampus, 2016, 26, 417-422.	0.9	84
813	Synergistic stress exacerbation in hippocampal neurons: Evidence favoring the dualâ€hit hypothesis of neurodegeneration. Hippocampus, 2016, 26, 980-994.	0.9	20
814	Identification of learning-induced changes in protein networks in the hippocampi of a mouse model of Alzheimer's disease. Translational Psychiatry, 2016, 6, e849-e849.	2.4	14
815	First magenetic resonance imaging studies on aluminium maltolateâ€ŧreated aged New Zealand rabbits: an Alzheimer's animal model. Psychogeriatrics, 2016, 16, 263-267.	0.6	4
816	Tau in Late-Life Depression: A Systematic Review and Meta-Analysis. Journal of Alzheimer's Disease, 2016, 54, 615-633.	1.2	23
817	Apolipoprotein E Related Co-Morbidities and Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 935-948.	1.2	15
818	Insular atrophy and diminished disgust reactivity Emotion, 2016, 16, 903-912.	1.5	35
819	High Resolution Dissection of Reactive Glial Nets in Alzheimer's Disease. Scientific Reports, 2016, 6, 24544.	1.6	56
820	Subtle changes in daily functioning predict conversion from normal to mild cognitive impairment or dementia: an analysis of the NACC database. International Psychogeriatrics, 2016, 28, 2009-2018.	0.6	23
821	Chapter 14 Deep Brain Stimulation for Memory Dysfunction. , 2016, , 257-274.		0
822	Analysis of primary visual cortex in dementia with Lewy bodies indicates GABAergic involvement associated with recurrent complex visual hallucinations. Acta Neuropathologica Communications, 2016, 4, 66.	2.4	58
823	Frontal, Striatal, and Medial Temporal Sensitivity to Value Distinguishes Risk-Taking from Risk-Aversive Older Adults during Decision Making. Journal of Neuroscience, 2016, 36, 12498-12509.	1.7	22
824	What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?. Journal of Alzheimer's Disease, 2016, 51, 793-800.	1.2	7
825	Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 54, 157-168.	1.2	23
826	An Overview of Quantitative Magnetic Resonance Imaging Analysis Studies in the Assessment of Alzheimer's Disease. IFMBE Proceedings, 2016, , 281-286.	0.2	2
827	Imaging the accumulation and suppression of tau pathology using multiparametric MRI. Neurobiology of Aging, 2016, 39, 184-194.	1.5	42
828	Extracellular Vesicles Isolated from the Brains of rTg4510 Mice Seed Tau Protein Aggregation in a Threshold-dependent Manner. Journal of Biological Chemistry, 2016, 291, 12445-12466.	1.6	208
829	Cortical thinning of parahippocampal subregions in very early Alzheimer's disease. Neurobiology of Aging, 2016, 38, 188-196.	1.5	49

	CITATION RE	PORT	
# 830	ARTICLE Pathological tau deposition in Motor Neurone Disease and frontotemporal lobar degeneration associated with TDP-43 proteinopathy. Acta Neuropathologica Communications, 2016, 4, 33.	IF 2.4	Citations 33
831	Cyclooxygenase inhibition targets neurons to prevent early behavioural decline in Alzheimer's disease model mice. Brain, 2016, 139, 2063-2081.	3.7	86
832	Increased 4R-Tau Induces Pathological Changes in a Human-Tau Mouse Model. Neuron, 2016, 90, 941-947.	3.8	143
833	Critical residues involved in tau binding to fyn: implications for tau phosphorylation in Alzheimer's disease. Acta Neuropathologica Communications, 2016, 4, 49.	2.4	60
834	Fornix Microstructure and Memory Performance Is Associated with Altered Neural Connectivity during Episodic Recognition. Journal of the International Neuropsychological Society, 2016, 22, 191-204.	1.2	19
835	Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain. Proceedings of the Royal Society B: Biological Sciences, 2016, 283, 20152397.	1.2	176
836	Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-β Alterations in a Monkey Model of Type 1 Diabetes. Journal of Neuroscience, 2016, 36, 4248-4258.	1.7	66
837	Automated identification of dementia using medical imaging: a survey from a pattern classification perspective. Brain Informatics, 2016, 3, 17-27.	1.8	35
838	The effect of MAPT haplotype on neocortical Lewy body pathology in Parkinson disease. Journal of Neural Transmission, 2016, 123, 583-588.	1.4	11
839	Synaptic pathology: A shared mechanism in neurological disease. Ageing Research Reviews, 2016, 28, 72-84.	5.0	122
840	Machine Learning and Interpretation in Neuroimaging. Lecture Notes in Computer Science, 2016, , .	1.0	0
841	Haloperidol inactivates AMPK and reduces tau phosphorylation in a tau mouse model of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 121-130.	1.8	23
842	Potential mechanisms and implications for the formation of tau oligomeric strains. Critical Reviews in Biochemistry and Molecular Biology, 2016, 51, 482-496.	2.3	64
843	Amyloid βâ€induced astrogliosis is mediated by β1â€integrin via NADPH oxidase 2 in Alzheimer's disease. Aging Cell, 2016, 15, 1140-1152.	3.0	53
844	Dementias. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 138, 123-151.	1.0	35
845	Prion diseases: New considerations. Clinical Neurology and Neurosurgery, 2016, 150, 125-132.	0.6	11
846	Reduced Efficacy of Anti-AÂ Immunotherapy in a Mouse Model of Amyloid Deposition and Vascular Cognitive Impairment Comorbidity. Journal of Neuroscience, 2016, 36, 9896-9907.	1.7	25
847	Antibody-Mediated Targeting of Tau InÂVivo Does Not Require Effector Function and Microglial Engagement. Cell Reports, 2016, 16, 1690-1700.	2.9	102

#	Article	IF	CITATIONS
848	Prionâ€like propagation as a pathogenic principle in frontotemporal dementia. Journal of Neurochemistry, 2016, 138, 163-183.	2.1	54
849	Conserved size and periodicity of pyramidal patches in layer 2 of medial/caudal entorhinal cortex. Journal of Comparative Neurology, 2016, 524, 783-806.	0.9	35
850	The effect of βâ€∎myloid positivity on cerebral metabolism in cognitively normal seniors. Alzheimer's and Dementia, 2016, 12, 1250-1258.	0.4	8
851	Gender-Specific Degeneration of Dementia-Related Subcortical Structures Throughout the Lifespan. Journal of Alzheimer's Disease, 2016, 55, 865-880.	1.2	11
852	Specialized roles of neurofilament proteins in synapses: Relevance to neuropsychiatric disorders. Brain Research Bulletin, 2016, 126, 334-346.	1.4	63
853	Tool use disorders in neurodegenerative diseases: Roles of semantic memory and technical reasoning. Cortex, 2016, 82, 119-132.	1.1	38
854	Melanopsin retinal ganglion cell loss in <scp>A</scp> lzheimer disease. Annals of Neurology, 2016, 79, 90-109.	2.8	299
855	The neural correlates of auditory and visuospatial span in logopenic progressive aphasia and Alzheimer's disease. Cortex, 2016, 83, 39-50.	1.1	49
856	Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease. Expert Opinion on Pharmacotherapy, 2016, 17, 2417-2429.	0.9	18
857	Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. JAMA Psychiatry, 2016, 73, 1230.	6.0	164
858	Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer's disease and track disease progression and cognitive decline. Acta Neuropathologica, 2016, 132, 875-895.	3.9	105
859	Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma. Journal of Biological Chemistry, 2016, 291, 27204-27218.	1.6	42
860	Integrative network analysis of nineteen brain regions identifies molecular signatures and networks underlying selective regional vulnerability to Alzheimer's disease. Genome Medicine, 2016, 8, 104.	3.6	224
861	Discrepancy in Expression of β-Secretase and Amyloid-β Protein Precursor in Alzheimer-Related Genes in the Rat Medial Temporal Lobe Cortex Following Transient Global Brain Ischemia. Journal of Alzheimer's Disease, 2016, 51, 1023-1031.	1.2	45
862	Hippocampal phospho-tau/MAPT neuropathology in the fornix in Alzheimer disease: an immunohistochemical autopsy study. Acta Neuropathologica Communications, 2016, 4, 114.	2.4	11
863	Passive Immunotherapy for Tau Pathology. , 2016, , 371-384.		2
864	The Prion-Like Properties of Amyloid-β Assemblies: Implications for Alzheimer's Disease. Cold Spring Harbor Perspectives in Medicine, 2016, 6, a024398.	2.9	71
865	Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer's disease. Neurobiology of Aging, 2016, 43, 89-100.	1.5	68

#	Article	IF	CITATIONS
866	Profiling the human hippocampal proteome at all pathologic stages of Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 654-668.	0.4	153
867	Stereological approaches to dementia research using human brain tissue. Journal of Chemical Neuroanatomy, 2016, 76, 73-81.	1.0	5
868	Living with a diagnosis of behavioural-variant frontotemporal dementia: The person's experience. Dementia, 2016, 15, 1622-1642.	1.0	19
869	Paradigm shift: semantic memory decline as a biomarker of preclinical Alzheimer's disease. Biomarkers in Medicine, 2016, 10, 5-8.	0.6	26
870	Epitope mapping and structural basis for the recognition of phosphorylated tau by the antiâ€ŧau antibody AT8. Proteins: Structure, Function and Bioinformatics, 2016, 84, 427-434.	1.5	84
871	Tau pathology-dependent remodelling of cerebral arteries precedes Alzheimer's disease-related microvascular cerebral amyloid angiopathy. Acta Neuropathologica, 2016, 131, 737-752.	3.9	84
872	The use of human neurons for novel drug discovery in dementia research. Expert Opinion on Drug Discovery, 2016, 11, 355-367.	2.5	12
873	The Cellular Phase of Alzheimer's Disease. Cell, 2016, 164, 603-615.	13.5	1,346
874	Association of APOE with tau-tangle pathology with and without β-amyloid. Neurobiology of Aging, 2016, 37, 19-25.	1.5	97
875	Prions and Protein Assemblies that Convey Biological Information in Health and Disease. Neuron, 2016, 89, 433-448.	3.8	74
876	MRI morphometry in Alzheimer's disease. Ageing Research Reviews, 2016, 30, 17-24.	5.0	122
877	Brain atrophy in Alzheimer's Disease and aging. Ageing Research Reviews, 2016, 30, 25-48.	5.0	507
878	Diagnostic Profiles of Patients Differentially Failing Executive Functioning Measures. American Journal of Alzheimer's Disease and Other Dementias, 2016, 31, 214-222.	0.9	0
879	Gait and cognition: Mapping the global and discrete relationships in ageing and neurodegenerative disease. Neuroscience and Biobehavioral Reviews, 2016, 64, 326-345.	2.9	216
880	Circadian Rhythms, Sleep, and Disorders of Aging. Trends in Endocrinology and Metabolism, 2016, 27, 192-203.	3.1	247
881	Potential Animal Models of Alzheimer Disease and Their Importance in Investigating the Pathogenesis of Alzheimer Disease. , 2016, , 77-111.		0
882	Oxidative stress and hippocampal synaptic protein levels in elderly cognitively intact individuals with Alzheimer's disease pathology. Neurobiology of Aging, 2016, 42, 1-12.	1.5	69
883	Synaptic Amyloid-β Oligomers Precede p-Tau and Differentiate High Pathology Control Cases. American Journal of Pathology, 2016, 186, 185-198.	1.9	94

#	Article	IF	CITATIONS
884	Targeting Prefrontal Cortical Systems for Drug Development: Potential Therapies for Cognitive Disorders. Annual Review of Pharmacology and Toxicology, 2016, 56, 339-360.	4.2	67
885	Systems Biology Approaches to the Study of Biological Networks Underlying Alzheimer's Disease: Role of miRNAs. Methods in Molecular Biology, 2016, 1303, 349-377.	0.4	19
886	Entorhinal cortex: a good biomarker of mild cognitive impairment and mild Alzheimer's disease. Reviews in the Neurosciences, 2016, 27, 185-195.	1.4	66
887	A neuronal aging pattern unique to humans and common chimpanzees. Brain Structure and Function, 2016, 221, 647-664.	1.2	18
888	Portuguese version of Wechsler Memory Scale–3rd edition's utility with demented elderly adults. Applied Neuropsychology Adult, 2017, 24, 212-225.	0.7	5
889	The Nucleation of Protein Aggregates - From Crystals to Amyloid Fibrils. International Review of Cell and Molecular Biology, 2017, 329, 187-226.	1.6	46
890	Cortical Thickness and Microstructural White Matter Changes Detect Amnestic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 56, 415-428.	1.2	21
891	The Polyphenol Altenusin Inhibits in Vitro Fibrillization of Tau and Reduces Induced Tau Pathology in Primary Neurons. ACS Chemical Neuroscience, 2017, 8, 743-751.	1.7	32
892	Health benefits of methylxanthines in neurodegenerative diseases. Molecular Nutrition and Food Research, 2017, 61, 1600670.	1.5	65
893	The neuropathological signature of bulbar-onset ALS: A systematic review. Neuroscience and Biobehavioral Reviews, 2017, 75, 378-392.	2.9	45
894	Differentiating cognitive impairment due to corticobasal degeneration and Alzheimer disease. Neurology, 2017, 88, 1273-1281.	1.5	34
895	Total Synthesis Confirms the Molecular Structure Proposed for Oxidized Levuglandin D2. Journal of Natural Products, 2017, 80, 488-498.	1.5	7
896	Câ€ŧerminal truncation of <scp>GSK</scp> â€3β enhances its dephosphorylation by <scp>PP</scp> 2A. FEBS Letters, 2017, 591, 1053-1063.	1.3	11
897	Progressive Disintegration of Brain Networking from Normal Aging to Alzheimer Disease: Analysis of Independent Components of ¹⁸ F-FDG PET Data. Journal of Nuclear Medicine, 2017, 58, 1132-1139.	2.8	41
898	A nonmusician with severe Alzheimer's dementia learns a new song. Neurocase, 2017, 23, 36-40.	0.2	20
899	Mitophagy and Alzheimer's Disease: Cellular and Molecular Mechanisms. Trends in Neurosciences, 2017, 40, 151-166.	4.2	553
900	Mitochondria in Alzheimer's Disease and Diabetes-Associated Neurodegeneration: License to Heal!. Handbook of Experimental Pharmacology, 2017, 240, 281-308.	0.9	22
901	Sleep and hippocampal neurogenesis: Implications for Alzheimer's disease. Frontiers in Neuroendocrinology, 2017, 45, 35-52.	2.5	38

#	ARTICLE	IF	CITATIONS
902	<scp>H</scp> ippocampal subfields at ultra high field MRI: <scp>A</scp> n overview of segmentation and measurement methods. Hippocampus, 2017, 27, 481-494.	0.9	51
903	Diagnosing the frontal variant of Alzheimer's disease: a clinician's yellow brick road. Journal of Clinical Movement Disorders, 2017, 4, 2.	2.2	27
904	Quantification of Tau Load Using [18F]AV1451 PET. Molecular Imaging and Biology, 2017, 19, 963-971.	1.3	42
905	Is Tau Imaging More Than Just Upside-Down ¹⁸ F-FDG Imaging?. Journal of Nuclear Medicine, 2017, 58, 1357-1359.	2.8	21
906	Tau pathology and cognitive reserve in Alzheimer's disease. Neurobiology of Aging, 2017, 57, 1-7.	1.5	50
907	Multi-modal classification of neurodegenerative disease by progressive graph-based transductive learning. Medical Image Analysis, 2017, 39, 218-230.	7.0	47
908	The functional neuroanatomy of verbal memory in Alzheimer's disease: [¹⁸ F]-Fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) correlates of recency and recognition memory. Journal of Clinical and Experimental Neuropsychology, 2017, 39, 682-693.	0.8	12
909	How the cognitive reserve interacts with β-amyloid deposition in mitigating FDG metabolism. Medicine (United States), 2017, 96, e5876.	0.4	8
910	Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue. Acta Neuropathologica Communications, 2017, 5, 41.	2.4	78
911	Increased subjective experience of non-target emotions in patients with frontotemporal dementia and Alzheimer's disease. Current Opinion in Behavioral Sciences, 2017, 15, 77-84.	2.0	22
912	Alzheimer's brains show inter-related changes in RNA and lipid metabolism. Neurobiology of Disease, 2017, 106, 1-13.	2.1	43
913	Pimozide reduces toxic forms of tau in TauC3 mice via 5′ adenosine monophosphateâ€activated protein kinaseâ€mediated autophagy. Journal of Neurochemistry, 2017, 142, 734-746.	2.1	28
914	Imaging mass spectrometry (IMS) of cortical lipids from preclinical to severe stages of Alzheimer's disease. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1604-1614.	1.4	52
915	Effect of PICALM rs3851179 polymorphism on the default mode network function in mild cognitive impairment. Behavioural Brain Research, 2017, 331, 225-232.	1.2	20
916	Alzheimer Disease. Mayo Clinic Proceedings, 2017, 92, 978-994.	1.4	57
917	A 31-residue peptide induces aggregation of tau's microtubule-binding region in cells. Nature Chemistry, 2017, 9, 874-881.	6.6	67
918	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. Neurobiology of Aging, 2017, 55, 78-90.	1.5	48
919	Early classification of Alzheimer's disease using hippocampal texture from structural MRI. Proceedings of SPIE, 2017, , .	0.8	2

#	Article	IF	CITATIONS
920	Associations between amyloid β and white matter hyperintensities: A systematic review. Alzheimer's and Dementia, 2017, 13, 1154-1167.	0.4	89
921	Biodistribution and Radiation Dosimetry for the Tau Tracer ¹⁸ F-THK-5351 in Healthy Human Subjects. Journal of Nuclear Medicine, 2017, 58, 1498-1503.	2.8	21
922	Sphingosine 1-phosphate – A double edged sword in the brain. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 1573-1582.	1.4	61
923	Roles of tau protein in health and disease. Acta Neuropathologica, 2017, 133, 665-704.	3.9	639
924	Entorhinal Cortex: Antemortem Cortical Thickness and Postmortem Neurofibrillary Tangles and Amyloid Pathology. American Journal of Neuroradiology, 2017, 38, 961-965.	1.2	30
925	Radiological-Pathological Correlation in Alzheimer's Disease: Systematic Review of Antemortem Magnetic Resonance Imaging Findings. Journal of Alzheimer's Disease, 2017, 57, 575-601.	1.2	51
926	Cognitive decline associated with pathological burden in primary ageâ€related tauopathy. Alzheimer's and Dementia, 2017, 13, 1048-1053.	0.4	47
927	Magnetic Resonance Imaging and Anatomical Correlation of Human Temporal Lobe Landmarks, in 3D Euclidean Space: A Study of Control and Alzheimer's Disease Subjects. Journal of Alzheimer's Disease, 2017, 57, 461-473.	1.2	4
928	Clinical validity of presynaptic dopaminergic imaging withÂ123I-ioflupaneÂand noradrenergic imaging with 123I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. Neurobiology of Aging, 2017, 52, 228-242.	1.5	34
929	Neurophysiological assessment of neural network plasticity and connectivity: Progress towards early functional biomarkers for disease interception therapies in Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2017, 73, 340-358.	2.9	30
930	Hippocampal α-Synuclein in Dementia with Lewy Bodies Contributes to Memory Impairment and Is Consistent with Spread of Pathology. Journal of Neuroscience, 2017, 37, 1675-1684.	1.7	92
931	The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement. Alzheimer's and Dementia, 2017, 13, 561-571.	0.4	266
932	Relation of Dysglycemia to Structural Brain Changes in a Multiethnic Elderly Cohort. Journal of the American Geriatrics Society, 2017, 65, 277-285.	1.3	41
934	Prion-like Protein Seeding and the Pathobiology of Alzheimer's Disease. , 2017, , 57-82.		0
935	Short-term mechanisms influencing volumetric brain dynamics. NeuroImage: Clinical, 2017, 16, 507-513.	1.4	32
936	Different deficit patterns on word lists and short stories predict conversion to Alzheimer's disease in patients with amnestic mild cognitive impairment. Journal of Neurology, 2017, 264, 2258-2267.	1.8	21
937	Proteomic mapping of differentially vulnerable pre-synaptic populations identifies regulators of neuronal stability in vivo. Scientific Reports, 2017, 7, 12412.	1.6	34
938	Tau-based therapies in neurodegeneration: opportunities and challenges. Nature Reviews Drug Discovery, 2017, 16, 863-883.	21.5	193

ARTICLE IF CITATIONS Heterogeneous Association of Alzheimer's Disease-Linked Amyloid-Î² and Amyloid-Î² Protein Precursor 939 1.2 20 with Synapses. Journal of Alzheimer's Disease, 2017, 60, 511-524. What Can Quantitative Gait Analysis Tell Us about Dementia and Its Subtypes? A Structured Review. 940 1.2 59 Journal of Alzheimer's Disease, 2017, 60, 1295-1312. Comparative Effects of Education and Bilingualism on the Onset of Mild Cognitive Impairment. 941 0.7 29 Dementia and Geriatric Cognitive Disorders, 2017, 44, 222-231. <i>N</i>-Acetyl-l-Cysteine Protects Astrocytes against Proteotoxicity without Recourse to 942 Glutathione. Molecular Pharmacology, 2017, 92, 564-575. The Aging Navigational System. Neuron, 2017, 95, 1019-1035. 943 3.8 256 Brain Perfusion SPECT in Alzheimer's Disease. , 2017, , 211-220. Blood Pressure Variability and Cognitive Function Among Older African Americans: Introducing a New 945 0.5 12 Blood Pressure Variability Measure. Cognitive and Behavioral Neurology, 2017, 30, 90-97. Structural Neuroimaging in Alzheimer's Disease. , 2017, , 21-38. 946 Small-molecule PET Tracers for Imaging Proteinopathies. Seminars in Nuclear Medicine, 2017, 47, 947 2.5 91 553-575. 948 Refining Alzheimer's disease diagnosis with MRI. Brain, 2017, 140, 524-526. Necroptosis activation in Alzheimer's disease. Nature Neuroscience, 2017, 20, 1236-1246. 949 305 7.1Prediction of MCI to AD conversion using Laplace Eigenmaps learned from FDG and MRI images of AD patients and healthy controls., 2017,,. Tau-imaging in neurodegeneration. Methods, 2017, 130, 114-123. 951 1.9 34 Tracking Cognitive Decline in Amnestic Mild Cognitive Impairment and Early-Stage Alzheimer Dementia: Mini-Mental State Examination versus Neuropsychological Battery. Dementia and Geriatric Cognitive Disorders, 2017, 44, 105-117. Hyperhomocysteinemia-Induced Gene Expression Changes in the Cell Types of the Brain. ASN Neuro, 953 30 1.5 2017, 9, 175909141774229. The AÎ² oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque 954 pathology. Scientific Reports, 2017, 7, 16275. Activation of G-protein-gated inwardly rectifying potassium (Kir3/GirK) channels rescues hippocampal 955 1.6 41 functions in a mouse model of early amyloid-l² pathology. Scientific Reports, 2017, 7, 14658. A clinicopathological approach to the diagnosis of dementia. Nature Reviews Neurology, 2017, 13, 457-476.

#	Article	IF	CITATIONS
957	Alzheimer's Disease: Insights from Genetic Mouse Models and Current Advances in Human IPSC-Derived Neurons. Advances in Neurobiology, 2017, 15, 3-29.	1.3	4
958	The Brief Odor Detection Test (B-ODT) for Very Early Diagnosis of Cognitive Decline: A Preliminary Study. Brain Impairment, 2017, 18, 197-210.	0.5	0
959	Radiosynthesis of [18F]AV1451 in pharmaceutical conditions and its biological characteristics. Applied Radiation and Isotopes, 2017, 128, 101-107.	0.7	5
960	Oligomeric tau-targeted immunotherapy in Tg4510 mice. Alzheimer's Research and Therapy, 2017, 9, 46.	3.0	13
961	Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain. Alzheimer's Research and Therapy, 2017, 9, 25.	3.0	285
962	Quantitative proteomics identifies altered Oâ€GlcNAcylation of structural, synaptic and memoryâ€associated proteins in Alzheimer's disease. Journal of Pathology, 2017, 243, 78-88.	2.1	105
963	Morphometric alterations of Golgi apparatus in Alzheimer's disease are related to tau hyperphosphorylation. Neurobiology of Disease, 2017, 97, 11-23.	2.1	24
964	Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease. Journal of Neural Transmission, 2017, 124, 273-284.	1.4	9
965	Assessment of free and cued recall in Alzheimer's disease and vascular and frontotemporal dementia with 24-item Grober and Buschke test. Neurological Sciences, 2017, 38, 115-122.	0.9	17
966	Visual system manifestations of Alzheimer's disease. Acta Ophthalmologica, 2017, 95, e668-e676.	0.6	48
968	Cortical Manifestations in Amyotrophic Lateral Sclerosis. , 2017, , 223-242.		1
969	Cl-NQTrp Alleviates Tauopathy Symptoms in a Model Organism through the Inhibition of Tau Aggregation-Engendered Toxicity. Neurodegenerative Diseases, 2017, 17, 73-82.	0.8	24
970	Education is associated with sub-regions of the hippocampus and the amygdala vulnerable to neuropathologies of Alzheimer's disease. Brain Structure and Function, 2017, 222, 1469-1479.	1.2	24
971	The DIANâ€TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimer's and Dementia, 2017, 13, 8-19.	0.4	230
972	Multi-template analysis of human perirhinal cortex in brain MRI: Explicitly accounting for anatomical variability. NeuroImage, 2017, 144, 183-202.	2.1	30
973	Does medial temporal lobe thickness mediate the association between risk factor burden and memory performance in middle-aged or older adults with metabolic syndrome?. Neuroscience Letters, 2017, 636, 225-232.	1.0	11
974	Longitudinal brain structural changes in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2017, 13, 499-509.	0.4	65
975	Multiregional analysis of global 5â€methylcytosine and 5â€hydroxymethylcytosine throughout the progression of Alzheimer's disease. Journal of Neurochemistry, 2017, 140, 383-394.	2.1	42

	CITATION	REPORT	
#	Article	IF	Citations
11	ARTICLE		CHAHONS
976	Widespread tau seeding activity at early Braak stages. Acta Neuropathologica, 2017, 133, 91-100.	3.9	122
977	On-going electroencephalographic rhythms related to cortical arousal in wild-type mice: the effect of aging. Neurobiology of Aging, 2017, 49, 20-30.	1.5	11
978	¹⁸ F-AV-1451 positron emission tomography in Alzheimer's disease and progressive supranuclear palsy. Brain, 2017, 140, aww340.	3.7	174
979	Neuropathology of dementia. , 2016, , 94-122.		5
980	PET Tau and Amyloid-β Burden in Mild Alzheimer's Disease: Divergent Relationship with Age, Cognition, and Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2017, 60, 283-293.	1.2	67
981	Diaschisis-Like Association of Hippocampal Atrophy and Posterior Cingulate Cortex Hypometabolism in Cognitively Normal Elderly Depends on Impaired Integrity of Parahippocampal Cingulum Fibers. Journal of Alzheimer's Disease, 2017, 60, 1285-1294.	1.2	3
982	Hypertension, cerebrovascular impairment, and cognitive decline in aged AβPP/PS1 mice. Theranostics, 2017, 7, 1277-1289.	4.6	39
983	Neurodegenerative Disorders. , 2017, , 1-16.		18
984	In Search of Sleep Biomarkers of Alzheimer's Disease: K-Complexes Do Not Discriminate between Patients with Mild Cognitive Impairment and Healthy Controls. Brain Sciences, 2017, 7, 51.	1.1	37
985	Getting Lost Behavior in Patients with Mild Alzheimer's Disease: A Cognitive and Anatomical Model. Frontiers in Medicine, 2017, 4, 201.	1.2	12
986	White Matter Deterioration May Foreshadow Impairment of Emotional Valence Determination in Early-Stage Dementia of the Alzheimer Type. Frontiers in Aging Neuroscience, 2017, 9, 37.	1.7	4
987	Early-Onset Network Hyperexcitability in Presymptomatic Alzheimer's Disease Transgenic Mice Is Suppressed by Passive Immunization with Anti-Human APP/Aβ Antibody and by mGluR5 Blockade. Frontiers in Aging Neuroscience, 2017, 9, 71.	1.7	75
988	Glia Maturation Factor and Mitochondrial Uncoupling Proteins 2 and 4 Expression in the Temporal Cortex of Alzheimer's Disease Brain. Frontiers in Aging Neuroscience, 2017, 9, 150.	1.7	31
989	Lower Activation in Frontal Cortex and Posterior Cingulate Cortex Observed during Sex Determination Test in Early-Stage Dementia of the Alzheimer Type. Frontiers in Aging Neuroscience, 2017, 9, 156.	1.7	0
990	A Novel Virtual Reality-Based Training Protocol for the Enhancement of the "Mental Frame Syncing―in Individuals with Alzheimer's Disease: A Development-of-Concept Trial. Frontiers in Aging Neuroscience, 2017, 9, 240.	1.7	65
991	Altered Behavioral and Autonomic Pain Responses in Alzheimer's Disease Are Associated with Dysfunctional Affective, Self-Reflective and Salience Network Resting-State Connectivity. Frontiers in Aging Neuroscience, 2017, 9, 297.	1.7	17
992	Expression of Tau Pathology-Related Proteins in Different Brain Regions: A Molecular Basis of Tau Pathogenesis. Frontiers in Aging Neuroscience, 2017, 9, 311.	1.7	40
993	Periodontitis, Microbiomes and their Role in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2017, 9, 336.	1.7	68

#	Article	IF	CITATIONS
994	Disrupted Thalamus White Matter Anatomy and Posterior Default Mode Network Effective Connectivity in Amnestic Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2017, 9, 370.	1.7	22
995	Visual Dysfunction in Posterior Cortical Atrophy. Frontiers in Neurology, 2017, 8, 389.	1.1	43
996	Classification of Healthy Subjects and Alzheimer's Disease Patients with Dementia from Cortical Sources of Resting State EEG Rhythms: A Study Using Artificial Neural Networks. Frontiers in Neuroscience, 2016, 10, 604.	1.4	51
997	Hippocampal activation is associated with longitudinal amyloid accumulation and cognitive decline. ELife, 2017, 6, .	2.8	95
998	Studying tau protein propagation and pathology in the mouse brain using adeno-associated viruses. Methods in Cell Biology, 2017, 141, 307-322.	0.5	23
999	Tau accumulation in the retina promotes early neuronal dysfunction and precedes brain pathology in a mouse model of Alzheimer's disease. Molecular Neurodegeneration, 2017, 12, 58.	4.4	99
1000	The CNS in inbred transgenic models of 4-repeat Tauopathy develops consistent tau seeding capacity yet focal and diverse patterns of protein deposition. Molecular Neurodegeneration, 2017, 12, 72.	4.4	14
1001	Practical considerations for choosing a mouse model of Alzheimer's disease. Molecular Neurodegeneration, 2017, 12, 89.	4.4	305
1002	Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy. Alzheimer's Research and Therapy, 2017, 9, 77.	3.0	53
1003	Effect of Mild Cognitive Impairment and Alzheimer Disease on Auditory Steady-State Responses. Basic and Clinical Neuroscience, 2017, 8, 299-306.	0.3	4
1004	Preliminary Evidence: Diagnosed Alzheimer's Disease but not MCI Affects Working Memory: 0.6 of 2.6 Memory Pointers Lost. , 2017, 07, .		0
1005	Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer's Disease. ENeuro, 2017, 4, ENEURO.0149-16.2017.	0.9	149
1006	Tau-mediated Neurodegeneration and Potential Implications in Diagnosis and Treatment of Alzheimer's Disease. Chinese Medical Journal, 2017, 130, 2978-2990.	0.9	49
1007	Prions. , 2018, , .		0
1008	Alzheimer risk loci and associated neuropathology in a population-based study (Vantaa 85+). Neurology: Genetics, 2018, 4, e211.	0.9	16
1009	Functional Imbalance of Anterolateral Entorhinal Cortex and Hippocampal Dentate/CA3ÂUnderlies Age-Related Object Pattern Separation Deficits. Neuron, 2018, 97, 1187-1198.e4.	3.8	156
1010	Tau protein liquid–liquid phase separation can initiate tau aggregation. EMBO Journal, 2018, 37, .	3.5	696
1011	Early Tau Burden Correlates with Higher Rate of Atrophy in Transentorhinal Cortex. Journal of Alzheimer's Disease, 2018, 62, 85-92	1.2	29

#	Article	IF	CITATIONS
1012	Diminution of context association memory structure in subjects with subjective cognitive decline. Human Brain Mapping, 2018, 39, 2549-2562.	1.9	26
1013	Protein Semisynthesis Provides Access to Tau Disease-Associated Post-translational Modifications (PTMs) and Paves the Way to Deciphering the Tau PTM Code in Health and Diseased States. Journal of the American Chemical Society, 2018, 140, 6611-6621.	6.6	82
1014	Age-Dependent Changes to Sphingolipid Balance in the Human Hippocampus are Gender-Specific and May Sensitize to Neurodegeneration. Journal of Alzheimer's Disease, 2018, 63, 503-514.	1.2	39
1015	Critical review: involvement of endoplasmic reticulum stress in the aetiology of Alzheimer's disease. Open Biology, 2018, 8, 180024.	1.5	106
1016	Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinson's Disease Substantia Nigra. Neurotoxicity Research, 2018, 33, 560-568.	1.3	31
1017	A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date. Journal of Neurotrauma, 2018, 35, 2015-2024.	1.7	25
1018	Automated Multi-Atlas Segmentation of Hippocampal and Extrahippocampal Subregions in Alzheimer's Disease at 3T and 7T: What Atlas Composition Works Best?. Journal of Alzheimer's Disease, 2018, 63, 217-225.	1.2	11
1019	Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. Journal of Alzheimer's Disease, 2018, 62, 1815-1826.	1.2	11
1020	Amyloidâ€beta 1â€40 is associated with alterations in NG2+ pericyte population exÂvivo and inÂvitro. Aging Cell, 2018, 17, e12728.	3.0	49
1021	Phos-tau peptide immunization of amyloid-tg-mice reduced non-mutant phos-tau pathology, improved cognition and reduced amyloid plaques. Experimental Neurology, 2018, 303, 48-58.	2.0	9
1022	The Impact of Music on the Self in Dementia. Journal of Alzheimer's Disease, 2018, 61, 827-841.	1.2	57
1023	Can Addressing Personality Change Enhance Cognitive Functioning and Delay Development of Mild Cognitive Impairment?. Journal of the American Geriatrics Society, 2018, 66, 650-651.	1.3	0
1024	Characterization of a 3xTgâ€AD mouse model of Alzheimer's disease with the senescence accelerated mouse prone 8 (SAMP8) background. Synapse, 2018, 72, e22025.	0.6	16
1025	Clinical Utility of Select Neuropsychological Assessment Battery Tests in Predicting Functional Abilities in Dementia. Archives of Clinical Neuropsychology, 2018, 33, 530-540.	0.3	21
1026	lonic wave propagation and collision in an excitable circuit model of microtubules. Chaos, 2018, 28, 023106.	1.0	8
1027	Tau Positron Emission Tomography in Autosomal Dominant Alzheimer Disease. JAMA Neurology, 2018, 75, 536.	4.5	17
1028	Neuropathology correlates of cognitive assessments. Irish Journal of Medical Science, 2018, 187, 835-844.	0.8	1
1029	Core Differences in Synaptic Signaling Between Primary Visual and Dorsolateral Prefrontal Cortex. Cerebral Cortex, 2018, 28, 1458-1471.	1.6	26

# 1030	ARTICLE The effect of Alzheimer's disease on spatial navigation strategies. Neurobiology of Aging, 2018, 64, 107-115.	lF 1.5	CITATIONS
1031	Editorial: Pathogenic templating proteins in Neurodegenerative Disease. Neurobiology of Disease, 2018, 109, 175-177.	2.1	2
1032	Networks of tau distribution in Alzheimer's disease. Brain, 2018, 141, 568-581.	3.7	140
1033	Volumetric comparison of hippocampal subfields extracted from 4-minute accelerated vs. 8-minute high-resolution T2-weighted 3T MRI scans. Brain Imaging and Behavior, 2018, 12, 1583-1595.	1.1	13
1034	Tau burden and the functional connectome in Alzheimer's disease and progressive supranuclear palsy. Brain, 2018, 141, 550-567.	3.7	190
1035	Elevated Markers of Inflammation Are Associated With Longitudinal Changes in Brain Function in Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 770-778.	1.7	55
1036	Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer's disease brain. Acta Neuropathologica Communications, 2018, 6, 25.	2.4	37
1037	Uncommon and/or bizarre features of dementia: PartÂIII. Acta Neurologica Belgica, 2018, 118, 211-216.	0.5	2
1038	Hippocampal Radial Glial Subtypes and Their Neurogenic Potential in Human Fetuses and Healthy and Alzheimer's Disease Adults. Cerebral Cortex, 2018, 28, 2458-2478.	1.6	128
1039	Longitudinal evaluation of Tauâ€₽301L transgenic mice reveals no cognitive impairments at 17Âmonths of age. Brain and Behavior, 2018, 8, e00896.	1.0	14
1040	Neuropsychology in a Memory Disorder Clinic. Archives of Clinical Neuropsychology, 2018, 33, 301-309.	0.3	6
1041	Toward a New Concept of Alzheimer's Disease Models: A Perspective from Neuroinflammation. Journal of Alzheimer's Disease, 2018, 64, S329-S338.	1.2	22
1042	Tau Kinetics in Neurons and the Human Central Nervous System. Neuron, 2018, 97, 1284-1298.e7.	3.8	381
1043	Role of Mitochondria in Neurodegenerative Diseases: The Dark Side of the "Energy Factoryâ€, , 2018, , 213-239.		6
1044	Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. Journal of Alzheimer's Disease, 2018, 64, S47-S105.	1.2	122
1045	Biomarkers for Alzheimer's Disease and Frontotemporal Lobar Degeneration: Imaging. , 2018, , 253-277.		0
1046	Forgetting of the recollection and familiarity components of recognition in patients with amnestic mild cognitive impairment. Journal of Neuropsychology, 2018, 12, 231-247.	0.6	7
1047	Quantitative sodium MR imaging: A review of its evolving role in medicine. Neurolmage, 2018, 168, 250-268.	2.1	78

#	Article	IF	CITATIONS
1048	Human astrocytes in the diseased brain. Brain Research Bulletin, 2018, 136, 139-156.	1.4	183
1049	Variations in Acetylcholinesterase Activity within Human Cortical Pyramidal Neurons Across Age and Cognitive Trajectories. Cerebral Cortex, 2018, 28, 1329-1337.	1.6	32
1050	Development of tau PET Imaging Ligands and their Utility in Preclinical and Clinical Studies. Nuclear Medicine and Molecular Imaging, 2018, 52, 24-30.	0.6	13
1051	Pain, aging and dementia: Towards a biopsychosocial model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 87, 207-215.	2.5	58
1052	Distinct patterns of amyloidâ€dependent tau accumulation in Lewy body diseases. Movement Disorders, 2018, 33, 262-272.	2.2	54
1053	Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease. Neuropeptides, 2018, 67, 79-86.	0.9	12
1054	Chronic deep brain stimulation in an Alzheimer's disease mouse model enhances memory and reduces pathological hallmarks. Brain Stimulation, 2018, 11, 435-444.	0.7	49
1055	Neocortical origin and progression of gray matter atrophy in nonamnestic Alzheimer's disease. Neurobiology of Aging, 2018, 63, 75-87.	1.5	61
1056	Amyloid-β and tau complexity — towards improved biomarkers and targeted therapies. Nature Reviews Neurology, 2018, 14, 22-39.	4.9	303
1057	Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians. Psychopharmacology, 2018, 235, 761-770.	1.5	19
1058	Deficits in synaptic function occur at medial perforant path-dentate granule cell synapses prior to Schaffer collateral-CA1 pyramidal cell synapses in the novel TgF344-Alzheimer's Disease Rat Model. Neurobiology of Disease, 2018, 110, 166-179.	2.1	45
1059	Von Economo neurons of the anterior cingulate across the lifespan and in Alzheimer's disease. Cortex, 2018, 99, 69-77.	1.1	47
1060	Protein production is an early biomarker for <scp>RNA</scp> â€ŧargeted therapies. Annals of Clinical and Translational Neurology, 2018, 5, 1492-1504.	1.7	8
1061	The Role of MRI Biomarkers and Their Interactions with Cognitive Status and APOE ε4 in Nondemented Elderly Subjects. Neurodegenerative Diseases, 2018, 18, 270-280.	0.8	7
1062	Topological Biomarker of Alzheimer's Disease. , 0, , .		1
1063	New longitudinal Visual Rating Scale Identifies Structural Alterations in People with Mild Cognitive Impairment and Those who are Cognitively Normal. International Journal of Gerontology, 2018, , .	0.7	1
1064	Progressive impairment of directional and spatially precise trajectories by TgF344-Alzheimer's disease rats in the Morris Water Task. Scientific Reports, 2018, 8, 16153.	1.6	50
1065	Pathologies Underlying Longitudinal Cognitive Decline in the Oldest Old. Alzheimer Disease and Associated Disorders, 2018, 32, 265-269.	0.6	10

#	Article	IF	CITATIONS
1066	InÂvivo coupling of tau pathology and cortical thinning in Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 678-687.	1.2	24
1067	Calpain-mediated tau fragmentation is altered in Alzheimer's disease progression. Scientific Reports, 2018, 8, 16725.	1.6	35
1068	Amnestic Mild Cognitive Impairment Is Associated With Frequency-Specific Brain Network Alterations in Temporal Poles. Frontiers in Aging Neuroscience, 2018, 10, 400.	1.7	29
1069	Cell-Type-Specific Proteomics: A Neuroscience Perspective. Proteomes, 2018, 6, 51.	1.7	29
1070	Regional tau pathology and loneliness in cognitively normal older adults. Translational Psychiatry, 2018, 8, 282.	2.4	46
1071	Multivariate Deep Learning Classification of Alzheimer's Disease Based on Hierarchical Partner Matching Independent Component Analysis. Frontiers in Aging Neuroscience, 2018, 10, 417.	1.7	26
1072	Spatiotemporal activation of the C/EBPβ/δ-secretase axis regulates the pathogenesis of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E12427-E12434.	3.3	21
1073	Proteomic Investigation of Murine Neuronal α7-Nicotinic Acetylcholine Receptor Interacting Proteins. Journal of Proteome Research, 2018, 17, 3959-3975.	1.8	8
1074	Aβ and the dementia syndrome: Simple versus complex perspectives. European Journal of Clinical Investigation, 2018, 48, e13025.	1.7	11
1075	Forgetting Rate on the Recency Portion of a Word List Differentiates Mild to Moderate Alzheimer's Disease from Other Forms of Dementi. Journal of Alzheimer's Disease, 2018, 66, 461-470.	1.2	11
1076	Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology. Molecular Neurodegeneration, 2018, 13, 54.	4.4	80
1077	Regional White Matter Hyperintensity Influences Grey Matter Atrophy in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 66, 533-549.	1.2	28
1078	Human chorionic gonadotropin decreases the phosphorylated tau protein level in streptozotocin-Alzheimeric male rats' hippocampus. Folia Neuropathologica, 2018, 56, 141-150.	0.5	2
1079	Impact of small vessel disease on severity of motor and cognitive impairment in Parkinson's disease. Journal of Clinical Neuroscience, 2018, 58, 70-74.	0.8	19
1080	Alzheimer's Disease Biomarkers Have Distinct Associations with Specific Hippocampal Subfield Volumes. Journal of Alzheimer's Disease, 2018, 66, 811-823.	1.2	6
1081	Adaptive fusion of texture-based grading for Alzheimer's disease classification. Computerized Medical Imaging and Graphics, 2018, 70, 8-16.	3.5	44
1082	Rodent models for Alzheimer disease. Nature Reviews Neuroscience, 2018, 19, 583-598.	4.9	240
1083	Chronic Traumatic Encephalopathy and Neurodegeneration in Contact Sports and American Football. Journal of Alzheimer's Disease, 2018, 66, 37-55.	1.2	16

#	Article	IF	CITATIONS
1084	Abnormal Functional Brain Networks in Mild Cognitive Impairment and Alzheimer's Disease: A Minimum Spanning Tree Analysis. Journal of Alzheimer's Disease, 2018, 65, 1093-1107.	1.2	22
1085	Unconventional Secretion Mediates the Trans-cellular Spreading of Tau. Cell Reports, 2018, 23, 2039-2055.	2.9	194
1086	Self-Reported Physical Activity is Associated with Tau Burden Measured by Positron Emission Tomography. Journal of Alzheimer's Disease, 2018, 63, 1299-1305.	1.2	28
1087	O-GlcNAcylation and neuronal energy status: Implications for Alzheimer's disease. Ageing Research Reviews, 2018, 46, 32-41.	5.0	25
1088	Secretion of full-length Tau or Tau fragments in cell culture models. Propagation of Tau in vivo and in vitro. Biomolecular Concepts, 2018, 9, 1-11.	1.0	14
1089	Cognitive impairment and medial temporal lobe structure in young adults with a depressive episode. Journal of Affective Disorders, 2018, 237, 112-117.	2.0	14
1090	Novel monoclonal antibodies targeting the microtubule-binding domain of human tau. PLoS ONE, 2018, 13, e0195211.	1.1	12
1091	In Vivo Positron Emission Tomography of Extrastriatal Non-Dopaminergic Pathology in Parkinson Disease. Contemporary Clinical Neuroscience, 2018, , 143-170.	0.3	1
1094	Induction of a transmissible tau pathology by traumatic brain injury. Brain, 2018, 141, 2685-2699.	3.7	74
1095	Characterization of dural sinus-associated lymphatic vasculature in human Alzheimer's dementia subjects. Brain, Behavior, and Immunity, 2018, 73, 34-40.	2.0	43
1096	Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. Alzheimer's Research and Therapy, 2018, 10, 54.	3.0	24
1097	Alterations of Reil's Insula in Alzheimer's Disease. , 2018, , 169-174.		1
1098	Neuropathology and cognitive performance in self-reported cognitively healthy centenarians. Acta Neuropathologica Communications, 2018, 6, 64.	2.4	36
1099	Integrative Analysis of Hippocampus Gene Expression Profiles Identifies Network Alterations in Aging and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 153.	1.7	58
1100	Multimodal Discrimination between Normal Aging, Mild Cognitive Impairment and Alzheimer's Disease and Prediction of Cognitive Decline. Diagnostics, 2018, 8, 14.	1.3	21
1101	Genetic variants associated with Alzheimer's disease confer different cerebral cortex cell-type population structure. Genome Medicine, 2018, 10, 43.	3.6	62
1102	Dendritic Tau in Alzheimer's Disease. Neuron, 2018, 99, 13-27.	3.8	178
1103	Recent advancements toward therapeutic vaccines against Alzheimer's disease. Expert Review of Vaccines, 2018, 17, 707-721.	2.0	46

#	Article	IF	CITATIONS
1104	Untangling the Tauopathy for Alzheimer's disease and parkinsonism. Journal of Biomedical Science, 2018, 25, 54.	2.6	37
1105	The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype. Neurobiology of Aging, 2018, 71, 72-80.	1.5	42
1106	Exosomes taken up by neurons hijack the endosomal pathway to spread to interconnected neurons. Acta Neuropathologica Communications, 2018, 6, 10.	2.4	127
1107	Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART. Acta Neuropathologica, 2018, 136, 57-67.	3.9	173
1108	Hippocampal place cell dysfunction and the effects of muscarinic M ₁ receptor agonism in a rat model of Alzheimer's disease. Hippocampus, 2018, 28, 568-585.	0.9	13
1109	Molecular and functional signatures in a novel Alzheimer's disease mouse model assessed by quantitative proteomics. Molecular Neurodegeneration, 2018, 13, 2.	4.4	62
1110	latrogenic Creutzfeldt-Jakob disease with Amyloid-β pathology: an international study. Acta Neuropathologica Communications, 2018, 6, 5.	2.4	79
1111	Magnetic resonance imaging relaxation time in Alzheimer's disease. Brain Research Bulletin, 2018, 140, 176-189.	1.4	34
1112	The human brainome: network analysis identifies HSPA2 as a novel Alzheimer's disease target. Brain, 2018, 141, 2721-2739.	3.7	31
1113	Distinctive temporal profiles of detergent-soluble and -insoluble tau and Aβ species in human Alzheimer's disease. Brain Research, 2018, 1699, 121-134.	1.1	19
1114	TFEB enhances astroglial uptake of extracellular tau species and reduces tau spreading. Journal of Experimental Medicine, 2018, 215, 2355-2377.	4.2	173
1115	Different Abnormalities of Cortical Neural Synchronization Mechanisms in Patients with Mild Cognitive Impairment due to Alzheimer's and Chronic Kidney Diseases: An EEG Study. Journal of Alzheimer's Disease, 2018, 65, 897-915.	1.2	12
1116	Transcriptional network analysis of human astrocytic endfoot genes reveals region-specific associations with dementia status and tau pathology. Scientific Reports, 2018, 8, 12389.	1.6	46
1117	Diagnostic and prognostic role of semantic processing in preclinical Alzheimer's disease. Biomarkers in Medicine, 2018, 12, 637-651.	0.6	32
1118	The Correlations between Postmortem Brain Pathologies and Cognitive Dysfunction in Aging and Alzheimer's Disease. Current Alzheimer Research, 2018, 15, 462-473.	0.7	16
1119	The Neuroimaging of Brain Diseases. Contemporary Clinical Neuroscience, 2018, , .	0.3	1
1120	Pseudo-phosphorylation at AT8 epitopes regulates the tau truncation at aspartate 421. Experimental Cell Research, 2018, 370, 103-115.	1.2	9
1121	Variably protease-sensitive prionopathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 175-190.	1.0	29

#	Article	IF	CITATIONS
1122	Prion-like mechanisms in Alzheimer disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 153, 303-319.	1.0	42
1123	Tau-induced focal neurotoxicity and network disruption related to apathy in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1208-1214.	0.9	30
1124	Associations of plasma clusterin and Alzheimer's disease-related MRI markers in adults at mid-life: The CARDIA Brain MRI sub-study. PLoS ONE, 2018, 13, e0190478.	1.1	15
1125	Stereological Quantification of Plaques and Tangles in Neocortex from Alzheimer's Disease Patients. Journal of Alzheimer's Disease, 2018, 64, 723-734.	1.2	4
1126	Alterations to task positive and task negative networks during executive functioning in Mild Cognitive Impairment. NeuroImage: Clinical, 2018, 19, 970-981.	1.4	29
1127	Brain Imaging of Alzheimer Dementia Patients and Elderly Controls with ¹⁸ F-MK-6240, a PET Tracer Targeting Neurofibrillary Tangles. Journal of Nuclear Medicine, 2019, 60, 107-114.	2.8	92
1128	Melatonin: Clinical Perspectives in Neurodegeneration. Frontiers in Endocrinology, 2019, 10, 480.	1.5	129
1129	Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans. Acta Neuropathologica Communications, 2019, 7, 129.	2.4	32
1130	Cell-autonomous and non-cell autonomous effects of neuronal BIN1 loss in vivo. PLoS ONE, 2019, 14, e0220125.	1.1	17
1131	Microglia Express Insulin-Like Growth Factor-1 in the Hippocampus of Aged APPswe/PS1ΔE9 Transgenic Mice. Frontiers in Cellular Neuroscience, 2019, 13, 308.	1.8	24
1132	The quantitative neuroradiology initiative framework: application to dementia. British Journal of Radiology, 2019, 92, 20190365.	1.0	32
1134	Single amyloidâ€beta injection exacerbates 4â€aminopyridineâ€induced seizures and changes synaptic coupling in the hippocampus. Hippocampus, 2019, 29, 1150-1164.	0.9	16
1135	coMethDMR: accurate identification of co-methylated and differentially methylated regions in epigenome-wide association studies with continuous phenotypes. Nucleic Acids Research, 2019, 47, e98-e98.	6.5	28
1136	Associations among amyloid status, age, and longitudinal regional brain atrophy in cognitively unimpaired older adults. Neurobiology of Aging, 2019, 82, 110-119.	1.5	11
1137	The complexities of behavioural assessment in neurodegenerative disorders: A focus on Alzheimer's disease. Pharmacological Research, 2019, 147, 104363.	3.1	9
1138	Experimental evidence for the age dependence of tau protein spread in the brain. Science Advances, 2019, 5, eaaw6404.	4.7	103
1139	BIN1 favors the spreading of Tau via extracellular vesicles. Scientific Reports, 2019, 9, 9477.	1.6	107
1140	Is Alzheimer's Disease a Neurogenesis Disorder?. Cell Stem Cell, 2019, 25, 7-8.	5.2	65

#	Article	IF	CITATIONS
1141	Common BACE2 Polymorphisms are Associated with Altered Risk for Alzheimer's Disease and CSF Amyloid Biomarkers in APOE ε4 Non-Carriers. Scientific Reports, 2019, 9, 9640.	1.6	14
1142	Quantifying mechanisms in neurodegenerative diseases (NDDs) using candidate mechanism perturbation amplitude (CMPA) algorithm. BMC Bioinformatics, 2019, 20, 494.	1.2	3
1143	MRâ€based ageâ€related effects on the striatum, globus pallidus, and thalamus in healthy individuals across the adult lifespan. Human Brain Mapping, 2019, 40, 5269-5288.	1.9	55
1144	Sphingosine Kinase 2 Potentiates Amyloid Deposition but Protects against Hippocampal Volume Loss and Demyelination in a Mouse Model of Alzheimer's Disease. Journal of Neuroscience, 2019, 39, 9645-9659.	1.7	22
1145	From molecules to system failure: translational frontiers of multimodal imaging in neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2816-2818.	3.3	0
1146	Extracellular vesicles as an emerging tool for the early detection of Alzheimer's disease. Mechanisms of Ageing and Development, 2019, 184, 111175.	2.2	47
1147	The retinal choroid as an oculovascular biomarker for Alzheimer's dementia: A histopathological study in severe disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 775-783.	1.2	13
1148	Brainâ€derived and circulating vesicle profiles indicate neurovascular unit dysfunction in early Alzheimer's disease. Brain Pathology, 2019, 29, 593-605.	2.1	44
1149	Exploring the relationship between physical activity, beta-amyloid and tau: A narrative review. Ageing Research Reviews, 2019, 50, 9-18.	5.0	67
1150	Cognitive-Motor Integration Performance Is Affected by Sex, APOE Status, and Family History of Dementia. Journal of Alzheimer's Disease, 2019, 71, 685-701.	1.2	13
1151	Attention-based 3D Convolutional Network for Alzheimer's Disease Diagnosis and Biomarkers Exploration. , 2019, , .		33
1152	Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. Translational Neurodegeneration, 2019, 8, 28.	3.6	70
1153	Dorsal hippocampal changes in T2 relaxation times are associated with early spatial cognitive deficits in 5XFAD mice. Brain Research Bulletin, 2019, 153, 150-161.	1.4	5
1154	In vivo detection of cerebral tau pathology in long-term survivors of traumatic brain injury. Science Translational Medicine, 2019, 11, .	5.8	56
1155	Altered microglia and neurovasculature in the Alzheimer's disease cerebellum. Neurobiology of Disease, 2019, 132, 104589.	2.1	36
1156	Multimodal Hippocampal Subfield Grading For Alzheimer's Disease Classification. Scientific Reports, 2019, 9, 13845.	1.6	33
1157	Optimization of ultrastructural preservation of human brain for transmission electron microscopy after long post-mortem intervals. Acta Neuropathologica Communications, 2019, 7, 144.	2.4	17
1158	Prediction and Classification of Alzheimer's Disease Based on Combined Features From Apolipoprotein-E Genotype, Cerebrospinal Fluid, MR, and FDG-PET Imaging Biomarkers. Frontiers in Computational Neuroscience, 2019, 13, 72.	1.2	97

#	Article	IF	CITATIONS
1159	Neurodegenerative disorders of the human frontal lobes. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 163, 391-410.	1.0	13
1160	Plasma tau/amyloid-β1–42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease. Brain, 2019, 142, 771-786.	3.7	117
1161	Genetic analysis suggests high misassignment rates in clinical Alzheimer's cases and controls. Neurobiology of Aging, 2019, 77, 178-182.	1.5	10
1162	State of the science on mild cognitive impairment (MCI). CNS Spectrums, 2019, 24, 78-87.	0.7	228
1163	Mesoscopic Neural Representations in Spatial Navigation. Trends in Cognitive Sciences, 2019, 23, 615-630.	4.0	53
1164	Activity-Dependent Reconnection of Adult-Born Dentate Granule Cells in a Mouse Model of Frontotemporal Dementia. Journal of Neuroscience, 2019, 39, 5794-5815.	1.7	12
1165	A comparison of the prevalence of orthostatic hypotension between older patients with Alzheimer's Disease, Lewy body dementia, and without dementia. Experimental Gerontology, 2019, 124, 110628.	1.2	30
1166	Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players. Acta Neuropathologica, 2019, 138, 389-399.	3.9	108
1167	Photobiomodulation as a treatment for neurodegenerative disorders: current and future trends. Biomedical Engineering Letters, 2019, 9, 359-366.	2.1	36
1168	Tau Phosphorylation Rates Measured by Mass Spectrometry Differ in the Intracellular Brain vs. Extracellular Cerebrospinal Fluid Compartments and Are Differentially Affected by Alzheimer's Disease. Frontiers in Aging Neuroscience, 2019, 11, 121.	1.7	104
1169	Virtual Enactment Effect on Memory in Young and Aged Populations: A Systematic Review. Journal of Clinical Medicine, 2019, 8, 620.	1.0	32
1170	Neuropsychological assessment in preclinical and prodromal Alzheimer disease: a global perspective. Journal of Global Health, 2019, 9, 010317.	1.2	15
1171	Regional Molecular Mapping of Primate Synapses during Normal Healthy Aging. Cell Reports, 2019, 27, 1018-1026.e4.	2.9	20
1172	Major Differences between the Self-Assembly and Seeding Behavior of Heparin-Induced and in Vitro Phosphorylated Tau and Their Modulation by Potential Inhibitors. ACS Chemical Biology, 2019, 14, 1363-1379.	1.6	34
1173	Automated segmentation of medial temporal lobe subregions on in vivo T1â€weighted MRI in early stages of Alzheimer's disease. Human Brain Mapping, 2019, 40, 3431-3451.	1.9	71
1174	Levels of glial cell lineâ€derived neurotrophic factor are decreased, but fibroblast growth factor 2 and cerebral dopamine neurotrophic factor are increased in the hippocampus in Parkinson's disease. Brain Pathology, 2019, 29, 813-825.	2.1	24
1175	Novelty processing and memory impairment in Alzheimer's disease: A review. Neuroscience and Biobehavioral Reviews, 2019, 100, 237-249.	2.9	26
1176	Pathogenic tau modifications occur in axons before the somatodendritic compartment in mossy fiber and Schaffer collateral pathways. Acta Neuropathologica Communications, 2019, 7, 29.	2.4	14

ARTICLE IF CITATIONS Adenoâ€associated virusâ€based Alzheimer's disease mouse models and potential new therapeutic avenues. 1177 2.7 22 British Journal of Pharmacology, 2019, 176, 3649-3665. The elusive tau molecular structures: can we translate the recent breakthroughs into new targets 1178 2.4 49 for intervention?. Acta Neuropathologica Communications, 2019, 7, 31. Adult hippocampal neurogenesis is abundant in neurologically healthy subjects and drops sharply in 1179 1,070 15.2patients with Alzheimer's disease. Nature Medicine, 2019, 25, 554-560. Propagation of Protein Aggregation in Neurodegenerative Diseases. Annual Review of Biochemistry, 1180 5.0 2019, 88, 785-810. Subacute to chronic Alzheimer-like alterations after controlled cortical impact in human tau 1181 1.6 8 transgenic mice. Scientific Reports, 2019, 9, 3789. Loss of ferritinâ€positive microglia relates to increased iron, RNA oxidation, and dystrophic microglia 0.8 in the brains of aged male marmosets. American Journal of Primatology, 2019, 81, e22956. Jujuboside A prevents sleep loss-induced disturbance of hippocampal neuronal excitability and memory 1183 1.6 21 impairment in young APP/PS1 mice. Scientific Reports, 2019, 9, 4512. The Hypothalamus in Alzheimer's Disease: A Golgi and Electron and Microscope Study. , 0, , . 1184 The Retina in Alzheimer's Disease: Histomorphometric Analysis of an Ophthalmologic Biomarker., 2019, 1185 55 60, 1491. Pharmacological doses of melatonin impede cognitive decline in tauâ€related Alzheimer models, once 3.4 tauopathy is initiated, by restoring the autophagic flux. Journal of Pineal Research, 2019, 67, e12578. Dammarane-type saponins from Gynostemma pentaphyllum and their potential anti-AD activity. 1187 4 0.6 Phytochemistry Letters, 2019, 31, 147-154. An integrative memory model of recollection and familiarity to understand memory deficits. 0.4 74 Behavioral and Brain Sciences, 2019, 42, e281. Pathological Alterations of Tau in Alzheimer's Disease and 3xTg-AD Mouse Brains. Molecular 1189 1.9 29 Neurobiology, 2019, 56, 6168-6183. A walk through tau therapeutic strategies. Acta Neuropathologica Communications, 2019, 7, 22. 1190 2.4 MAPT mutations, tauopathy, and mechanisms of neurodegeneration. Laboratory Investigation, 2019, 99, 1191 190 1.7 912-928. Exploring Structural and Functional Brain Changes in Mild Cognitive Impairment: A Whole Brain ALE 33 Meta-Analysis for Multimodal MRI. ACS Chemical Neuroscience, 2019, 10, 2823-2829. The relationship between the morphological subtypes of microglia and Alzheimer's disease 1193 2.163 neuropathology. Brain Pathology, 2019, 29, 726-740. Correlations Between Single Nucleotide Polymorphisms, Cognitive Dysfunction, and Postmortem 1194 1.5 Brain Pathology in Alzheimer's Disease Ámong Han Chinese. Neuroscience Bulletin, 2019, 35, 193-204.

\sim	 	D	PORT
	ON	ᆝᄼᅣ	ד גוראנ
\sim		IVEL	

#	Article	IF	CITATIONS
1195	There is more to memory than recollection and familiarity. Behavioral and Brain Sciences, 2019, 42, e292.	0.4	0
1196	Alzheimer's disease: A clinical perspective and future nonhuman primate research opportunities. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 26224-26229.	3.3	61
1197	Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain. Science Translational Medicine, 2019, 11, .	5.8	30
1198	A Case of Overlap Posterior Cortical Atrophy and Logopenic Variant Primary Progressive Aphasia. Neurologist, 2019, 24, 62-65.	0.4	14
1199	A Longitudinal Study of Epileptic Seizures in Alzheimer's Disease. Frontiers in Neurology, 2019, 10, 1266.	1.1	36
1200	Interleukin-1β drives NEDD8 nuclear-to-cytoplasmic translocation, fostering parkin activation via NEDD8 binding to the P-ubiquitin activating site. Journal of Neuroinflammation, 2019, 16, 275.	3.1	17
1201	A post-translational modification signature defines changes in soluble tau correlating with oligomerization in early stage Alzheimer's disease brain. Acta Neuropathologica Communications, 2019, 7, 192.	2.4	54
1202	The amyloid-β degradation intermediate Aβ34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer's disease. Acta Neuropathologica Communications, 2019, 7, 194.	2.4	20
1203	Automated Volumetry of Medial Temporal Lobe Subregions in Mild Cognitive Impairment and Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2019, 33, 206-211.	0.6	9
1204	Decreased meta-memory is associated with early tauopathy in cognitively unimpaired older adults. NeuroImage: Clinical, 2019, 24, 102097.	1.4	7
1205	The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 324-333.	3.3	6
1206	Mechanisms of Cell-to-Cell Transmission of Pathological Tau. JAMA Neurology, 2019, 76, 101.	4.5	162
1207	Taskâ€enhanced arterial spin labeled perfusion MRI predicts longitudinal neurodegeneration in mild cognitive impairment. Hippocampus, 2019, 29, 26-36.	0.9	11
1208	Hippocampal vascularization patterns: A high-resolution 7 Tesla time-of-flight magnetic resonance angiography study. NeuroImage: Clinical, 2019, 21, 101609.	1.4	47
1209	Associative memory for conceptually unitized word pairs in mild cognitive impairment is related to the volume of the perirhinal cortex. Hippocampus, 2019, 29, 630-638.	0.9	11
1210	Friend or foe—Post-translational modifications as regulators of phase separation and RNP granule dynamics. Journal of Biological Chemistry, 2019, 294, 7137-7150.	1.6	275
1211	Neuropathologic, genetic, and longitudinal cognitive profiles in primary ageâ€related tauopathy (PART) and Alzheimer's disease. Alzheimer's and Dementia, 2019, 15, 8-16.	0.4	83
1212	Synaptic distributions of pS214â€ŧau in rhesus monkey prefrontal cortex are associated with spine density, but not with cognitive decline. Journal of Comparative Neurology, 2019, 527, 856-873.	0.9	4

#	Article	IF	CITATIONS
1213	Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 2048-2059.	1.8	48
1214	Early functional connectivity deficits and progressive microstructural alterations in the TgF344-AD rat model of Alzheimer's Disease: A longitudinal MRI study. Neurobiology of Disease, 2019, 124, 93-107.	2.1	46
1215	A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis. Alzheimer's and Dementia, 2019, 15, 93-105.	0.4	65
1216	Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies. , 2019, 195, 186-198.		141
1217	A parameter-efficient deep learning approach to predict conversion from mild cognitive impairment to Alzheimer's disease. NeuroImage, 2019, 189, 276-287.	2.1	260
1218	Molecular Pathogenesis of the Tauopathies. Annual Review of Pathology: Mechanisms of Disease, 2019, 14, 239-261.	9.6	161
1219	Predicting progression to Alzheimer's disease in subjects with amnestic mild cognitive impairment using performance on recall and recognition tests. Journal of Neurology, 2019, 266, 102-111.	1.8	44
1220	Neuroendocrine-Metabolic Dysfunction and Sleep Disturbances in Neurodegenerative Disorders: Focus on Alzheimer's Disease and Melatonin. Neuroendocrinology, 2019, 108, 354-364.	1.2	37
1221	Hippocampal transcriptome profiling combined with protein-protein interaction analysis elucidates Alzheimer's disease pathways and genes. Neurobiology of Aging, 2019, 74, 225-233.	1.5	30
1222	Pathological Changes of Tau Related to Alzheimer's Disease. ACS Chemical Neuroscience, 2019, 10, 931-944.	1.7	54
1223	Imaging brain microstructure with diffusion MRI: practicality and applications. NMR in Biomedicine, 2019, 32, e3841.	1.6	266
1224	The Evolving Dialogue of Microglia and Neurons in Alzheimer's Disease: Microglia as Necessary Transducers of Pathology. Neuroscience, 2019, 405, 24-34.	1.1	60
1225	Cognitive trajectories and spectrum of neuropathology in <scp>S</scp> uper <scp>A</scp> gers: The first 10 cases. Hippocampus, 2019, 29, 458-467.	0.9	44
1226	A methodological approach to studying resilience mechanisms: demonstration of utility in age and Alzheimer's disease-related brain pathology. Brain Imaging and Behavior, 2019, 13, 162-171.	1.1	6
1227	Mechanistic complexities of bone loss in Alzheimer's disease: a review. Connective Tissue Research, 2020, 61, 4-18.	1.1	22
1228	Changes in functional and structural brain connectome along the Alzheimer's disease continuum. Molecular Psychiatry, 2020, 25, 230-239.	4.1	78
1229	Test–retest repeatability of [¹⁸ F]Flortaucipir PET in Alzheimer's disease and cognitively normal individuals. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 2464-2474.	2.4	23
1230	Lost or unavailable? Exploring mechanisms that affect retrograde memory in mild cognitive impairment and Alzheimer's disease patients. Journal of Neurology, 2020, 267, 113-124.	1.8	7

#	Article	IF	CITATIONS
1231	Three-year changes of cortical 18F-FDC in amnestic vs. non-amnestic sporadic early-onset Alzheimer's disease. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 304-318.	3.3	4
1232	Traumatic Brain Injury Induces Tau Aggregation and Spreading. Journal of Neurotrauma, 2020, 37, 80-92.	1.7	113
1233	C99 selectively accumulates in vulnerable neurons in Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 273-282.	0.4	42
1234	Reelin in the Years: decline in the number of reelin immunoreactive neurons in layer II of the entorhinal cortex in aged monkeys with memory impairment. Neurobiology of Aging, 2020, 87, 132-137.	1.5	24
1235	Real-space navigation testing differentiates between amyloid-positive and -negative aMCI. Neurology, 2020, 94, e861-e873.	1.5	24
1236	Interaction Between Odor Identification Deficit and APOE4 Predicts 6-Year Cognitive Decline in Elderly Individuals. Behavior Genetics, 2020, 50, 3-13.	1.4	15
1237	MRI and cognitive scores complement each other to accurately predict Alzheimer's dementia 2 to 7 years before clinical onset. NeuroImage: Clinical, 2020, 25, 102121.	1.4	16
1238	Aging and Alzheimer's disease pathology. Neuropathology, 2020, 40, 22-29.	0.7	166
1239	Effect of Phosphorylated Tau on Cortical Pyramidal Neuron Morphology during Hibernation. Cerebral Cortex Communications, 2020, 1, tgaa018.	0.7	3
1240	Nuclear Transport Deficits in Tau-Related Neurodegenerative Diseases. Frontiers in Neurology, 2020, 11, 1056.	1.1	23
1241	Dysfunctional proteins in neuropsychiatric disorders: From neurodegeneration to autism spectrum disorders. Neurochemistry International, 2020, 141, 104853.	1.9	14
1242	Clinical Evaluation of 18F-PI-2620 as a Potent PET Radiotracer Imaging Tau Protein in Alzheimer Disease and Other Neurodegenerative Diseases Compared With 18F-THK-5351. Clinical Nuclear Medicine, 2020, 45, 841-847.	0.7	16
1243	Local Sleep and Alzheimer's Disease Pathophysiology. Frontiers in Neuroscience, 2020, 14, 525970.	1.4	50
1244	The Cell Biology of Tau Secretion. Frontiers in Molecular Neuroscience, 2020, 13, 569818.	1.4	28
1245	Yuan-Hu Zhi Tong Prescription Mitigates Tau Pathology and Alleviates Memory Deficiency in the Preclinical Models of Alzheimer's Disease. Frontiers in Pharmacology, 2020, 11, 584770.	1.6	24
1246	Kinin B2 Receptor Activation Prevents the Evolution of Alzheimer's Disease Pathological Characteristics in a Transgenic Mouse Model. Pharmaceuticals, 2020, 13, 288.	1.7	5
1247	Cellular Biology of Tau Diversity and Pathogenic Conformers. Frontiers in Neurology, 2020, 11, 590199.	1.1	12
1248	Gene-environment interaction promotes Alzheimer's risk as revealed by synergy of repeated mild traumatic brain injury and mouse App knock-in. Neurobiology of Disease, 2020, 145, 105059.	2.1	2

#	Article	IF	CITATIONS
1249	Autonomic function in amnestic and non-amnestic mild cognitive impairment: spectral heart rate variability analysis provides evidence for a brain–heart axis. Scientific Reports, 2020, 10, 11661.	1.6	27
1250	The unfolded protein response is activated in the olfactory system in Alzheimer's disease. Acta Neuropathologica Communications, 2020, 8, 109.	2.4	22
1251	Passive immunotherapies targeting Aβ and tau in Alzheimer's disease. Neurobiology of Disease, 2020, 144, 105010.	2.1	81
1253	Genetic risk for Alzheimer disease affects the brain throughout the lifespan. Neurology: Genetics, 2020, 6, e516.	0.9	1
1254	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	1.4	17
1255	Targeting Tau to Treat Clinical Features of Huntington's Disease. Frontiers in Neurology, 2020, 11, 580732.	1.1	13
1256	Role of Cofilin in Alzheimer's Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 584898.	1.8	25
1257	Epigenome-wide meta-analysis of DNA methylation differences in prefrontal cortex implicates the immune processes in Alzheimer's disease. Nature Communications, 2020, 11, 6114.	5.8	75
1258	Current Evidence on the Protective Effects of Recombinant Human Erythropoietin and Its Molecular Variants against Pathological Hallmarks of Alzheimer's Disease. Pharmaceuticals, 2020, 13, 424.	1.7	17
1259	Chronic BACE-1 Inhibitor Administration in TASTPM Mice (APP KM670/671NL and PSEN1 M146V Mutation): An EEG Study. International Journal of Molecular Sciences, 2020, 21, 9072.	1.8	1
1260	RT-QuIC detection of tauopathies using full-length tau substrates. Prion, 2020, 14, 249-256.	0.9	16
1261	Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12096.	1.8	15
1262	Characterizing tau deposition in chronic traumatic encephalopathy (CTE): utility of the McKee CTE staging scheme. Acta Neuropathologica, 2020, 140, 495-512.	3.9	66
1263	Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. Journal of Nuclear Medicine, 2020, 61, 1413-1418.	2.8	17
1264	Recall and Recognition in Alzheimer's Disease and Frontotemporal Dementia. Journal of Alzheimer's Disease, 2020, 77, 655-666.	1.2	5
1265	Impaired glymphatic function and clearance of tau in an Alzheimer's disease model. Brain, 2020, 143, 2576-2593.	3.7	227
1266	Quantitative immunohistochemical analysis of myeloid cell marker expression in human cortex captures microglia heterogeneity with anatomical context. Scientific Reports, 2020, 10, 11693.	1.6	33
1267	3D Mapping of TAU Neurofibrillary Tangle Pathology in the Human Medial Temporal Lobe. , 2020, , .		6

#	Article	IF	CITATIONS
1268	CMS121, a fatty acid synthase inhibitor, protects against excess lipid peroxidation and inflammation and alleviates cognitive loss in a transgenic mouse model of Alzheimer's disease. Redox Biology, 2020, 36, 101648.	3.9	70
1269	Truncation of Tau selectively facilitates its pathological activities. Journal of Biological Chemistry, 2020, 295, 13812-13828.	1.6	54
1270	Escitalopram Alleviates Alzheimer's Disease-Type Tau Pathologies in the Aged P301L Tau Transgenic Mice. Journal of Alzheimer's Disease, 2020, 77, 807-819.	1.2	10
1271	Functional Alterations in the Olfactory Neuronal Circuit Occur before Hippocampal Plasticity Deficits in the P301S Mouse Model of Tauopathy: Implications for Early Diagnosis and Translational Research in Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 5431.	1.8	8
1272	Imaging Alzheimer's genetic risk using diffusion MRI: A systematic review. NeuroImage: Clinical, 2020, 27, 102359.	1.4	24
1273	Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer's disease. Molecular Neurodegeneration, 2020, 15, 43.	4.4	104
1274	Morphological landscape of endothelial cell networks reveals a functional role of glutamate receptors in angiogenesis. Scientific Reports, 2020, 10, 13829.	1.6	10
1275	Degradation and Transmission of Tau by Autophagic-Endolysosomal Networks and Potential Therapeutic Targets for Tauopathy. Frontiers in Molecular Neuroscience, 2020, 13, 586731.	1.4	56
1276	Distinct changes in all major components of the neurovascular unit across different neuropathological stages of Alzheimer's disease. Brain Pathology, 2020, 30, 1056-1070.	2.1	24
1277	Interaction between Cognitive Reserve and Biomarkers in Alzheimer Disease. International Journal of Molecular Sciences, 2020, 21, 6279.	1.8	10
1278	Molecular abnormalities in autopsied brain tissue from the inferior horn of the lateral ventricles of nonagenarians and Alzheimer disease patients. BMC Neurology, 2020, 20, 317.	0.8	15
1279	Tau Acetylation in Entorhinal Cortex Induces its Chronic Hippocampal Propagation and Cognitive Deficits in Mice. Journal of Alzheimer's Disease, 2020, 77, 241-255.	1.2	10
1280	Alzheimer's Disease Progressively Alters the Face-Evoked Visual-Processing Network. Journal of Alzheimer's Disease, 2020, 77, 1025-1042.	1.2	11
1281	Proteomic Profiling of Extracellular Vesicles Derived from Cerebrospinal Fluid of Alzheimer's Disease Patients: A Pilot Study. Cells, 2020, 9, 1959.	1.8	75
1282	Regional Cerebral Associations Between Psychometric Tests and Imaging Biomarkers in Alzheimer's Disease. Frontiers in Psychiatry, 2020, 11, 793.	1.3	7
1283	Longitudinal atrophy in early Braak regions in preclinical Alzheimer's disease. Human Brain Mapping, 2020, 41, 4704-4717.	1.9	34
1284	T2 heterogeneity: a novel marker of microstructural integrity associated with cognitive decline in people with mild cognitive impairment. Alzheimer's Research and Therapy, 2020, 12, 105.	3.0	16
1285	Quantification of neurons in the hippocampal formation of chimpanzees: comparison to rhesus monkeys and humans. Brain Structure and Function, 2020, 225, 2521-2531.	1.2	9

#	Article	IF	CITATIONS
1286	c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer's Diseases. International Journal of Molecular Sciences, 2020, 21, 9677.	1.8	28
1287	Comparison of subtyping methods for neuroimaging studies in Alzheimer's disease: a call for harmonization. Brain Communications, 2020, 2, fcaa192.	1.5	24
1288	New Insights Into Drug Discovery Targeting Tau Protein. Frontiers in Molecular Neuroscience, 2020, 13, 590896.	1.4	78
1289	Tau accumulation in astrocytes of the dentate gyrus induces neuronal dysfunction and memory deficits in Alzheimer's disease. Nature Neuroscience, 2020, 23, 1567-1579.	7.1	121
1290	Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer's disease. Molecular Neurodegeneration, 2020, 15, 64.	4.4	19
1291	The <i>MUC6/AP2A2</i> Locus and Its Relevance toÂAlzheimer's Disease: A Review. Journal of Neuropathology and Experimental Neurology, 2020, 79, 568-584.	0.9	24
1292	Spect-neuropsychology correlations in very mild Alzheimer's disease and amnesic mild cognitive impairment. Archives of Gerontology and Geriatrics, 2020, 89, 104085.	1.4	1
1293	M1 muscarinic acetylcholine receptor dysfunction in moderate Alzheimer's disease pathology. Brain Communications, 2020, 2, fcaa058.	1.5	16
1294	Summary-Based Methylome-Wide Association Analyses Suggest Potential Genetically Driven Epigenetic Heterogeneity of Alzheimer's Disease. Journal of Clinical Medicine, 2020, 9, 1489.	1.0	10
1295	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, 883-895.	0.4	10
1296	Alzheimer's disease progression characterized by alterations in the molecular profiles and biogenesis of brain extracellular vesicles. Alzheimer's Research and Therapy, 2020, 12, 54.	3.0	47
1297	Cholinergic and inflammatory phenotypes in transgenic tau mouse models of Alzheimer's disease and frontotemporal lobar degeneration. Brain Communications, 2020, 2, fcaa033.	1.5	12
1298	An investigation of the correlation between the S-glutathionylated GAPDH levels in blood and Alzheimer's disease progression. PLoS ONE, 2020, 15, e0233289.	1.1	13
1299	Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. International Journal of Molecular Sciences, 2020, 21, 3802.	1.8	24
1300	A Healthy Heart and a Healthy Brain: Looking at Mitophagy. Frontiers in Cell and Developmental Biology, 2020, 8, 294.	1.8	20
1301	The effects of stress on cardiovascular disease and Alzheimer's disease: Physical exercise as a counteract measure. International Review of Neurobiology, 2020, 152, 157-193.	0.9	3
1302	Analysis of the Relationship Between Metalloprotease-9 and Tau Protein in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 76, 553-569.	1.2	10
1303	MRI Segmentation and Classification of Human Brain Using Deep Learning for Diagnosis of Alzheimer's Disease: A Survey. Sensors, 2020, 20, 3243.	2.1	109

#	Article	IF	CITATIONS
1304	Progressive Memory Circuit Impairments along with Alzheimer's Disease Neuropathology Spread: Evidence from in vivo Neuroimaging. Cerebral Cortex, 2020, 30, 5863-5873.	1.6	6
1305	Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease. Molecular Neurobiology, 2020, 57, 3258-3272.	1.9	33
1306	FastSurfer - A fast and accurate deep learning based neuroimaging pipeline. NeuroImage, 2020, 219, 117012.	2.1	229
1307	Genetic Risk for Alzheimer's Disease Moderates the Association Between Medial Temporal Lobe Volume and Episodic Memory Performance Among Older Adults. Journal of Alzheimer's Disease, 2020, 76, 1-10.	1.2	1
1308	APOEÎμ4 potentiates the relationship between amyloid-β and tau pathologies. Molecular Psychiatry, 2021, 26, 5977-5988.	4.1	51
1309	Terms and Measures of Cognitive Health Associated With Dementia and Alzheimer's Disease: A Scoping Review. Research on Aging, 2020, 42, 174-185.	0.9	2
1310	Testing Navigation in Real Space: Contributions to Understanding the Physiology and Pathology of Human Navigation Control. Frontiers in Neural Circuits, 2020, 14, 6.	1.4	18
1311	Cytoplasmic mislocalization and mitochondrial colocalization of TDP-43 are common features between normal aged and young mice. Experimental Biology and Medicine, 2020, 245, 1584-1593.	1.1	7
1312	Frequency-dependent electrical stimulation of fimbria-fornix preferentially affects the mesolimbic dopamine system or prefrontal cortex. Brain Stimulation, 2020, 13, 753-764.	0.7	5
1313	<p>Periodontal Disease and Periodontal Disease-Related Bacteria Involved in the Pathogenesis of Alzheimer's Disease</p> . Journal of Inflammation Research, 2020, Volume 13, 275-283.	1.6	24
1314	Dysautonomia in Alzheimer's Disease. Medicina (Lithuania), 2020, 56, 337.	0.8	11
1315	Invited Review – Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. Neuropathology and Applied Neurobiology, 2020, 46, 623-640.	1.8	20
1316	Potential Bidirectional Relationship Between Periodontitis and Alzheimer's Disease. Frontiers in Physiology, 2020, 11, 683.	1.3	49
1317	Preliminary Assessment of Intravoxel Incoherent Motion <scp>Diffusionâ€Weighted MRI</scp> (<scp>IVIMâ€DWI</scp>) Metrics in Alzheimer's Disease. Journal of Magnetic Resonance Imaging, 2020, 52, 1811-1826.	1.9	30
1318	Tau-tubulin kinase 1 and amyloid-β peptide induce phosphorylation of collapsin response mediator protein-2 and enhance neurite degeneration in Alzheimer disease mouse models. Acta Neuropathologica Communications, 2020, 8, 12.	2.4	19
1319	Dysregulation of histone acetylation pathways in hippocampus and frontal cortex of Alzheimer's disease patients. European Neuropsychopharmacology, 2020, 33, 101-116.	0.3	44
1320	White Matter Network Alterations in Alzheimer's Disease Patients. Applied Sciences (Switzerland), 2020, 10, 919.	1.3	6
1321	Why is music therapeutic for neurological disorders? The Therapeutic Music Capacities Model. Neuroscience and Biobehavioral Reviews, 2020, 112, 600-615.	2.9	66

#	Article	IF	CITATIONS
1322	Impaired Innate Immunity Mechanisms in the Brain of Alzheimer's Disease. International Journal of Molecular Sciences, 2020, 21, 1126.	1.8	13
1323	ls tau in the absence of amyloid on the Alzheimer's continuum?: A study of discordant PET positivity. Brain Communications, 2020, 2, fcz046.	1.5	53
1324	Identifying Morphological Patterns of Hippocampal Atrophy in Patients With Mesial Temporal Lobe Epilepsy and Alzheimer Disease. Frontiers in Neurology, 2020, 11, 21.	1.1	12
1325	Hippocampal Neurogenesis Is Enhanced in Adult Tau Deficient Mice. Cells, 2020, 9, 210.	1.8	19
1326	University College London/University of Gothenburg PhD course "Biomarkers in neurodegenerative diseases―2019—course organisation. Alzheimer's Research and Therapy, 2020, 12, 18.	3.0	0
1327	Physiological Tau Interactome in Brain and Its Link to Tauopathies. Journal of Proteome Research, 2020, 19, 2429-2442.	1.8	22
1328	Consequences of hyperphosphorylated tau on the morphology and excitability of hippocampal neurons in aged tau transgenic mice. Neurobiology of Aging, 2020, 93, 109-123.	1.5	17
1329	Multimodal Phenotyping of Alzheimer's Disease with Longitudinal Magnetic Resonance Imaging and Cognitive Function Data. Scientific Reports, 2020, 10, 5527.	1.6	18
1330	TDP-43 Related Neuropathologies and Phosphorylation State: Associations with Age and Clinical Dementia in the Cambridge City over-75s Cohort. Journal of Alzheimer's Disease, 2020, 75, 337-350.	1.2	12
1331	The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer's Disease. Frontiers in Immunology, 2020, 11, 754.	2.2	100
1332	Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathologica Communications, 2020, 8, 13.	2.4	61
1333	Neuronal volume of the hippocampal regions in ageing. Journal of Anatomy, 2020, 237, 301-310.	0.9	6
1334	Reduced uptake of [11C]â€ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimer's dementia. Brain and Behavior, 2020, 10, e01632.	1.0	14
1335	A Practical Guide to the Automated Analysis of Vascular Growth, Maturation and Injury in the Brain. Frontiers in Neuroscience, 2020, 14, 244.	1.4	31
1336	Modulation of tau protein aggregation using †Trojan' sequences. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129569.	1.1	10
1337	Hippocampal activation and connectivity in the aging brain. Brain Imaging and Behavior, 2021, 15, 711-726.	1.1	15
1338	δ-Secretase-cleaved Tau stimulates Aβ production via upregulating STAT1-BACE1 signaling in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 586-603.	4.1	54
1339	The sensitivity of diffusion MRI to microstructural properties and experimental factors. Journal of Neuroscience Methods, 2021, 347, 108951.	1.3	53

#	Article	IF	Citations
1340	Multi-scale graph-based grading for Alzheimer's disease prediction. Medical Image Analysis, 2021, 67, 101850.	7.0	28
1341	Smaller Volume in Left-Lateralized Brain Structures Correlates with Greater Experience of Negative Non-target Emotions in Neurodegenerative Diseases. Cerebral Cortex, 2021, 31, 15-31.	1.6	6
1342	Mediators of mitophagy that regulate mitochondrial quality control play crucial role in diverse pathophysiology. Cell Biology and Toxicology, 2021, 37, 333-366.	2.4	14
1343	Heterogeneity of Age-Related Neural Hyperactivity along the CA3 Transverse Axis. Journal of Neuroscience, 2021, 41, 663-673.	1.7	18
1344	Exploring the role of mitochondrial proteins as molecular target in Alzheimer's disease. Mitochondrion, 2021, 56, 62-72.	1.6	15
1345	Altered heart rate variability during sleep in mild cognitive impairment. Sleep, 2021, 44, .	0.6	14
1346	Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults. Journal of Neuroscience, 2021, 41, 366-375.	1.7	29
1347	Multiple system agingâ€related tau astrogliopathy with complex proteinopathy in an oligosymptomatic octogenarian. Neuropathology, 2021, 41, 72-83.	0.7	11
1348	Regional Strength of Large-Scale Functional Brain Networks is Associated with Regional Volumes in Older Adults and in Alzheimer's Disease. Brain Connectivity, 2021, 11, 201-212.	0.8	8
1349	Coâ€incidental <i>C9orf72</i> expansion mutationâ€related frontotemporal lobar degeneration pathology and sporadic Creutzfeldtâ^Jakob disease. European Journal of Neurology, 2021, 28, 1009-1015.	1.7	2
1350	Stacked autoencoders as new models for an accurate Alzheimer's disease classification support using resting-state EEG and MRI measurements. Clinical Neurophysiology, 2021, 132, 232-245.	0.7	30
1351	Topographic Distribution of Amyloid-β, Tau, and Atrophy in Patients With Behavioral/Dysexecutive Alzheimer Disease. Neurology, 2021, 96, e81-e92.	1.5	31
1352	Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes. Molecular Therapy, 2021, 29, 859-872.	3.7	26
1353	Neuroimaging Advances in Diagnosis and Differentiation of HIV, Comorbidities, and Aging in the cART Era. Current Topics in Behavioral Neurosciences, 2021, 50, 105-143.	0.8	2
1354	Association of CSF Biomarkers With Hippocampal-Dependent Memory in Preclinical Alzheimer Disease. Neurology, 2021, 96, e1470-e1481.	1.5	19
1355	Association of Cognitive Function Trajectories in Centenarians With Postmortem Neuropathology, Physical Health, and Other Risk Factors for Cognitive Decline. JAMA Network Open, 2021, 4, e2031654.	2.8	29
1356	PART and ARTAG tauopathies at a relatively young age as a concomitant finding in sporadic Creutzfeldt-Jakob disease. Prion, 2021, 15, 138-142.	0.9	0
1357	Degenerative Diseases of the CNS. , 2021, , 353-389.		0

#	Article	IF	CITATIONS
1358	Similarities and Differences in the Pattern of Tau Hyperphosphorylation in Physiological and Pathological Conditions: Impacts on the Elaboration of Therapies to Prevent Tau Pathology. Frontiers in Neurology, 2020, 11, 607680.	1.1	17
1359	Molecular mechanisms of neurodegeneration in the entorhinal cortex that underlie its selective vulnerability during the pathogenesis of Alzheimer's disease. Biology Open, 2021, 10, .	0.6	38
1360	Phosphorylation of Truncated Tau Promotes Abnormal Native Tau Pathology and Neurodegeneration. SSRN Electronic Journal, 0, , .	0.4	0
1361	Decreased Orexin Receptor 1 mRNA Expression in the Locus Coeruleus in Both Tau Transgenic rTg4510 and Tau Knockout Mice and Accompanying Ascending Arousal System Tau Invasion in rTg4510. Journal of Alzheimer's Disease, 2021, 79, 693-708.	1.2	7
1362	Hydrogen sulfide is neuroprotective in Alzheimer's disease by sulfhydrating GSK3β and inhibiting Tau hyperphosphorylation. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	124
1363	Intermittent Hypoxic Conditioning Rescues Cognition and Mitochondrial Bioenergetic Profile in the Triple Transgenic Mouse Model of Alzheimer's Disease. International Journal of Molecular Sciences, 2021, 22, 461.	1.8	14
1364	Klinik der Demenzen. , 2021, , 59-92.		0
1365	Mitochondrial Dysfunction in Alzheimer's Disease: A Biomarker of the Future?. Biomedicines, 2021, 9, 63.	1.4	62
1366	Individual differences in theta-band oscillations in a spatial memory network revealed by electroencephalography predict rapid place learning. Brain and Neuroscience Advances, 2021, 5, 239821282110027.	1.8	2
1368	Adding cognition to AT(N) models improves prediction of cognitive and functional decline. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12174.	1.2	8
1369	Molecular characterization of selectively vulnerable neurons in Alzheimer's disease. Nature Neuroscience, 2021, 24, 276-287.	7.1	238
1370	PET and SPECT Imaging of Neurodegenerative Diseases. , 2021, , 1309-1334.		0
1371	Sex and gender differences in neuropsychological symptoms for clinical diagnosis of Alzheimer's disease. , 2021, , 163-185.		0
1373	The molecular tweezer CLR01 improves behavioral deficits and reduces tau pathology in P301S-tau transgenic mice. Alzheimer's Research and Therapy, 2021, 13, 6.	3.0	15
1374	The combination of MMSE with VSRAD and eZIS has greater accuracy for discriminating mild cognitive impairment from early Alzheimer's disease than MMSE alone. PLoS ONE, 2021, 16, e0247427.	1.1	9
1375	Seeding-Competent Tau in Gray Matter Versus White Matter of Alzheimer's Disease Brain. Journal of Alzheimer's Disease, 2021, 79, 1647-1659.	1.2	4
1376	Alzheimer's disease brain contains tau fractions with differential prion-like activities. Acta Neuropathologica Communications, 2021, 9, 28.	2.4	35
1377	Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation. Cell Communication and Signaling, 2021, 19, 16.	2.7	30

#	Article	IF	CITATIONS
1379	Targeting GRK5 for Treating Chronic Degenerative Diseases. International Journal of Molecular Sciences, 2021, 22, 1920.	1.8	12
1380	Metformin attenuates plaque-associated tau pathology and reduces amyloid-β burden in APP/PS1 mice. Alzheimer's Research and Therapy, 2021, 13, 40.	3.0	53
1381	Iron loading is a prominent feature of activated microglia in Alzheimer's disease patients. Acta Neuropathologica Communications, 2021, 9, 27.	2.4	79
1382	Embracing the Unknown in the Diagnosis of Traumatic Encephalopathy Syndrome. Neurology, 2021, 96, 835-836.	1.5	4
1383	Effect of Acupuncture Stimulation of Hegu (LI4) and Taichong (LR3) on the Resting-State Networks in Alzheimer's Disease: Beyond the Default Mode Network. Neural Plasticity, 2021, 2021, 1-9.	1.0	13
1384	Particulate Matter Exposure Exacerbates Amyloid-β Plaque Deposition and Gliosis in APP/PS1 Mice. Journal of Alzheimer's Disease, 2021, 80, 761-774.	1.2	33
1385	Neuronal Network Excitability in Alzheimer's Disease: The Puzzle of Similar versus Divergent Roles of Amyloid β and Tau. ENeuro, 2021, 8, ENEURO.0418-20.2020.	0.9	46
1386	A CNN based framework for classification of Alzheimer's disease. Neural Computing and Applications, 2021, 33, 10415-10428.	3.2	51
1387	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. Brain, 2021, 144, 2771-2783.	3.7	78
1388	Combining ADAS-Cog Assessment with Hypometabolic Region of 18F-FDG PET/CT Brain Imaging for Alzheimer's Disease Detection. , 2021, , .		0
1389	Social Isolation, Social Interaction, and Alzheimer's Disease: A Mendelian Randomization Study. Journal of Alzheimer's Disease, 2021, 80, 665-672.	1.2	8
1390	Relationship between brain AD biomarkers and episodic memory performance in healthy aging. Brain and Cognition, 2021, 148, 105680.	0.8	13
1391	Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression. Alzheimer's and Dementia, 2021, 17, 1474-1486.	0.4	37
1392	Spatial correlation maps of the hippocampus with <scp>cerebrospinal fluid</scp> biomarkers and cognition in Alzheimer's disease: A longitudinal study. Human Brain Mapping, 2021, 42, 2931-2940.	1.9	7
1393	Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. Alzheimer's and Dementia, 2021, 17, 1554-1574.	0.4	114
1394	Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease. JAMA Neurology, 2021, 78, 445.	4.5	33
1395	Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Communications, 2021, 3, fcab073.	1.5	15
1397	Direct Comparison of the Tau PET Tracers ¹⁸ F-Flortaucipir and ¹⁸ F-MK-6240 in Human Subjects. Journal of Nuclear Medicine, 2022, 63, 108-116.	2.8	39

#	Article	IF	CITATIONS
1398	Elevated Inflammatory Markers and Arterial Stiffening Exacerbate Tau but Not Amyloid Pathology in Older Adults with Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 80, 1451-1463.	1.2	7
1399	T1AM-TAAR1 signalling protects against OGD-induced synaptic dysfunction in the entorhinal cortex. Neurobiology of Disease, 2021, 151, 105271.	2.1	7
1400	Kinetics of tau aggregation reveals patient-specific tau characteristics among Alzheimer's cases. Brain Communications, 2021, 3, fcab096.	1.5	7
1401	Liquid–liquid phase separation of tau: From molecular biophysics to physiology and disease. Protein Science, 2021, 30, 1294-1314.	3.1	54
1402	Increased excitatory to inhibitory synaptic ratio in parietal cortex samples from individuals with Alzheimer's disease. Nature Communications, 2021, 12, 2603.	5.8	72
1403	Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Science Translational Medicine, 2021, 13, .	5.8	50
1404	Network interdigitations of Tau and amyloidâ€beta deposits define cognitive levels in aging. Human Brain Mapping, 2021, 42, 2990-3004.	1.9	7
1406	Saccadic Eye Movement in Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis. Neuropsychology Review, 2022, 32, 193-227.	2.5	36
1408	PET Agents in Dementia: An Overview. Seminars in Nuclear Medicine, 2021, 51, 196-229.	2.5	23
1409	Causal structural covariance network revealing atrophy progression in Alzheimer's disease continuum. Human Brain Mapping, 2021, 42, 3950-3962.	1.9	16
1410	FKBP52 overexpression accelerates hippocampal-dependent memory impairments in a tau transgenic mouse model. Npj Aging and Mechanisms of Disease, 2021, 7, 9.	4.5	10
1412	Mediterranean Diet, Alzheimer Disease Biomarkers, and Brain Atrophy in Old Age. Neurology, 2021, 96, .	1.5	72
1413	Alzheimer's Pathology Is Associated with Dedifferentiation of Intrinsic Functional Memory Networks in Aging. Cerebral Cortex, 2021, 31, 4781-4793.	1.6	24
1414	Identification of cis-acting determinants mediating the unconventional secretion of tau. Scientific Reports, 2021, 11, 12946.	1.6	13
1415	Exosomal and vesicleâ€free tau seeds—propagation and convergence in endolysosomal permeabilization. FEBS Journal, 2022, 289, 6891-6907.	2.2	24
1416	Autonomic Imbalance and Risk of Dementia and Stroke: The Framingham Study. Stroke, 2021, 52, 2068-2076.	1.0	22
1417	Hippocampal vascularization patterns exert local and distant effects on brain structure but not vascular pathology in old age. Brain Communications, 2021, 3, fcab127.	1.5	9
1418	C. elegans detects toxicity of traumatic brain injury generated tau. Neurobiology of Disease, 2021, 153, 105330.	2.1	5

#	Article	IF	CITATIONS
1420	Decreased MEF2A Expression Regulated by Its Enhancer Methylation Inhibits Autophagy and May Play an Important Role in the Progression of Alzheimer's Disease. Frontiers in Neuroscience, 2021, 15, 682247.	1.4	9
1421	The informed road map to prevention of Alzheimer Disease: A call to arms. Molecular Neurodegeneration, 2021, 16, 49.	4.4	43
1422	Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer's disease. Brain Pathology, 2021, 31, e12996.	2.1	33
1423	The potential role of glial cells in driving the prion-like transcellular propagation of tau in tauopathies. Brain, Behavior, & Immunity - Health, 2021, 14, 100242.	1.3	14
1425	Neuronal VCP loss of function recapitulates FTLD-TDP pathology. Cell Reports, 2021, 36, 109399.	2.9	25
1426	Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe. Brain, 2021, 144, 2784-2797.	3.7	38
1427	Orthostatic hypotension in patients with Alzheimer's disease: a meta-analysis of prospective studies. Neurological Sciences, 2022, 43, 999-1006.	0.9	11
1429	Disease Burden Affects Aging Brain Function. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2022, 77, 1810-1818.	1.7	3
1430	Right entorhinal cortical thickness is associated with Mini-Mental State Examination scores from multi-country datasets using MRI. Neuroradiology, 2022, 64, 279-288.	1.1	4
1432	Alzheimer's Disease Progressively Reduces Visual Functional Network Connectivity. Journal of Alzheimer's Disease Reports, 2021, 5, 549-562.	1.2	17
1433	Associations Between Amyloid and Tau Pathology, and Connectome Alterations, in Alzheimer's Disease and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2021, 82, 541-560.	1.2	18
1434	Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance. Journal of Neurochemistry, 2021, 158, 1394-1411.	2.1	42
1435	Hippocampal sub-networks exhibit distinct spatial representation deficits in Alzheimer's disease model mice. Current Biology, 2021, 31, 3292-3302.e6.	1.8	8
1436	A current view on Tau protein phosphorylation in Alzheimer's disease. Current Opinion in Neurobiology, 2021, 69, 131-138.	2.0	167
1437	Orientational changes of white matter fibers in Alzheimer's disease and amnestic mild cognitive impairment. Human Brain Mapping, 2021, 42, 5397-5408.	1.9	4
1438	Small Neuron-Derived Extracellular Vesicles from Individuals with Down Syndrome Propagate Tau Pathology in the Wildtype Mouse Brain. Journal of Clinical Medicine, 2021, 10, 3931.	1.0	10
1440	Tau Protein Interaction Partners and Their Roles in Alzheimer's Disease and Other Tauopathies. International Journal of Molecular Sciences, 2021, 22, 9207.	1.8	50
1441	The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review. Journal of Alzheimer's Disease, 2021, 83, 5-22.	1.2	52

#	Article	IF	CITATIONS
1442	Distinct conformers of amyloid beta accumulate in the neocortex of patients with rapidly progressive Alzheimer's disease. Journal of Biological Chemistry, 2021, 297, 101267.	1.6	25
1443	Alzheimer's Disease and other Tauopathies: Exploring Efficacy of Medicinal Plant-derived Compounds in Alleviating Tau-mediated Neurodegeneration. Current Molecular Pharmacology, 2022, 15, 361-379.	0.7	16
1444	A critical appraisal of tauâ€ŧargeting therapies for primary and secondary tauopathies. Alzheimer's and Dementia, 2022, 18, 1008-1037.	0.4	29
1445	Tau pathology mediates age effects on medial temporal lobe structure. Neurobiology of Aging, 2022, 109, 135-144.	1.5	8
1446	Case Report: Coexistence of Alzheimer-Type Neuropathology in Fragile X-Associated Tremor Ataxia Syndrome. Frontiers in Neuroscience, 2021, 15, 720253.	1.4	8
1447	The relationship of functional hippocampal activity, amyloid deposition, and longitudinal memory decline to memory complaints in cognitively healthy older adults. Neurobiology of Aging, 2021, 105, 318-326.	1.5	11
1448	Mitochondria in the Cerebral and Cerebellar Cortex in Alzheimer's Disease, Target for a Therapeutic Approach. , 0, , .		0
1449	Inflammatory Cascade in Alzheimer's Disease Pathogenesis: A Review of Experimental Findings. Cells, 2021, 10, 2581.	1.8	42
1450	Hippocampal Connectivity with Retrosplenial Cortex is Linked to Neocortical Tau Accumulation and Memory Function. Journal of Neuroscience, 2021, 41, 8839-8847.	1.7	12
1451	Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy. Neurobiology of Aging, 2022, 109, 52-63.	1.5	16
1452	Content-specific vulnerability of recent episodic memories in Alzheimer's disease. Neuropsychologia, 2021, 160, 107976.	0.7	10
1453	Oxygen Sensing and Signaling in Alzheimer's Disease: A Breathtaking Story!. Cellular and Molecular Neurobiology, 2022, 42, 3-21.	1.7	6
1455	T2 heterogeneity as an in vivo marker of microstructural integrity in medial temporal lobe subfields in ageing and mild cognitive impairment. NeuroImage, 2021, 238, 118214.	2.1	1
1456	Inflammatory Pathways Are Impaired in Alzheimer Disease and Differentially Associated With Apolipoprotein E Status. Journal of Neuropathology and Experimental Neurology, 2021, 80, 922-932.	0.9	12
1457	Abnormal tau in amyloid PET negative individuals. Neurobiology of Aging, 2022, 109, 125-134.	1.5	22
1458	Dysregulated clock gene expression and abnormal diurnal regulation of hippocampal inhibitory transmission and spatial memory in amyloid precursor protein transgenic mice. Neurobiology of Disease, 2021, 158, 105454.	2.1	15
1459	The histone code in dementia: Transcriptional and chromatin plasticity fades away. Current Opinion in Pharmacology, 2021, 60, 117-122.	1.7	6
1460	Resting-state brain connectivity in healthy young and middle-aged adults at risk of progressive Alzheimer's disease. Neuroscience and Biobehavioral Reviews, 2021, 129, 142-153.	2.9	18

#	Article	IF	CITATIONS
1461	Influence of common reference regions on regional tau patterns in cross-sectional and longitudinal [18F]-AV-1451 PET data. NeuroImage, 2021, 243, 118553.	2.1	23
1462	Dorsolateral prefrontal cortex excitability abnormalities in Alzheimer's Dementia: Findings from transcranial magnetic stimulation and electroencephalography study. International Journal of Psychophysiology, 2021, 169, 55-62.	0.5	16
1463	Exosomes induce endolysosomal permeabilization as a gateway by which exosomal tau seeds escape into the cytosol. Acta Neuropathologica, 2021, 141, 235-256.	3.9	66
1464	Interdisciplinary Research in Alzheimer's Disease and the Roles International Societies Can Play. , 2021, 12, 36.		10
1465	Modulation of the microbiota-gut-brain axis by bioactive food, prebiotics, and probiotics decelerates the course of Alzheimer's disease. Studies in Natural Products Chemistry, 2021, , 51-86.	0.8	2
1466	Differential vulnerability of the cerebellum in healthy ageing and Alzheimer's disease. NeuroImage: Clinical, 2021, 30, 102605.	1.4	31
1467	Visual Abnormalities Associate With Hippocampus in Mild Cognitive Impairment and Early Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 597491.	1.7	19
1469	Relationship between amyloid and tau levels and its impact on tau spreading. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2225-2232.	3.3	30
1470	Analysis of Biomedical Image for Alzheimer's Disease Detection. , 2021, , 170-190.		0
1471	The proteome of granulovacuolar degeneration and neurofibrillary tangles in Alzheimer's disease. Acta Neuropathologica, 2021, 141, 341-358.	3.9	29
1472	Chemical analysis of the human brain by imaging mass spectrometry. Analyst, The, 2021, 146, 5451-5473.	1.7	11
1473	Cortical and subcortical pathological burden and neuronal loss in an autopsy series of FTLD-TDP-type C. Brain, 2022, 145, 1069-1078.	3.7	12
1474	Trajectory of Unawareness of Memory Decline in Individuals With Autosomal Dominant Alzheimer Disease. JAMA Network Open, 2020, 3, e2027472.	2.8	22
1476	Metabolic Magnetic Resonance Imaging: A Case for Bioscales in Medicine. , 2011, , 911-928.		3
1478	Human Tau Transgenic Mice. Advances in Experimental Medicine and Biology, 2001, , 71-83.	0.8	7
1479	Temporal Sequence of Alzheimer's Disease-Related Pathology. Cerebral Cortex, 1999, , 475-512.	0.6	71
1482	Automatic Clustering and Thickness Measurement of Anatomical Variants of the Human Perirhinal Cortex. Lecture Notes in Computer Science, 2014, 17, 81-88.	1.0	9
1483	A Biophysical Model of Shape Changes due to Atrophy in the Brain with Alzheimer's Disease. Lecture Notes in Computer Science, 2014, 17, 41-48.	1.0	2

#	Article	IF	CITATIONS
1484	A Mixed-Effects Model with Time Reparametrization for Longitudinal Univariate Manifold-Valued Data. Lecture Notes in Computer Science, 2015, 24, 564-575.	1.0	14
1485	Accounting for the Confound of Meninges in Segmenting Entorhinal and Perirhinal Cortices in T1-Weighted MRI. Lecture Notes in Computer Science, 2016, 9901, 564-571.	1.0	21
1486	Fate Through Fat: Neutral Lipids as Regulators of Neural Stem Cells. Pancreatic Islet Biology, 2017, , 87-115.	0.1	1
1487	Shape-Based Alignment of Hippocampal Subfields: Evaluation in Postmortem MRI. Lecture Notes in Computer Science, 2008, 11, 510-517.	1.0	9
1488	FreeSurfer Automatic Brain Segmentation Adaptation to Medial Temporal Lobe Structures: Volumetric Assessment and Diagnosis of Mild Cognitive Impairment. Lecture Notes in Computer Science, 2011, , 112-119.	1.0	1
1489	Neurodegenerative Alzheimer-like Pathology in PDAPP 717V → F Transgenic Mice. Research and Perspectives in Alzheimer's Disease, 1997, , 105-119.	0.1	17
1490	Molekulare Medizin der Alzheimer-Krankheit. , 1999, , 195-236.		5
1491	Effect of advanced glycation endproducts on cell cycle and their relevance for Alzheimer's disease. Journal of Neural Transmission Supplementum, 2003, , 63-71.	0.5	22
1492	Is there room for Darwinian medicine and the hygiene hypothesis in Alzheimer pathogenesis?. , 2009, , 257-278.		1
1493	Liquid-Liquid Phase Separation of Tau Protein in Neurobiology and Pathology. Advances in Experimental Medicine and Biology, 2019, 1184, 341-357.	0.8	13
1494	Experimental Models of Tauopathy– From Mechanisms to Therapies. Advances in Experimental Medicine and Biology, 2019, 1184, 381-391.	0.8	16
1495	Tau and Axonal Transport Misregulation in Tauopathies. Advances in Experimental Medicine and Biology, 2019, 1184, 81-95.	0.8	46
1496	Tau in Alzheimer's Disease: Pathological Alterations and an Attractive Therapeutic Target. Current Medical Science, 2020, 40, 1009-1021.	0.7	16
1497	Single-Base Resolution Mapping of 5-Hydroxymethylcytosine Modifications in Hippocampus of Alzheimer's Disease Subjects. Journal of Molecular Neuroscience, 2017, 63, 185-197.	1.1	28
1498	Cognitive Development in Alzheimer's Disease: Charting the Decline Process. , 1998, , 231-245.		1
1499	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer's disease. , 2020, , 469-504.		5
1500	Neurobiological Models of Aging in the Dog and Other Vertebrate Species. , 2001, , 457-468.		27
1501	A probabilistic atlas of locus coeruleus pathways to transentorhinal cortex for connectome imaging in Alzheimer's disease. NeuroImage, 2020, 223, 117301.	2.1	24

#	Article	IF	CITATIONS
1502	Influences of cognitive support on episodic remembering: tracing the process of loss from normal aging to Alzheimer's disease. Psychology and Aging, 1998, 13, 267-76.	1.4	26
1503	Cognitive predictors of incident Alzheimer's disease: a prospective longitudinal study. Neuropsychology, 1997, 11, 413-20.	1.0	84
1504	Aged rats with intact memory show distinctive recruitment in cortical regions relative to young adults in a cue mismatch task Behavioral Neuroscience, 2019, 133, 537-544.	0.6	4
1505	Timing impairments in early Alzheimer's disease: Evidence from a mouse model Behavioral Neuroscience, 2020, 134, 82-100.	0.6	4
1518	Memory Dysfunction. CONTINUUM Lifelong Learning in Neurology, 2018, 24, 727-744.	0.4	11
1519	The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology, 1999, 52, 1158-1158.	1.5	704
1520	KIF5A and KLC1 expression in Alzheimer's disease: relationship and genetic influences. AMRC Open Research, 0, 1, 1.	1.7	1
1521	Alzheimer's Disease Diagnosis Using Misfolding Proteins in Blood. Dementia and Neurocognitive Disorders, 2020, 19, 1.	0.4	9
1522	Rapid Changes in Phospho-MAP/Tau Epitopes during Neuronal Stress: Cofilin-Actin Rods Primarily Recruit Microtubule Binding Domain Epitopes. PLoS ONE, 2011, 6, e20878.	1.1	26
1523	Hierarchical Anatomical Brain Networks for MCI Prediction: Revisiting Volumetric Measures. PLoS ONE, 2011, 6, e21935.	1.1	72
1524	Neocortex and Allocortex Respond Differentially to Cellular Stress In Vitro and Aging In Vivo. PLoS ONE, 2013, 8, e58596.	1.1	30
1525	No Overt Deficits in Aged Tau-Deficient C57Bl/6.Mapttm1(EGFP)Kit GFP Knockin Mice. PLoS ONE, 2016, 11, e0163236.	1.1	35
1526	Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer's disease: An autopsy-confirmed study. PLoS ONE, 2017, 12, e0171524.	1.1	29
1527	Probing the putative α7 nAChR/NMDAR complex in human and murine cortex and hippocampus: Different degrees of complex formation in healthy and Alzheimer brain tissue. PLoS ONE, 2017, 12, e0189513.	1.1	8
1528	Genetic Interaction of APOE and FGF1 is Associated with Memory Impairment and Hippocampal Atrophy in Alzheimer's Disease. , 2019, 10, 510.		10
1529	Ellagic Acid Administration Reverses ColchicineInduced Dementia in Rats. Journal of Pharmaceutical Technology Research and Management, 2016, 4, 31-46.	0.3	6
1530	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. Revista Brasileira De Psiquiatria, 2020, 42, 431-441.	0.9	42
1531	Recent Developments in Diffusion Tensor Imaging of Brain. Radiology - Open Journal, 2016, 1, 1-12.	0.1	7

\sim			-		
(11	ГАТ	ION	R	FΡ(ORT

#	Article	IF	CITATIONS
1532	The application of weighted gene co-expression network analysis in identifying key modules and hub genes associated with disease status in Alzheimer's disease. Annals of Translational Medicine, 2019, 7, 800-800.	0.7	30
1533	A High-Throughput Screening Assay for Determining Cellular Levels of Total Tau Protein. Current Alzheimer Research, 2013, 10, 679-687.	0.7	25
1534	Resilient Brain Aging: Characterization of Discordance between Alzheimer's Disease Pathology and Cognition. Current Alzheimer Research, 2013, 10, 844-851.	0.7	63
1535	Proteomics Analysis of CA1 Region of the Hippocampus in Pre-, Progression and Pathological Stages in a Mouse Model of the Alzheimer's Disease. Current Alzheimer Research, 2019, 16, 613-621.	0.7	14
1536	Methods for Studying and Structure–Function Relationships of Non-Fibrillar Protein Assemblies in Alzheimer's Disease and Related Disorders. , 2014, , 291-374.		1
1537	Coherence and phase synchrony analyses of EEG signals in Mild Cognitive Impairment (MCI): A study of functional brain connectivity. Polish Journal of Medical Physics and Engineering, 2018, 24, 1-9.	0.2	16
1538	Primary age-related tauopathy and the amyloid cascade hypothesis: the exception that proves the rule?. Journal of Neurology and Neuromedicine, 2016, 1, 53-57.	0.9	43
1539	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. Journal of Nuclear Medicine, 2021, 62, 614-619.	2.8	21
1540	NMDA receptor function, memory, and brain aging. Dialogues in Clinical Neuroscience, 2000, 2, 219-232.	1.8	157
1541	Pathways linking late-life depression to persistent cognitive impairment and dementia. Dialogues in Clinical Neuroscience, 2008, 10, 345-357.	1.8	401
1542	Is there a neuropathology difference between mild cognitive impairment and dementia?. Dialogues in Clinical Neuroscience, 2009, 11, 171-179.	1.8	38
1543	Diffusion tensor imaging in Alzheimer's disease and mild cognitive impairment. Behavioural Neurology, 2009, 21, 39-49.	1.1	133
1544	Unpicking the semantic impairment in Alzheimer's disease: qualitative changes with disease severity. Behavioural Neurology, 2012, 25, 23-34.	1.1	11
1545	Ongoing Electroencephalographic Rhythms Related to Exploratory Movements in Transgenic TASTPM Mice. Journal of Alzheimer's Disease, 2020, 78, 291-308.	1.2	2
1546	Spatial Pattern Separation in Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 76, 121-138.	1.2	22
1547	Neuronal dark matter: the emerging role of microRNAs in neurodegeneration. Frontiers in Cellular Neuroscience, 2013, 7, 178.	1.8	167
1548	Cognition in Preclinical Dementia: Current Knowledge and Future Prospects. Acta Psychologica Sinica, 2009, 41, 1040-1048.	0.4	2
1549	A game for crowdsourcing the segmentation of BigBrain data. Research Ideas and Outcomes, 0, 2, e8816.	1.0	2

#	Article	IF	CITATIONS
1550	Alzheimer's Disease A Century Later. Journal of Clinical Psychiatry, 2006, 67, 1784-1800.	1.1	99
1551	Shifting equilibriums in Alzheimer's disease: the complex roles of microglia in neuroinflammation, neuronal survival and neurogenesis. Neural Regeneration Research, 2020, 15, 1208.	1.6	49
1552	Multimodality neuroimaging in mild cognitive impairment: A cross-sectional comparison study. Annals of Indian Academy of Neurology, 2018, 21, 133.	0.2	8
1553	Commentary on the Paper "PART, a Distinct Tauopathy, Different from Classical Sporadic Alzheimer Disease". Journal of Clinical & Cellular Immunology, 2016, 07, .	1.5	3
1554	The Relationship of Cognitive Impairment to Hypnotic Susceptibility in a Sample of Elderly: A Pilot Study. Psychology, 2012, 03, 62-64.	0.3	4
1555	Mild Traumatic Brain Injury of Tau.P301L Mice Results in an Impairment of Neural Plasticity. Archives of Neuroscience, 2016, 3, .	0.1	3
1556	Differences in topological progression profile among neurodegenerative diseases from imaging data. ELife, 2019, 8, .	2.8	11
1557	Cortical Thickness and Semantic Fluency in Alzheimer's Disease and Mild Cognitive Impairment. American Journal of Alzheimer's Disease (Columbia, Mo), 2013, 1, 81-92.	0.3	12
1558	Early Diagnosis of Alzheimer's Disease Using 3D Residual Attention Network Based on Hippocampal Multi-indices Feature Fusion. Lecture Notes in Computer Science, 2021, , 449-457.	1.0	1
1560	Amyloidâ€dependent and amyloidâ€independent effects of Tau in individuals without dementia. Annals of Clinical and Translational Neurology, 2021, 8, 2083-2092.	1.7	7
1561	Tau Post-Translational Modifications: Potentiators of Selective Vulnerability in Sporadic Alzheimer's Disease. Biology, 2021, 10, 1047.	1.3	14
1562	Medial Temporal Lobe Subregional Atrophy in Aging and Alzheimer's Disease: A Longitudinal Study. Frontiers in Aging Neuroscience, 2021, 13, 750154.	1.7	19
1563	Impact of neurodegenerative diseases on human adult hippocampal neurogenesis. Science, 2021, 374, 1106-1113.	6.0	136
1564	Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathology. Acta Neuropathologica Communications, 2021, 9, 173.	2.4	14
1566	Alzheimer's disease clinical trial update 2019–2021. Journal of Neurology, 2022, 269, 1038-1051.	1.8	39
1567	Association Between Polygenic Risk Score and the Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1323-1335.	1.2	7
1568	Exclusive Mediotemporal Pathology Within the Spectrum of Frontotemporal Dementia. , 2001, , 171-174.		0
1569	Molecular Genetics and Molecular Biology of Alzheimer's Disease. , 2001, , 1187-1218.		0

#	Article	IF	Citations
1570	Glutamatergic transmission. Pharmaceutical Science Series, 2001, , 385-406.	0.0	0
1571	Title is missing!. Japanese Journal of Oral Biology, 2002, 44, 195-202.	0.1	0
1572	Ethical dilemmas in neurodegenerative disease: respecting patients at the twilight of agency. , 2004, , 87-102.		1
1575	Metabolic Abnormalities in Alzheimer Disease. , 2009, , 483-530.		0
1576	Impact of A β and Tau on Cognition in Mouse Models of Alzheimer's Disease. , 2009, , 1-15.		0
1577	The Molecular and Genetic Basis of Neurodegenerative Diseases. , 2009, , 2039-2068.		0
1578	Synapses and Alzheimers's Disease: Effect of Immunotherapy?. , 2011, , 269-287.		0
1581	Chapter 28 Alpha-Synucleinopathy and Neuropsychological Symptoms in a Population-Based Cohort of the Elderly. , 2012, , 309-316.		0
1583	Therapeutic Opportunities in Alzheimer Disease: Current Concepts. , 2012, , 767-788.		0
1584	Chapter 33 Alpha-Synucleinopathy and Neuropsychological Symptoms in a Population-Based Cohort of the Elderly. , 2013, , 361-368.		0
1585	FRONTOTEMPORAL DEMENTIA (FTD): INSIGHTS INTO WISDOM AND ALTRUISM. , 2013, , .		0
1586	Detection of Alzheimer's Disease Using Multitracer Positron Emission Tomography Imaging. International Journal of Engineering, Transactions B: Applications, 2014, 27, .	0.6	3
1587	Geriatrische Syndrome: Kognition. , 2014, , 1-11.		0
1588	Neurotransmitterveräderungen bei der Alzheimer Demenz. , 1999, , 67-86.		0
1589	Molekulargenetik und Molekularbiologie der Alzheimer-Krankheit. , 1999, , 117-165.		0
1591	An Oblique Approach to Prediction of Conversion to Alzheimer's Disease with Multikernel Gaussian Processes. Lecture Notes in Computer Science, 2016, , 122-128.	1.0	1
1592	Small Molecule-Assisted PET: Approaches to Imaging of Conformational Diseases of the Brain. World Journal of Neuroscience, 2017, 07, 106-139.	0.1	1
1593	Prion-Like Propagation in Neurodegenerative Diseases. , 2018, , 189-242.		Ο

#	Article	IF	CITATIONS
1594	Biomarqueurs du liquide cérébrospinal dans la maladie d'Alzheimer. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 307-320.	0.0	1
1595	Clinical Meaningfulness of Biomarker Endpoints in Alzheimer's Disease Research. Neuromethods, 2018, , 235-248.	0.2	0
1596	Characterizing Anatomical Variability and Alzheimer's Disease Related Cortical Thinning in the Medial Temporal Lobe Using Graph-Based Groupwise Registration and Point Set Geodesic Shooting. Lecture Notes in Computer Science, 2018, 11167, 28-37.	1.0	4
1599	Que penser de l'approche médicamenteuse préventive de la maladie d'Alzheimer ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 679-690.	0.0	0
1600	4. Pathogenesis and Treatment of Dementia. The Journal of the Japanese Society of Internal Medicine, 2018, 107, 1804-1809.	0.0	0
1602	ALZHEIMER'S DISEASE: A CONSEQUENCE OF IMPAIRED MITOPHAGY?. Asian Journal of Pharmaceutical and Clinical Research, 0, , 75-80.	0.3	1
1606	KIF5A and KLC1 expression in Alzheimer's disease: relationship and genetic influences. AMRC Open Research, 0, 1, 1.	1.7	0
1607	Neurofibrillary Pathology in the Infundibular Nucleus in Relation to Age and Abnormal Hormone Levels. Majalah Obstetri Dan Ginekologi Indonesia, 0, , 196-207.	0.0	0
1610	Spatial navigation and Alzheimer's disease. , 2020, , 677-692.		0
1611	Analysis of Biomedical Image for Alzheimer's Disease Detection. Advances in Computational Intelligence and Robotics Book Series, 2020, , 224-251.	0.4	1
1617	Building memories on prior knowledge: behavioral and fMRI evidence of impairment in early Alzheimer's disease. Neurobiology of Aging, 2022, 110, 1-12.	1.5	2
1618	Elevated Aortic Pulse Wave Velocity Relates to Longitudinal Gray and White Matter Changes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 3015-3024.	1.1	9
1619	Dysregulated Protein Phosphorylation as Main Contributor of Granulovacuolar Degeneration at the First Stages of Neurofibrillary Tangles Pathology. Neuroscience, 2023, 518, 119-140.	1.1	9
1620	Genome-wide association study and functional validation implicates JADE1 in tauopathy. Acta Neuropathologica, 2022, 143, 33-53.	3.9	19
1621	Diffusion MRI: Applications in the Brain. Advances in Magnetic Resonance Technology and Applications, 2020, 1, 605-636.	0.0	0
1622	Differential Changes in Arteriolar Cerebral Blood Volume between Parkinson's Disease Patients with Normal and Impaired Cognition and Mild Cognitive Impairment (MCI) Patients without Movement Disorder—An Exploratory Study. Tomography, 2020, 6, 333-342.	0.8	7
1623	Multivariate Data Analysis and Machine Learning for Prediction of MCI-to-AD Conversion. Advances in Experimental Medicine and Biology, 2020, 1194, 81-103.	0.8	7
1624	Does Episodic Memory Training Improve Episodic Memory of Older Adults with Alzheimer's Disease?. Brain & Neurorehabilitation, 2020, 13, .	0.4	Ο

#	Article	IF	Citations
1625	Autophagic Dysfunction in Neurodegeneration. Advances in Medical Diagnosis, Treatment, and Care, 2020, , 25-62.	0.1	0
1627	Sloping Shoulders Sign: A Practical Radiological Sign for the Differentiation of Alzheimer's Disease and Argyrophilic Grain Disease. Journal of Alzheimer's Disease, 2021, 84, 1719-1727.	1.2	3
1628	Case Report: Concomitant Alzheimer's and Lewy-Related Pathology Extending the Spectrum of Underlying Pathologies of Corticobasal Syndrome. Frontiers in Neuroscience, 2021, 15, 742042.	1.4	0
1629	P62 accumulates through neuroanatomical circuits in response to tauopathy propagation. Acta Neuropathologica Communications, 2021, 9, 177.	2.4	8
1632	Impact of β-Amyloid on the Tau Pathology in Tau Transgenic Mouse and Tissue Culture Models. , 2007, , 198-215.		0
1636	Medial Temporal Atrophy Alone is Insufficient to Predict Underlying Alzheimer's Disease Pathology. Korean Journal of Family Medicine, 2020, 41, 352-358.	0.4	2
1637	Comparisons between global and focal brain atrophy rates in normal aging and Alzheimer disease: Boundary Shift Integral versus tracing of the entorhinal cortex and hippocampus. Alzheimer Disease and Associated Disorders, 2004, 18, 196-201.	0.6	49
1641	Leptin signaling and Alzheimer's disease. American Journal of Neurodegenerative Disease, 2012, 1, 245-65.	0.1	45
1642	Therapeutic application of melatonin in mild cognitive impairment. American Journal of Neurodegenerative Disease, 2012, 1, 280-91.	0.1	71
1643	Voxel-based Morphometry of Brain MRI in Normal Aging and Alzheimer's Disease. , 2013, 4, 29-37.		61
1647	Neurocardiovascular Instability and Cognition. Yale Journal of Biology and Medicine, 2016, 89, 59-71.	0.2	26
1650	Increased Pittsburgh Compound-B Accumulation in the Subcortical White Matter of Alzheimer's Disease Brain. Kobe Journal of Medical Sciences, 2017, 62, E136-E141.	0.2	2
1651	Changes in brain morphology in Alzheimer disease and normal aging: is Alzheimer disease an exaggerated aging process?. American Journal of Neuroradiology, 2001, 22, 1680-5.	1.2	122
1652	Tau in Health and Neurodegenerative Diseases. , 0, , .		0
1653	Machine Learning to Predict Brain Amyloid Pathology in Pre-dementia Alzheimer's Disease Using QEEG Features and Genetic Algorithm Heuristic. Frontiers in Computational Neuroscience, 2021, 15, 755499.	1.2	10
1654	Cognitive and Neuroimaging Profiles of Older Adults With Attention Deficit/Hyperactivity Disorder Presenting to a Memory Clinic. Journal of Attention Disorders, 2021, , 108705472110605.	1.5	8
1655	Evidence against altered excitatory/inhibitory balance in the posteromedial cortex of young adult APOE E4 carriers: A resting state 1H-MRS study. NeuroImage Reports, 2021, 1, 100059.	0.5	0
1656	Baseline [18F]GTP1 tau PET imaging is associated with subsequent cognitive decline in Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 196.	3.0	13

#	Article	IF	CITATIONS
1658	Photo-Oxygenation: An Innovative New Therapeutic Approach Against Amyloidoses. Advances in Experimental Medicine and Biology, 2021, 1339, 415-422.	0.8	2
1660	Proteomic profiling in cerebral amyloid angiopathy reveals an overlap with CADASIL highlighting accumulation of HTRA1 and its substrates. Acta Neuropathologica Communications, 2022, 10, 6.	2.4	16
1661	Animal models in the study of Alzheimer's disease and Parkinson's disease: A historical perspective. Animal Models and Experimental Medicine, 2022, 5, 27-37.	1.3	10
1662	Analysis of mRNA and Protein Levels of CAP2, DLG1 and ADAM10 Genes in Post-Mortem Brain of Schizophrenia, Parkinson's and Alzheimer's Disease Patients. International Journal of Molecular Sciences, 2022, 23, 1539.	1.8	10
1663	Association between single moderate to severe traumatic brain injury and long-term tauopathy in humans and preclinical animal models: a systematic narrative review of the literature. Acta Neuropathologica Communications, 2022, 10, 13.	2.4	13
1664	New treatment approaches for Alzheimer's disease: preclinical studies and clinical trials centered on antidiabetic drugs. Expert Opinion on Investigational Drugs, 2022, 31, 105-123.	1.9	11
1665	Tubulin tyrosination regulates synaptic function and is disrupted in Alzheimer's disease. Brain, 2022, 145, 2486-2506.	3.7	17
1666	Mechanistic Modeling of Longitudinal Shape Changes: Equations of Motion and Inverse Problems. SIAM Journal on Applied Dynamical Systems, 2022, 21, 80-101.	0.7	4
1668	Neurodegeneration and neuroinflammation are linked, but independent of alphaâ€ s ynuclein inclusions, in a seeding/spreading mouse model of Parkinson's disease. Glia, 2022, 70, 935-960.	2.5	30
1669	Volumetric changes within hippocampal subfields in Alzheimer's disease continuum. Neurological Sciences, 2022, , 1.	0.9	1
1670	Genetically identical twins show comparable tau PET load and spatial distribution. Brain, 2022, 145, 3571-3581.	3.7	12
1671	Association of β-Amyloid Accumulation With Executive Function in Adults With Unimpaired Cognition. Neurology, 2022, 98, .	1.5	22
1672	Longitudinal associations between racial discrimination and hippocampal and white matter hyperintensity volumes among older Black adults. Social Science and Medicine, 2023, 316, 114789.	1.8	12
1673	Approche clinique des troubles neurocognitifs des pathologies dégénératives. La Presse Médicale Formation, 2022, 3, 57-57.	0.1	0
1674	18F-APN-1607 Tau Positron Emission Tomography Imaging for Evaluating Disease Progression in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2021, 13, 789054.	1.7	7
1675	Tau Ubiquitination in Alzheimer's Disease. Frontiers in Neurology, 2021, 12, 786353.	1.1	13
1676	Amyloid PET imaging and dementias: potential applications in detecting and quantifying early white matter damage. Alzheimer's Research and Therapy, 2022, 14, 33.	3.0	9
1677	A comparison between tau and amyloid-Î ² cerebrospinal fluid biomarkers in chronic traumatic encephalopathy and Alzheimer disease. Alzheimer's Research and Therapy, 2022, 14, 28.	3.0	16

# 1678	ARTICLE Lateral entorhinal cortex dysfunction in amnestic mild cognitive impairment. Neurobiology of Aging, 2022, 112, 151-160.	IF 1.5	CITATIONS
1679	Tau-PET imaging as a molecular modality for Alzheimer's disease. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 374-386.	1.0	0
1680	New Perspectives for Treatment in Alzheimerâ \in ${}^{\mathrm{Ms}}$ s Disease. , 2022, , 199-225.		0
1681	Increased retention of tau PET ligand [18F]-AV1451 in Alzheimer's Disease Psychosis. Translational Psychiatry, 2022, 12, 82.	2.4	6
1682	Classification of Alzheimer's Disease Based on Abnormal Hippocampal Functional Connectivity and Machine Learning. Frontiers in Aging Neuroscience, 2022, 14, 754334.	1.7	12
1683	The China Alzheimer Report 2022. Annals of General Psychiatry, 2022, 35, e100751.	1.1	79
1684	Novel approaches to measuring neurocognitive functions in Alzheimer's disease clinical trials. Current Opinion in Neurology, 2022, 35, 240-248.	1.8	3
1686	Neurochemical and cognitive changes precede structural abnormalities in the TgF344-AD rat model. Brain Communications, 2022, 4, fcac072.	1.5	11
1688	Voxel-based morphometry and a deep learning model for the diagnosis of early Alzheimer's disease based on cerebral gray matter changes. Cerebral Cortex, 2023, 33, 754-763.	1.6	18
1689	Amyloid \hat{I}^2 / PKC-dependent alterations in NMDA receptor composition are detected in early stages of AlzheimerÂ's disease. Cell Death and Disease, 2022, 13, 253.	2.7	16
1690	Therapeutically harnessing extracellular vesicles. Nature Reviews Drug Discovery, 2022, 21, 379-399.	21.5	263
1691	Alzheimer's Disease Neuroimaging Initiative. , 2022, , 455-464.		1
1692	Enhanced expression of autophagyâ€related p62 without increased deposits of neurodegenerationâ€associated proteins in glioblastoma and surrounding tissue – An autopsyâ€based study. Brain Pathology, 2022, 32, e13058.	2.1	5
1693	Unbiased proteomic profiling reveals the IP3R modulator AHCYL1/IRBIT as a novel interactor of microtubule-associated protein tau. Journal of Biological Chemistry, 2022, 298, 101774.	1.6	3
1694	Diminished preparatory physiological responses in frontotemporal lobar degeneration syndromes. Brain Communications, 2022, 4, fcac075.	1.5	2
1695	Volume of the posterior hippocampus mediates age-related differences in spatial context memory and is correlated with increased activity in lateral frontal, parietal and occipital regions in healthy aging. Neurolmage, 2022, 254, 119164.	2.1	11
1696	Amyloid-β and tau pathologies relate to distinctive brain dysconnectomics in preclinical autosomal-dominant Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2113641119.	3.3	26
1697	Deciphering the prion-like behavior of pathogenic protein aggregates in neurodegenerative diseases. Neurochemistry International, 2022, 155, 105307.	1.9	5

#	Article	IF	CITATIONS
1698	Dual-task gait and mild behavioral impairment: The interface between non-cognitive dementia markers. Experimental Gerontology, 2022, 162, 111743.	1.2	10
1699	PathwayMultiomics: An R Package for Efficient Integrative Analysis of Multi-Omics Datasets With Matched or Un-matched Samples. Frontiers in Genetics, 2021, 12, 783713.	1.1	9
1701	Inhibitory Control of Saccadic Eye Movements and Cognitive Impairment in Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 2022, 14, 871432.	1.7	8
1702	Somatic genomic changes in single Alzheimer's disease neurons. Nature, 2022, 604, 714-722.	13.7	92
1719	Prion-like strain effects in tauopathies. Cell and Tissue Research, 2023, 392, 179-199.	1.5	13
1720	Alzheimer's Disease and Parkinson's Disease May Result from Reactivation of Embryologic Pathways Silenced at Birth Discovery Medicine, 2021, 31, 89-94.	0.5	1
1721	Exercise and Alzheimer's disease. , 2022, , 413-421.		1
1722	Entorhinal Subfield Vulnerability to Neurofibrillary Tangles in Aging and the Preclinical Stage of Alzheimer's Disease. Journal of Alzheimer's Disease, 2022, 87, 1379-1399.	1.2	9
1723	Biomarker modeling of Alzheimer's disease using PET-based Braak staging. Nature Aging, 2022, 2, 526-535.	5.3	73
1724	Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer's Disease: A Review. Frontiers in Human Neuroscience, 2022, 16, 866434.	1.0	25
1725	Histologic lesion type correlates of magnetic resonance imaging biomarkers in four-repeat tauopathies. Brain Communications, 2022, 4, .	1.5	5
1726	Altered abundances of human immunoglobulin M and immunoglobulin G subclasses in Alzheimer's disease frontal cortex. Scientific Reports, 2022, 12, 6934.	1.6	1
1727	Evidence against a contribution of the CCAAT-enhancer binding protein homologous protein (CHOP) in mediating neurotoxicity in rTg4510 mice. Scientific Reports, 2022, 12, 7372.	1.6	4
1728	Deciphering the Structure and Formation of Amyloids in Neurodegenerative Diseases With Chemical Biology Tools. Frontiers in Chemistry, 2022, 10, .	1.8	6
1731	Pyramidal cell axon initial segment in Alzheimer´s disease. Scientific Reports, 2022, 12, .	1.6	7
1732	The Locus Coeruleus – Noradrenaline system: Looking into Alzheimer's therapeutics with rose coloured glasses. Biomedicine and Pharmacotherapy, 2022, 151, 113179.	2.5	7
1733	From cradle to grave: neurogenesis, neuroregeneration and neurodegeneration in Alzheimer's and Parkinson's diseases. Neural Regeneration Research, 2022, 17, 2606.	1.6	17
1735	Neuropsychological Performance Is Correlated With Tau Protein Deposition and Glucose Metabolism in Patients With Alzheimer's Disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	5

#	Article	IF	CITATIONS
1736	Targeting Necroptosis as a Promising Therapy for Alzheimer's Disease. ACS Chemical Neuroscience, 2022, 13, 1697-1713.	1.7	13
1737	Different Profiles of Spatial Navigation Deficits In Alzheimer's Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnestic Mild Cognitive Impairment. Frontiers in Aging Neuroscience, 0, 14, .	1.7	11
1739	Region-Specific Characteristics of Astrocytes and Microglia: A Possible Involvement in Aging and Diseases. Cells, 2022, 11, 1902.	1.8	10
1740	Loss of functional heterogeneity along the CA3 transverse axis in aging. Current Biology, 2022, 32, 2681-2693.e4.	1.8	5
1741	Modified cued recall test in the French population with Down syndrome: A retrospective medical records analysis. Journal of Intellectual Disability Research, 2022, 66, 690-703.	1.2	2
1742	Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease. JAMA Neurology, 2022, 79, 758.	4.5	52
1743	Staging of Alzheimer's disease: past, present, and future perspectives. Trends in Molecular Medicine, 2022, 28, 726-741.	3.5	36
1744	Therapeutic Potential of Astrocyte Transplantation. Cell Transplantation, 2022, 31, 096368972211054.	1.2	13
1745	Hypertension and Alzheimer's disease pathology at autopsy: A systematic review. Alzheimer's and Dementia, 2022, 18, 2308-2326.	0.4	17
1746	Longitudinal changes in brain oxygen extraction fraction (OEF) in older adults: Relationship to markers of vascular and Alzheimer's pathology. Alzheimer's and Dementia, 2023, 19, 569-577.	0.4	8
1747	Brain Neural Underpinnings of Interoception and Decision-Making in Alzheimer's Disease: A Narrative Review. Frontiers in Neuroscience, 0, 16, .	1.4	3
1748	SIRT1 deficiency increases O-GlcNAcylation of tau, mediating synaptic tauopathy. Molecular Psychiatry, 2022, 27, 4323-4334.	4.1	8
1749	Phosphorylation of Truncated Tau Promotes Abnormal Native Tau Pathology and Neurodegeneration. Molecular Neurobiology, 2022, 59, 6183-6199.	1.9	5
1751	Aging the brain: multi-region methylation principal component based clock in the context of Alzheimer's disease. Aging, 2022, 14, 5641-5668.	1.4	14
1752	Dose-dependent phosphorylation of endogenous Tau by intermittent hypoxia in rat brain. Journal of Applied Physiology, 2022, 133, 561-571.	1.2	5
1753	A CAD System for Alzheimer's Disease Classification Using Neuroimaging MRI 2D Slices. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-11.	0.7	8
1754	Disruption of nuclear envelope integrity as a possible initiating event in tauopathies. Cell Reports, 2022, 40, 111249.	2.9	19
1755	Spreading of P301S Aggregated Tau Investigated in Organotypic Mouse Brain Slice Cultures. Biomolecules, 2022, 12, 1164.	1.8	3

# 1756	ARTICLE Differential Vulnerability of Hippocampal Subfields in Primary Age-Related Tauopathy and Chronic Traumatic Encephalopathy. Journal of Neuropathology and Experimental Neurology, 2022, Publish Ahead of Print, .	IF 0.9	CITATIONS
1757	Tau positron emission tomography in preclinical Alzheimer's disease. Brain, 2023, 146, 700-711.	3.7	12
1758	Sex differences in brain functional connectivity of hippocampus in mild cognitive impairment. Frontiers in Aging Neuroscience, 0, 14, .	1.7	13
1759	Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer's disease. Nature Communications, 2022, 13, .	5.8	19
1760	Air Pollution–Related Neurotoxicity Across the Life Span. Annual Review of Pharmacology and Toxicology, 2023, 63, 143-163.	4.2	15
1761	Multimodal magnetic resonance imaging reveals distinct sensitivity of hippocampal subfields in asymptomatic stage of Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	1
1762	Does covid-19 impair endogenous neurogenesis?. Journal of Clinical Neuroscience, 2022, 105, 79-85.	0.8	4
1763	Progression of Alzheimer's disease parallels unusual structural plasticity of human dentate granule cells. Acta Neuropathologica Communications, 2022, 10, .	2.4	6
1765	Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer's disease. Alzheimer's Research and Therapy, 2022, 14, .	3.0	6
1766	Proteostasis unbalance in prion diseases: Mechanisms of neurodegeneration and therapeutic targets. Frontiers in Neuroscience, 0, 16, .	1.4	4
1767	Protein citrullination marks myelin protein aggregation and disease progression in mouse ALS models. Acta Neuropathologica Communications, 2022, 10, .	2.4	10
1768	<scp>Single ell</scp> analysis reveals transcriptomic reprogramming in aging primate entorhinal cortex and the relevance with Alzheimer's disease. Aging Cell, 2022, 21, .	3.0	4
1769	<i>In vivo</i> tau staging in Alzheimer's disease. Aging, 2022, 14, 6842-6843.	1.4	2
1771	Tau antibody <scp>77G7</scp> targeting microtubule binding domain suppresses proteopathic tau to seed tau aggregation. CNS Neuroscience and Therapeutics, 2022, 28, 2245-2259.	1.9	6
1772	Tau seeding activity in various regions of down syndrome brain assessed by two novel assays. Acta Neuropathologica Communications, 2022, 10, .	2.4	4
1773	From Small Peptides to Large Proteins against Alzheimer'sDisease. Biomolecules, 2022, 12, 1344.	1.8	5
1774	TREM2 risk variants are associated with atypical Alzheimer's disease. Acta Neuropathologica, 2022, 144, 1085-1102.	3.9	7
1775	Towards a Mechanistic Model of Tau-Mediated Pathology in Tauopathies: What Can We Learn from Cell-Based In Vitro Assays?. International Journal of Molecular Sciences, 2022, 23, 11527.	1.8	4

#	Article	IF	CITATIONS
1776	Mid―and laterâ€life risk factors for predicting neuropathological brain changes associated with Alzheimer's and vascular dementia: The Honolulu Asia Aging Study and the Age, Gene/Environment Susceptibilityâ€Reykjavik Study. Alzheimer's and Dementia, 2023, 19, 1705-1713.	0.4	2
1777	Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
1779	Animal models of Alzheimer's disease: Applications, evaluation, and perspectives. Zoological Research, 2022, 43, 1026-1040.	0.9	29
1780	Case Study 3: A 58-Year-Old Woman Referred for Evaluation of Suspected Alzheimer Dementia. Journal of Neuropsychiatry and Clinical Neurosciences, 2022, 34, 307-315.	0.9	0
1781	Molecular Mechanisms Mediating the Transfer of Disease-Associated Proteins and Effects on Neuronal Activity. Journal of Parkinson's Disease, 2022, 12, 2397-2422.	1.5	2
1782	Is microglial dystrophy a form of cellular senescence? An analysis of senescence markers in the aged human brain. Glia, 2023, 71, 377-390.	2.5	14
1783	Hypothesis review: Alzheimer's overture guidelines. Brain Pathology, 2023, 33, .	2.1	18
1784	Transversal functional connectivity and scene-specific processing in the human entorhinal-hippocampal circuitry. ELife, 0, 11, .	2.8	11
1785	Artificial intelligence-derived neurofibrillary tangle burden is associated with antemortem cognitive impairment. Acta Neuropathologica Communications, 2022, 10, .	2.4	17
1786	Forgetting rate for the familiarity and recollection components of recognition in amnestic mild cognitive impairment: A longitudinal study. Applied Neuropsychology Adult, 0, , 1-13.	0.7	0
1787	Longitudinal Tau PET Using ¹⁸ F-Flortaucipir: The Effect of Relative Cerebral Blood Flow on Quantitative and Semiquantitative Parameters. Journal of Nuclear Medicine, 2023, 64, 281-286.	2.8	2
1788	Artifacts in magnetic force microscopy of histological sections. Journal of Magnetism and Magnetic Materials, 2022, 564, 170116.	1.0	3
1789	Restorative neuroscience: concepts and perspectives. Swiss Medical Weekly, 0, , .	0.8	1
1790	Deep label fusion: A generalizable hybrid multi-atlas and deep convolutional neural network for medical image segmentation. Medical Image Analysis, 2023, 83, 102683.	7.0	12
1792	Medial temporal lobe structure, mnemonic and perceptual discrimination in healthy older adults and those at risk for mild cognitive impairment. Neurobiology of Aging, 2023, 122, 88-106.	1.5	4
1793	Reduced cortical neuron number and neuron density in schizophrenia with focus on area 24: a post-mortem case–control study. European Archives of Psychiatry and Clinical Neuroscience, 2023, 273, 1209-1223.	1.8	3
1794	Diverse limbic comorbidities cause limbic and temporal atrophy in lewy body disease. Parkinsonism and Related Disorders, 2022, 105, 52-57.	1.1	3
1795	Endocannabinoid System Biomarkers in Alzheimer's Disease. Cannabis and Cannabinoid Research, 0, , .	1.5	Ο

#	Article	IF	CITATIONS
1796	The Association of Age-Related and Off-Target Retention with Longitudinal Quantification of [¹⁸ F]MK6240 Tau PET in Target Regions. Journal of Nuclear Medicine, 2023, 64, 452-459.	2.8	2
1797	Interlacing the relevance of caspase activation in the onset and progression of Alzheimer's disease. Brain Research Bulletin, 2023, 192, 83-92.	1.4	4
1798	Decoding degeneration: the implementation of machine learning for clinical detection of neurodegenerative disorders. Neural Regeneration Research, 2023, 18, 1235.	1.6	3
1799	Metformin Attenuates Tau Pathology in Tau-Seeded PS19 Mice. Neurotherapeutics, 2023, 20, 452-463.	2.1	2
1800	CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals. Alzheimer's Research and Therapy, 2022, 14, .	3.0	8
1801	Enlarged perivascular spaces are associated with decreased brain tau deposition. CNS Neuroscience and Therapeutics, 2023, 29, 577-586.	1.9	4
1802	Activity disruption causes degeneration of entorhinal neurons in a mouse model of Alzheimer's circuit dysfunction. ELife, 0, 11, .	2.8	3
1804	PICALM rs3851179 Variants Modulate Left Postcentral Cortex Thickness, CSF Amyloid β42, and Phosphorylated Tau in the Elderly. Brain Sciences, 2022, 12, 1681.	1.1	2
1806	Medial temporal tau predicts memory decline in cognitively unimpaired elderly. Brain Communications, 2022, 5, .	1.5	5
1807	High resolution 16S rRNA gene Next Generation Sequencing study of brain areas associated with Alzheimer's and Parkinson's disease. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
1808	Tyrosine phosphatase STEP61 in human dementia and in animal models with amyloid and tau pathology. Molecular Brain, 2023, 16, .	1.3	1
1809	Insoluble Cellular Prion Protein and Other Neurodegeneration-Related Protein Aggregates in the Brain of Asymptomatic Individuals. , 2023, , 63-86.		0
1810	Increased functional connectivity patterns in mild Alzheimer's disease: A rsfMRI study. Frontiers in Aging Neuroscience, 0, 14, .	1.7	4
1811	Differential vulnerability of the dentate gyrus to tauopathies in dementias. Acta Neuropathologica Communications, 2023, 11, .	2.4	3
1812	Anatomically interpretable deep learning of brain age captures domain-specific cognitive impairment. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	21
1813	Progressive Spread of Beta-amyloid Pathology in an Olfactory-driven Amyloid Precursor Protein Mouse Model. Neuroscience, 2023, 516, 113-124.	1.1	Ο
1814	Thwarting Alzheimer's Disease through Healthy Lifestyle Habits: Hope for the Future. Neurology International, 2023, 15, 162-187.	1.3	3
1815	Individualized network analysis: A novel approach to investigate tau PET using graph theory in the Alzheimer's disease continuum. Frontiers in Neuroscience, 0, 17, .	1.4	2

#	Article	IF	CITATIONS
1816	Two simple assays for assessing the seeding activity of proteopathic tau. Frontiers in Aging Neuroscience, 0, 15, .	1.7	1
1817	Tuberous sclerosis complexâ€1 (TSC1) contributes to selective neuronal vulnerability in Alzheimer's disease. Neuropathology and Applied Neurobiology, 2023, 49, .	1.8	Ο
1818	Abnormal white matter changes in Alzheimer's disease based on diffusion tensor imaging: A systematic review. Ageing Research Reviews, 2023, 87, 101911.	5.0	15
1819	The unique neuropathological vulnerability of the human brain to aging. Ageing Research Reviews, 2023, 87, 101916.	5.0	4
1820	Passive immunization inhibits tau phosphorylation and improves recognition learning and memory in 3xTg-AD mice. Experimental Neurology, 2023, 362, 114337.	2.0	2
1821	Pentad: A reproducible cytoarchitectonic protocol and its application to parcellation of the human hippocampus. Frontiers in Neuroanatomy, 0, 17, .	0.9	7
1822	The Alzheimer's Disease Mitochondrial Cascade Hypothesis: A Current Overview. Journal of Alzheimer's Disease, 2023, 92, 751-768.	1.2	19
1824	Conserved reduction of m ⁶ A RNA modifications during aging and neurodegeneration is linked to changes in synaptic transcripts. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	20
1825	Change in Cerebrospinal Fluid Tau Microtubule Binding Region Detects Symptom Onset, Cognitive Decline, Tangles, and Atrophy in Dominantly Inherited Alzheimer's Disease. Annals of Neurology, 2023, 93, 1158-1172.	2.8	1
1826	Phosphomimetics at Ser199/Ser202/Thr205 in Tau Impairs Axonal Transport in Rat Hippocampal Neurons. Molecular Neurobiology, 2023, 60, 3423-3438.	1.9	6
1827	Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression. Alzheimer's Research and Therapy, 2023, 15, .	3.0	4
1828	Unexpected Classes of Aquaporin Channels Detected by Transcriptomic Analysis in Human Brain Are Associated with Both Patient Age and Alzheimer's Disease Status. Biomedicines, 2023, 11, 770.	1.4	1
1830	SOX9 Expression Is Increased in Alzheimer's Disease (AD) and Is Associated With Disease Progression and APOE4 Genotype: A Computational Approach. Cureus, 2023, , .	0.2	1
1831	Differential Laminar Activation Dissociates Encoding and Retrieval in the Human Medial and Lateral Entorhinal Cortex. Journal of Neuroscience, 2023, 43, 2874-2884.	1.7	1
1832	Soluble form of the APP fragment, sAPPβ, positively regulates tau secretion. Neuroscience Research, 2023, 193, 63-70.	1.0	1
1833	Voxel-Based and Surface-Based Morphometry Analysis in Patients with Pathologically Confirmed Argyrophilic Grain Disease and Alzheimer's Disease. Journal of Alzheimer's Disease, 2023, 93, 379-387.	1.2	4
1834	Neuronal accumulation of hyperphosphorylated tau protein predicts stable memory impairment in people living with HIV. Aids, 2023, 37, 1247-1256.	1.0	4
1835	Classification of Alzheimer's disease based on hippocampal multivariate morphometry statistics. CNS Neuroscience and Therapeutics, 0, , .	1.9	1

#	Article	IF	Citations
1837	Targeting the function of the transentorhinal cortex to identify early cognitive markers of Alzheimer's disease. Cognitive, Affective and Behavioral Neuroscience, 2023, 23, 986-996.	1.0	1
1838	Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects. Alzheimer's Research and Therapy, 2023, 15, .	3.0	4
1839	Compensatory Mechanisms in Early Alzheimer's Disease and Clinical Setting: The Need for Novel Neuropsychological Strategies. Journal of Alzheimer's Disease Reports, 0, , 1-13.	1.2	2
1840	Distinct and joint effects of low and high levels of Aβ and tau deposition on cortical thickness. NeuroImage: Clinical, 2023, 38, 103409.	1.4	2
1841	IoT-Enabled Gait Assessment: The Next Step for Habitual Monitoring. Sensors, 2023, 23, 4100.	2.1	5
1842	Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers. Nature Communications, 2023, 14, .	5.8	17
1854	Alzheimer's Disease Classification Using Abnormal Hippocampal Functional Connectivity and Machine Learning. , 2023, , .		0
1856	Clinical relevance of animal models in aging-related dementia research. Nature Aging, 2023, 3, 481-493.	5.3	5
1858	Quantitative Metabolic Magnetic Resonance Imaging: A Case for Bioscales in Medicine. , 2023, , 1239-1258.		0
1860	Human path integration and the neural underpinnings. , 2024, , .		0
1867	Biological and Clinical Implications of Sex-Specific Differences in Alzheimer's Disease. Handbook of Experimental Pharmacology, 2023, , 181-197.	0.9	2
1868	Nanodelivery of Histamine H3/H4 Receptor Modulators BF-2649 and Clobenpropit with Antibodies to Amyloid Beta Peptide in Combination with Alpha Synuclein Reduces Brain Pathology in Parkinson's Disease. Advances in Neurobiology, 2023, , 55-96.	1.3	0
1871	Understanding the multifaceted role of miRNAs in Alzheimer's disease pathology. Metabolic Brain Disease, 2024, 39, 217-237.	1.4	1
1881	The tauopathies. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 251-265.	1.0	2
1890	Aging and spatial navigation. , 2023, , .		0
1892	Neuroimaging determinants of cognitive impairment in the memory clinic: how important is the vascular burden?. Journal of Neurology, 0, , .	1.8	Ο
1905	Exploring the Role of Locus Coeruleus in Alzheimer's Disease: a Comprehensive Update on MRI Studies and Implications. Current Neurology and Neuroscience Reports, 0, , .	2.0	0
1923	Etiology, pathogenesis of Alzheimer's disease and amyloid beta hypothesis. , 2024, , 1-11.		0

ARTICLE

IF CITATIONS